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ABSTRACT 
 
 
 
In this thesis, I aim to explore the role of angiogenesis in epithelial ovarian 
cancer (EOC) and its correlation with risk of disease development, clinical 
outcome and disease response to platinum based chemotherapy.  
 
Immunohistochemical (IHC) techniques were used to examine the surgical 
specimens of 105 patients with primary EOC, FIGO stages I to IV. The results 
of vascular endothelial growth factor (VEGF) expression were correlated with 
clinicopathological variables and overall patient survival. No correlation 
between VEGF expression and clinicpathological factors was identified. 
However VEGF expression was found to significantly correlate with overall 
patient survival and a prognostic factor independent of the stage of the 
disease and residual tumour status (p< 0.0001).  
 
The association between VEGF-A expression in the tumour and the patient 
response to platinum based chemotherapy was examined by studying the 
expression of VEGF-A in 66 patients with advanced stage EOC (FIGO stages 
III-IV). Expression of the protein was correlated with platinum sensitivity and 
overall patient survival. I demonstrated that platinum resistant EOC was 
associated with a higher proportion of high VEGF expression in the tumour. 
 
To examine whether the differential production of VEGF is associated with the risk of 
EOC, I conducted a case control study to investigate whether the polymorphism in the 
VEGF gene – VEGF 1154 A/G genotype, which is known to be associated with the 
increased production of VEGF protein, is associated with the risk of EOC.There was a 
statistically significant difference in the distribution of the genotype of the VEGF 
1154 A/G marker in the cases as compared with the controls. For the high-risk (GG) 
genotype, the difference between the patient and the control groups was statistically 
significant. 
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1.1 GENERAL  
 
 
Ovarian cancer is the fourth most common cancer after lung, breast and colon 
among women, and the leading cause of death from a gynaecological 
malignancy. As symptoms preceding the development of ovarian cancer are 
vague and insidious 70% of patients present at an advanced stage, i.e. 
International Federation of Gynaecology and Obstetrics (FIGO) stages III and 
IV. Despite advances in surgery and chemotherapy the death rate has 
changed little over the last twenty five years. 
 
The molecular biology underlying epithelial ovarian cancer (EOC) remains 
poorly understood. Tumour angiogenesis is critical for tumour growth beyond 
2mm3 and is associated with prognostic significance in a variety of solid 
malignancies, including ovarian cancer. 
 
In this thesis, I aim to explore the role of angiogenesis in epithelial ovarian 
cancer and its correlation with risk of disease development, clinical outcome 
and disease response to platinum based chemotherapy.  
 
Immunohistochemical (IHC) techniques were used to examine the surgical 
specimens of 105 patients with primary epithelial ovarian cancer, FIGO stages 
I to IV. The results of vascular endothelial growth factor (VEGF) expression 
were correlated with clinicopathological variables and overall patient survival. 
No correlation between VEGF expression and clinicopathological factors was 
identified. However VEGF expression was found to significantly correlate with 
overall patient survival and a prognostic factor independent of the stage of the 
disease and residual tumour status (p< 0.0001).  
 
To further the understanding of the role of angiogenesis and disease 
response in EOC, the association between VEGF-A expression in the tumour 
and the patient response to platinum based chemotherapy was examined by 
studying the immunohistochemical expression of VEGF-A in 66 patients with  
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advanced stage EOC (FIGO stages III-IV). Expression of the protein was 
correlated with platinum sensitivity and overall patient survival. In this study I 
demonstrated that platinum resistant EOC was associated with a higher 
proportion of high VEGF expression in the tumour; 81% of these patients had 
a high VEGF score as compared to only 29% high VEGF expression in the 
group of patients that were sensitive to platinum based chemotherapy. I also 
illustrated that overall median survival was 10.79 months (SD7.75) in the 
patients with a high VEGF intra-tumour VEGF score versus 36.36 months 
(SD21.69) in patients with a low VEGF score in the tumour. VEGF expression 
was found to be significantly correlated with patient survival (p< 0.0001). 
 
To evaluate the role of angiogenesis and the development on EOC, and to 
examine whether the differential production of VEGF is associated with the 
risk of ovarian cancer, I conducted a case control study to investigate whether 
the polymorphism in the VEGF gene – VEGF 1154 A/G genotype, which is 
known to be associated with the increased production of VEGF protein, is 
associated with the risk of epithelial ovarian cancer. In this case control study 
I recruited 296 epithelial ovarian cases and 298 controls. The cases were 
recruited from 3 tertiary centres in Pakistan, in the cities of Karachi and 
Lahore. The controls were hospital matched controls selected from outpatient 
clinics, with no personal history of cancer. All study subjects were of Pakistani 
ancestry. Genotyping was performed using standard methods. STATA was 
used for statistical analysis and procedures such as logistic regression, chi 
square and ANOVA were used for analysis. I found that there was a 
statistically significant difference in the distribution of the genotype of the 
VEGF 1154 A/G marker in the cases as compared with the controls. For the 
high-risk (GG) genotype, the difference between the patient and the control 
groups was statistically significant (OR 0.43, 95% CI = 0.19-0.95, p=0.37). 
39% of the cases were found to be homozygous for the GG genotype, 
compared to only 16% of the control subjects. Our results illustrated a 
significant difference between the cases and controls in allele frequencies (p< 
0.042) and carriage of the 1154 G allele was associated with an increased 
risk of ovarian cancer. This result may be explained, and is biologically 
plausible, as the VEGF 1154 G/G polymorphism is known to be associated 
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with increased VEGF production. Validation of the effect of this SNP is 
required by larger sample sizes. 
  
 
 
1.2 ANGIOGENESIS  
 
“One is almost forced to the conclusion that 
there is, associated with the viable growing 
tumor, some blood vessel growth stimulating 
factor.” G. Ide et al, Am J Roentgenol 
1939;42:891-9. 
 
The functioning of cells in humans requires a highly dependable supply of 
oxygen and nutrients. Given that the diffusion of oxygen in tissues is limited to 
100-200µm, a highly developed vascular system has evolved to ensure that 
all cells are within this distance of an oxygen supply. Blood vessels are 
essentially composed of endothelial cells. These interconnect to form tubes 
that direct blood flow and maintain tissue perfusion. In higher organisms, the 
formation of blood vessels is through two distinct processes: vasculogenesis 
and angiogenesis. In vasculogenesis blood vessels are derived from 
mesoderm by the differentiation of angioblasts. These angioblasts are 
endothelial cells that have not formed a lumen and contribute to the formation 
of primitive vascular networks. This process predominantly takes place in the 
developing embryo through a process that involves endothelial cell division, 
selective degradation of the basement membrane and the surrounding 
extracellular matrix, endothelial cell migration and the formation of a tubular 
structure. The endothelial cells then undergo tissue-specific changes to 
generate structurally distinct vessels. Angiogenesis, on the other hand is the 
formation of vessels from pre-existing vasculature through processes such as 
sprouting, pruning and intussusception. However, the differentiation between 
these two processes, is often not a sharp one, and the term ‘angiogenesis’ is 
used to summarise all different types and modifications of arterial vessel 
growth. 
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The process of angiogenesis involves the migration of endothelial cells from 
the parent vessel towards a chemo-attractant. As well as the ability to 
promote endothelial cell migration, angiogenic factors must also degrade the 
extracellular matrix through which the cells move. Endothelial cell invasion as 
part of the angiogenic process involves secretion of urokinase-type 
plasminogen activator and its inhibitor (PAI-1). Fine maintenance of the 
proteolytic balance seems to be crucial for the correct development of new 
blood vessels 1. Having migrated, the endothelial cells must proliferate, lay 
down their basement membrane and form a lumen, which is the basis of the 
new capillary. This sequence of events (endothelial cell proliferation, 
migration, basement membrane degradation and new lumen organisation) is 
the basis of angiogenesis. The molecular mechanisms that regulate these 
individual processes are subject to a complex control system with pro and 
anti-angiogenic factors. 
 
Angiogenesis can be a physiological process and occurs in the highly ordered 
process in the female reproductive cycles (ovulation, menstruation, 
pregnancy) and wound healing. This process is usually focal and self-limited. 
However angiogenesis can also be a pathological process 2. The concept of 
angiogenesis dependent diseases originated in 1972 with the recognition that 
certain non-neoplastic conditions such as chronic inflammatory psoriasis 
depend on persistent neovascularisation to provide a channel for the 
continuing delivery of inflammatory cells to the inflammatory site 3-5. Following 
on from this, other non-neoplastic conditions were recognised to be 
angiogenesis dependent, including autoimmune disease, age related macular 
degeneration, atherosclerosis 1 3 6, peptic ulcers 7 and atherosclerosis 8. 
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Table 1.1. Role of angiogenesis in pathological processes. 
Adapted from Angiogenesis in Cancer and other diseases in Nature Sept 2000 
Carmeliet P 407, 249-257 
 
 
 
1.2.1   The Angiogenic Switch 
 
 
Angiogenesis is controlled and regulated by a range of pro-angiogenic and 
anti-angiogenic factors (Figure 1.1)2. Several years ago, Hanahan and 
Folkman postulated the angiogenic switch hypothesis 9. The “angiogenic 
switch” is a term that refers to the balance between pro- and anti-angiogenic 
factors. When the balance is in favour of the pro-angiogenic factors, the 
balance is tipped favouring angiogenesis. More than 20 stimulators and 
inhibitors have so far been described. The positive factors include vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), 
angiogenin and angiopoietin amongst many. These can be exported from the 
tumour cell, mobilized from the extracellular matrix or released by 
macrophages attracted to the tumour. Thus, angiogenesis is an interplay of 
positive and negative regulation of several factors.  
 
DISEASE SYMPTOMS 
Diabetic Neuropathy Loss of vision 
Rheumatoid Arthritis Pain and immobility    
Atherosclerotic Plaques Chest pain, dyspnoea 
Crohn’s Disease Intestinal Bleeding 
 
Psoriasis Persistent severe itching  
 
Uterine fibroids Vaginal bleeding, abdominal pain 
 
Cancer Bleeding, thrombosis, anaemia,  
    abdominal ascites; bone pain.  
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Stimulators of Angiogenesis 
Vascular endothelial growth factor 
PDECGF/TP 
Angiopoietin1 and 2 
Insulin like growth factor 
Epidermal growth factor 
Placental growth factor 
Tumour necrosis factor 
Matrix metalloproteinases 
Ephrin family 
Transforming growth actor 
Granulocyte macrophage  
      stimulating factor 
Interleukin 8 
 
  
   
   
 
 
 
 
Figure 1.1: The angiogenic switch: a balance of pro and anti-angiogenic factors 
 
 
One of the most widely studied angiogenic activators is vascular endothelial 
growth factor (VEGF). VEGF is widely distributed and has been shown to play 
a coordinated role in endothelial cell proliferation and assembly of the vessel 
wall in a variety of normal and abnormal circumstances. Members of the 
VEGF family together with members of another pro-angiogenic factor, 
angiopoietin, and at least one member of the Ephrin family all work in a 
complementary and coordinated manner to form functional vessels. In 
addition many other growth factors that are not vascular endothelium specific 
are also required for blood vessel formation, such as members of the platelet 
derived growth factors and transforming growth factors (TGF). These factors 
also have crucial roles in many other systems.  
 
 
Inhibitors of Angiogenesis 
Vascular endothelial growth factor 
inhibitor 
Thrombospondin 1 
Angiostatin 
Endostatin 
Vasostatin 
Interleukin 1, 2 
Restin 
Antithrombin 3 
Meth 1 and Meth 2 
Interferon a and i 
Interferon 6 
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1.2.2  Vascular Endothelial Growth Factor (VEGF) 
 
1.2.2.1 The VEGF ligand 
Vascular endothelial growth factor is a heparin binding glycoprotein, and was 
originally identified in the media of conditioned normal bovine pituitary 
follicostellate cells 10 and by a variety of transformed cell lines 11. It is a 
multifunctional cytokine with potent angiogenic activity. VEGF is a potent and 
specific mitogen for vascular endothelial cells 12-14. It stimulates the full 
cascade of events required for angiogenesis both in vitro and in vivo 14 15 and 
it greatly augments the permeability of existing microvasculature. It is a potent 
multifunctional cytokine that has several potentially independent effects on the 
vascular endothelium including: 
 
1) Endothelial mitogenesis 
2) Mitogenesis 
3) Vascular tone 
4) The production of vasoactive molecules. 
5) Stimulation of monocytes chemotaxis16 17 
 
VEGF also functions as a potent pro-survival (anti-apoptic) factor for 
endothelial cells in newly formed vessels. VEGF is a family of growth factors 
belonging to the platelet derived growth factor/VEGF supergene family, 
having a homodimer structure with 8 conserved cysteine residues 18 19. Figure 
1. 2 represents the three dimensional structure of VEGF.  
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The VEGF family has at least 7 members: VEGF A, VEGF-B, VEGF-C, 
VEGF-D, VEGF-E, VEGF-F and placental growth factor (PlGF) 20 21. All 
members of the family are encoded in the mammalian genome except for 
VEGF-E and VEGF-F, these having been discovered encoded by viruses and 
in the venom of some snakes respectively. The human VEGF gene is mapped 
to chromosome 6p21.3. All members of the VEGF family stimulate cellular 
responses by binding to tyrosine kinase receptors (VEGFRs) on the cell 
surface causing them to dimerise and become trans-phosphorylated. 
The best characterised of the VEGF family members is VEGF-A, a key player 
in vasculogenesis, the formation of blood vessels from progenitor cells, as 
well as angiogenesis.  
VEGF-A, a 34 to 42 kDa dimeric disulphide-bound glycoprotein, exists in at 
least 7 homodimeric isoforms. The monomers consist of 121, 145, 148, 165, 
183, 189 and 206 amino acids and are generated by alternative splicing 22. 
The major subtypes of VEGF-A in humans are the 121,165, and 189-amino 
acid type. The variation in size suggests different roles. VEGF 121 and 165 
are secreted in soluble forms, whereas VEGF 145, 189, and 206 remain 
associated with plasma cell membrane surface because of their interaction 
with proteoglycans. VEGF-A121 does not contain a basic stretch, whereas 
VEGF-A165 and VEGF-A189 carry basic stretches in the carboxyl terminal 
Figure 1.2. Ribbon representation of 
the receptor-biding domain of VEGF. 
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region. VEGF-A165 is the dominant subtype among VEGF-A proteins in terms 
of amount and biological activity. Via its basic stretch, VEGF-A165 modestly 
binds with neuropilin-1 (Nrp1) and heparin, which contributes to a gradient of 
VEGF-A165 surrounding VEGF-A-expressing cells. This gradient is known to 
be important for the stimulation of vascular endothelial cells and for strong 
angiogenesis 23. VEGF-A is one amino-acid shorter in mice. Mice carrying 
only the 164-allele (VEGF-A164/164 mice) are viable but the other two 
genotypes (VEGF-A120/120, and VEGF-A188/188 mice) are embryonic lethal, 
indicating that VEGF-A164 is essential and sufficient for normal development of 
blood vessels in mice 24. 
 
 
 
 
 
Figure 1.3. Gene structure of VEGF-A, VEGF-B, VEGF-C, and 
VEGF-D25.  
The VEGF-A gene consists of eight exons that give rise to seven 
isoforms of 121, 145, 148, 165, 183, 189, and 206 amino acids through 
differential splicing. An additional VEGF-A isoform of 110 amino acids 
results from proteolytic cleavage. VEGF-B exists as two isoforms of 167 
and 186 amino acids. VEGF-C and VEGF-D are proteolytically released 
from their respective proproteins. All VEGF family members share a 
highly preserved VEGF homology domain, encoded by exons 1 to 5.  
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The expression of the VEGF-A gene is up-regulated via hypoxia 26 27, 
estrogen, NF-B pathways, and others. Under hypoxic conditions, HIFα 
proteins (HIF1α and HIF2α) are stabilised due to a block of ubiquitin-
dependent degradation. Since the VHL (von Hippel-Lindau) protein plays a 
major role in the degradation of HIFα, renal cell carcinoma patients carrying a 
VHL-gene-deficiency generally show high levels of VEGF-A mRNA and 
protein in tumour tissues, and strong tumour angiogenesis. 
VEGF-A binds and activates VEGFR1 and VEGFR2 but not VEGFR3 (see 
below figure 4).  
 
 
 
Figure 1.4. Schematic representation of VEGF family ligands and their 
receptors 18. 
 
 
 
In contrast to VEGF-A, VEGF-B plays a less pronounced role in the vascular 
system appearing to only to play in role in the maintenance of newly formed 
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blood vessels during pathological conditions 28. High expression of VEGF-B is 
seen in adult myocardium, skeletal muscle and pancreas. Alternative splicing 
of VEGF-B, discovered in 1995, generates 2 isoforms of 167 and 186 amino 
acids. The 2 isoforms are differentially expressed, VEGF-B167 being dominant, 
suggesting that splicing events are strictly regulated. VEGF-B is abundantly 
expressed in the adult myocardium, skeletal muscle and pancreas. VEGF-B 
exerts its effects via VEGFR1 29 30. 
VEGF-C and VEGF-D, crucial regulators of lymphangiogenesis 31, are 
originally synthesized in premature forms, and processed by digestion with 
furin and other proprotein convertases to shorter forms 32. After processing, 
they acquire a strong ability to bind VEGFR3, and induce lymphangiogenesis. 
The VEGF-C gene starts to be expressed early in embryogenesis, and plays 
an essential role in the development of lymphatic endothelial cells from veins 
at embryonic E9.5-10.5 in mice. Not only homozygotes but also heterozygotes 
for the VEGF-C allele (VEGF-C+/- mice) often die in the perinatal stage due to 
a dysfunction of lymph vessels, severe systemic oedema and the 
accumulation of lipids in body fluids. This indicates that half the normal level 
of VEGF-C protein is insufficient for the absorption of tissue fluids and lipids. 
VEGF-C or VEGF-D-overexpressing tumours are lymphangiogenic and highly 
metastatic to lymph nodes. Thus, these ligands are important targets for 
suppression of lymph-node metastasis 33. 
 
 
1.2.2.2 The vascular endothelial growth factor receptor 
(VEGFR) 
The biological effects of VEGF are mediated through the activation of specific 
tyrosine kinase receptors expressed mainly on angioblast and endothelial 
cells 34. The VEGFR family consists of three members: VEGFR1, VEGFR2 
and VEGFR3. The VEGF receptors have an extracellular portion consisting of 
immunoglobulin-like domains, a single transmembrane spanning region and 
an intracellular portion containing a split tyrosine-kinase domain 19. VEGFR 1 
and 2 bind VEGF A and play a central role in the regulation of angiogenesis: 
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whereas VEGFR3 tightly binds VEGF C and D and stimulates 
lymphangiogenesis.  
VEGFR1 (fms-like tyrosine kinase Flt-1) has a very high affinity for VEGF-A at 
Kd=2 to 10 pM. Despite the high affinity, its tyrosine kinase activity is weak 
(about 10-fold lower than that of VEGFR2). Based on this weak activity, under 
physiological conditions, VEGFR1 only weakly stimulates endothelial 
proliferation. VEGFR1 is expressed not only on vascular endothelial cells but 
also in monocyte/macrophage-lineage cells. VEGFR-1 is a key receptor in 
developmental vasculogenesis and angiogenesis (i.e. the formation of vessels 
during embryogenesis) but does not appear to be critical to pathogenic 
angiogenesis. Its role appears to vary with stages of development, 
physiological and pathophysiological conditions and cell type. Thus, the 
binding of VEGF-A165 to VEGFR1 induces directed migration of mononuclear 
phagocytes across the endothelial cell monolayer as well as their stimulation 
10 12 35. Macrophages that have migrated via VEGF-A(or PlGF)-VEGFR1 
signalling into tumour tissues or inflammatory areas stimulate pathological 
angiogenesis as well as lymphangiogenesis by secretion of VEGF-A, VEGF-
C, and other cytokines 13-15. In addition, VEGFR1 modulates endothelial cell 
division at the earliest stages of vascular development just before the 
formation of the first primitive blood vessels. Mutant mice embryos lacking 
VEGFR1 (VEGFR1-/-) die at embryonic E8.5-9.0 due to an overgrowth and 
dysfunction of blood vessels, suggesting a negative role of VEGFR1 in 
angiogenesis early in embryogenesis 16. Surprisingly, VEGFR1 tyrosine 
kinase domain-deficient mice (flt-1 TK-/- mice) are basically healthy. Thus, the 
negative role of VEGFR1 is dependent on the extracellular region, most likely 
by trapping the endogenous VEGF-A to decrease its local concentration 17. flt-
1 TK-/- mice under physiological conditions have no phenotype except for a 
minor reduction of osteoclasts in bone marrow, but under pathological 
conditions such as rheumatoid arthritis (RA) and cancer, the levels of 
malignancy of these diseases are significantly reduced. In the RA model, 
inflammatory cell infiltration was strongly decreased, and inflammation at the 
joints was much less extensive in flt-1  TK-/- mice than in wild-type mice. In a 
tumour transplantation model, tumour growth at local sites decreased 
accompanied by less infiltration of macrophage and less angiogenesis. Pre-
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metastatic induction of MMP9 in distant tissues was about one-third, and the 
degree of metastasis was significantly reduced in flt-1 TK-/- mice compared 
with wild-type mice 36. Treatment of tumour-bearing wild-type mice with anti-
VEGFR1 neutralising antibody resulted in a similar reduction in metastasis 37. 
VEGFR2, also referred to as kinase domain region (KDR) in humans and fetal 
liver kinase (Flk-1) in mice, exhibits strong tyrosine kinase activity and plays a 
major role in signalling for angiogenesis. Despite this, its ability to bind with 
VEGF-A is about one order of magnitude weaker than that of VEGFR1. 
VEGFR2-signalling is essential for the development of vascular systems in 
the embryo 38: flk-1-/- mice die at E8.5 due to a lack of blood vessels. 
Activation of the Ras-pathway, which is involved in the signalling of 
representative tyrosine kinase receptors such as EGFR, is minor in VEGFR2 
signalling. Furthermore, a single autophosphorylation site, 1175-tyrosine, is 
critical for the binding of PLCγ and activation of the PLCγ-PKC pathway 39. 
The importance of 1175-tyrosine in vivo was proved by the finding that a 
phenylalanine mutation at this tyrosine in mice (flk-1 1173F/1173F mice) 
induces embryonic lethality at E8.5-9.0 due to a lack of development of blood 
vessels 40. VEGFR2 generates a variety of angiogenic signals not only for 
endothelial proliferation but for cell migration/morphogenesis including tubular 
formation. The 951-tyrosine was shown to regulate cell migration by binding 
with an adaptor, TSAd 41. Nrp1, a co-receptor for VEGF-A165, binds the basic 
stretch of VEGF-A165, increases the affinity of VEGF-A165 for VEGFR2, and 
enhances signalling 41.  
VEGFR3 is mainly expressed in lymph-endothelial cells, and regulates 
lymphangiogenesis with its ligands, VEGF-C and –D 41 42. An inactivation 
mutation at the VEGFR3 tyrosine kinase domain in humans results in familiar 
lymph-oedema syndrome (Milroy disease) due to insufficient development of 
lymph vessel systems. The signalling pathway from VEGFR3 is not fully 
understood yet. PLCã-PKC pathway was activated after VEGF-C stimulation 
41. On the other hand, activation of the Ras-pathway was also reported. It is of 
interest to see whether both pathways are equally activated or one of them 
plays a major role in lymphangiogenesis. 
Thus, VEGFR1 binds VEGF-A, and plays a central role in the regulation of 
angiogenesis, whereas VEGFR3 tightly binds VEGF-C and -D, and stimulates 
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lymphangiogenesis. The receptor VEGFR 2 binds VEGF, VEGF-C and 
VEGF-D and promotes the proliferation and motility of endothelial cells. Whilst 
having highest affinity for VEGF-A (Kd=15-100pM), VEGFR-1 shows 10 fold 
lower kinase activity than VEGFR-2, and has been proposed to act as a 
negative regulator of VEGF-induced endothelial cell proliferation 43. 
 
 
VEGF receptor  Ligand Function 
VEGFR-1 VEGF, VEGF-B, PIGF 
 
Essential for vascular development: 
VEGF signalling, release of growth 
factors 
VEGFR-2 VEGF, VEGF-C, VEGF-D, 
VEGF-E 
Essential for vascular development: 
proliferation, migration and 
angiogenesis 
VEGFR-3 VEGF-C and VEGF-D Proliferation, migration, role in 
vascular development, signals for 
lymphangiogenesis 
 
Table 1.2. Roles of VEGF Receptors and their respective Ligands 
 
VEGF is distributed widely in different tissues. Several studies have 
demonstrated its over-expression in a variety of tumours, including those of 
breast, ovary, bladder, vulva, uterus and cervix 38 44-46.  
Anti VEGF therapy, has been used in clinical trials to inhibit angiogenesis and 
its use is showing promising results in cancer treatment therapies. Preclinical 
models of solid tumours have shown anti-VEGF therapy, to cause a slowing 
of tumour progression, resolution of malignant effusions, and synergy with 
cytotoxic agents 39. 
Bevacizumab, a recombinant humanized monoclonal antibody to VEGF has 
been shown to induce apoptosis of breast cancer cells and has been used in 
a combination with 5 Fu for the first line treatment of metastatic colorectal 
cancer 47.  
The GOG 170-D is a proof of the principle that bevacizumab is active in 
Platinum and taxane resistant ovarian cancer 48. Other ongoing trials including 
GOG-218 and ICON-7 are studying the addition the addition of Bevacizumab 
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to standard frontline chemotherapy. Other agents that target VEGF pathway 
include VEGF Trap, a soluble decoy receptor 42. This causes fusion of the 
IgG1 Fc ligand binding domains of VEGFR-1 and VEGFR-2. It has been 
shown to suppress tumour angiogenesis and growth in multiple preclinical 
models 49 50. It is currently undergoing phase I evaluation.  
 
 
1.2.2.3 VEGF-independent regulation of angiogenesis 
Pro angiogenic Pathways 
(a) Platelet Derived Endothelial Growth Factor/Thymidine Phosphrylase  
Originally isolated from platelets in 1987 platelet derived endothelial growth 
factor (PDEGF) is a 47 kilodalton (KDa) protein that promotes cell growth and 
chemotaxis in endothelial cells in vitro and angiogenesis in vivo 51. It is a non-
glycosylated intracellular protein with no heparin binding activity, found in 
various tissues such as peripheral lymphocytes, placenta, lung and 
endometrium 52-54, as well as in certain cancers, including breast, bladder, 
colorectal, cervical, endometrial and ovarian tumours52 55-57. The enzyme 
thymidine phosphorylase (TP) which catalyses the reversible breakdown of 
thymidine to thymine and 2 deoxyribose phosphate has been identified as 
being homologous to PDEGF 58 59. The by-product 2-deoxy-D-ribose has been 
shown to have angiogenic activity 60. The role of PDEGF/TP is primarily 
metabolic, controlling the thymidine levels in the cell. Accumulation of 
thymidine is toxic to the cells and causes errors in DNA replication, integrity 
and repair. However high levels of TP have been identified in macrophages 
61, suggesting that it provides other functions such as angiogenic activity. 
PDGF is an important regulator of angiogenesis via stimulation of the 
proliferation and survival of smooth muscle cells and pericytes. However in 
certain culture conditions, PDGF also stimulates endothelial cell growth. It is 
therefore of interest that whether under pathological conditions or after 
massive anti-VEGF therapy, PDGF becomes a major player to stimulate the 
proliferation of vascular endothelial cells or not 33.   
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(b) Angiopoietin  
The angiopoietins are protein growth factors that promote angiogenesis. 
There are now four identified angiopoietins: Ang1, Ang2, Ang3, and Ang4. 
Ang1 and Ang2 are required for the formation of mature blood vessels, as 
demonstrated by mouse knock out studies 62. Angiopoietin 1 (Ang 1) and Ang 
2 are growth factors that are ligands for the “Tie” family of receptors. These 
are tyrosine kinases that are selectively expressed within the vascular 
endothelium, as are the VEGF receptors 63 64. Although both Ang1 and Ang2 
bind Tie2, Ang 1 functions as an agonist whereas Ang2 behaves as an 
antagonist at this receptor 65. Ang2 can cause regression of newly formed 
vessels by stimulating endothelial cell apoptosis, unless VEGF is present in 
which case the two collaborate to promote angiogenesis 66.  
 
(c) The Ephrin Family   
The ephrin (Eph) family represents the largest subgroup of receptor tyrosine 
kinases, with most vertebrate genomes having 14 members 67. Eph receptors 
can be divided into two classes based on sequence similarity and ligand 
binding affinity: an A-subclass containing 9 members (EphA1-8, 10) and the 
B-subclass containing 5 members 68 69. The Ephb2-4 signaling system is 
relatively specific to the vascular system. It is thought to regulate the 
differentiation of arteries and veins, being less effective for the proliferation of 
endothelial cells. Knockout studies have suggested roles for Ephrin B4 and its 
EphB4 receptors during vascular development, mouse embryo’s lacking 
ephrin B2 and ephrin B4 suffer fatal defects in early angiogenic remodeling 
that are similar to those seen in mice lacking Ang1 or the Tie2.  
 
(d) Tissue Selective Angiogenic Stimulators 
Recently the identification of an angiogenic mitogen selective for one 
endothelial cell type, the endocrine gland endothelium, has been reported and 
has been designated endocrine gland derived VEGF 70. The expression of 
this factor is mainly restricted to steroidogenic glands such as the ovary, 
testis, adrenal cortex and placenta 71. Although this protein shows no 
structural homology with the VEGF family, it displays several striking 
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biological similarities to VEGF; it induces endothelial proliferation and 
migration and has the ability to induce fenestration in capillary endothelial 
cells derived from endocrine glands 70 and it is also regulated by hypoxia.  
Angiogenesis Inhibitors   
Angiogenesis inhibitors may either be endogenous or exogenous drug or 
dietary. The endogenous angiogenesis inhibitors are a large, structurally 
diverse family of protein molecules. Some of these are internal fragments of 
various proteins that lack any anti-angiogenic activity 72 73 for example 
angiostatin is one or more fragments of plasminogen 74 and endostatin is a 
fragment of type XVIII collagen 75. Many of the precursor proteins are 
components of the extracellular matrix/basement membrane or members of 
the clotting/fibrinolytic pathways (plasminogen and anti-thrombin III) 76.  
 
 
Table 1.3. Role of various angiogenic inhibitors 
 
Inhibitors Mechanism 
soluble VEGFR-1 and NRP-1 decoy receptors for VEGF-B and PIGF 
Angiopoietin 2 antagonist of angiopoietin 1 
TSP-1 and TSP-2 inhibit cell migration, cell proliferation, cell adhesion and survival of endothelial cells 
angiostatin and related molecules inhibit cell proliferation and induce apoptosis of endothelial cells 
endostatin inhibit cell migration, cell proliferation and survival of endothelial cells 
vasostatin, calreticulin inhibit cell proliferation of endothelial cells 
platelet factor-4 inhibits binding of bFGF and VEGF 
TIMP and CDAI inhibit cell migration of endothelial cells 
Meth-1 and Meth-2  
IFN-α, -β and -γ, CXCL10, IL-4, -12 and -18 inhibit cell migration of endothelial cells, down-regulate bFGF 
prothrombin (kringle domain-2), antithrombin 
III fragment inhibit cell proliferation of endothelial cells 
prolactin inhibit bFGF and VEGF 
VEGI affects cell proliferation of endothelial cells 
SPARC inhibit binding and activity of VEGF 
osteopontin inhibit integrin signaling 
maspin inhibits proteases 
canstatin  
proliferin-related protein  
restin  
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Endogenous angiogenesis inhibitors act as tumour suppressor proteins, 
analogous to the tumour suppressor p53. Tumour growth in transgenic mice 
overexpressing endostatin in endothelial cells (a 1.6 fold increase in 
circulating levels) is 3 fold slower than the tumour growth in wild-type mice 77. 
These mice mimic humans with Down’s syndrome who have 1.6 -2.0 fold 
elevated levels of endostatin as a result of a third copy of collagen XVIII on 
the trisomic chromosome 21. Individuals with Down’s syndrome are the most 
protected against cancer of all humans 78. In these individuals the incidence of 
all malignant tumours is < 0.1 their expected amount, except for testicular 
cancer and megakaryocyte leukaemia 79. The high circulatory levels of 
endostatin also protect against two other angiogenesis dependent diseases: 
retinal neovascularization in diabetes and atherosclerosis 80. Individuals with 
Down’s syndrome have the same incidence of diabetes as the general 
population but have a low incidence of diabetic retinopathy, even with long 
standing diabetes. 
 
 
1.2.3 Drug Development in Angiogenesis 
 
1.2.3.1 Angiogenesis Inhibitors  
The first angiogenesis inhibitors were reported in the 1980’s from the Folkman 
group 81 82. Angiogenesis inhibitors were not known before the 1980’s and 
there was much speculation amongst the scientific community that such 
agents would be found. However the drive to isolate and purify them was 
driven by preliminary data, that led to the 1971 hypothesis that tumour growth 
is dependent on angiogenesis 3. After the mid 1980’s the Folkman group and 
other groups began to discover additional angiogenic inhibitors 74 83-85. Anti-
human VEGF-A neutralising antibody was previously shown to significantly 
decrease the growth of transplantable human tumours in nude mice, 
suggesting the blocking of VEGF-A to be useful for the suppression of solid 
tumour in humans 86.  
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At present there are approximately forty drugs, in which anti-angiogenic 
activity is central to therapeutic effect, and they have been approved by the 
FDA in the United States for the treatment of cancer and age related macular 
degeneration.  
 
 
Drug Company Target Clinical development 
Monoclonal antibodies targeting VEGF-A  
 Bevacizumab 
(Avastin®) Genentech VEGF-A Phase I, II, III 
 VEGF-Trap Regeneron VEGF-A Phase I 
        
Antibodies targeting VEGFR-2  
 IMC-1C11 Imclone VEGFR-2 Phase I 
        
Receptor tyrosine kinase inhibitors  
 SU5416 Sugen/Pharmacia VEGFR-2 Phase I, II, III 
 SU6668 Sugen/Pharmacia VEGFR-2, bFGFR, PDGFR Phase I, II 
 SU11248 Sugen/Pharmacia VEGFR-2, PDGFR,   
 c-Kit, Flt-3 Phase I     
 PTK787/ZK22854 Schering/Novartis VEGFR-1, VEGFR-2 Phase I 
 ZD6474 Astra Zeneca VEGFR-2, EGFR Phase I, II 
 CP-547,632 Pfizer VEGFR-2, EGFR, PDGFR Phase I 
        
Inhibitors of endothelial cell proliferation  
 ABT-510 Abbott Endothelial CD-36 Phase I, II 
 Angiostatin Entremed Various Phase I 
 Endostatin Entremed Various Phase I 
 TNP-470 TAP Methionine aminopeptidase, cyclin dependent kinase 2 Phase I 
 Thalidomide Grunenthal Reduction of TNF-  production Phase I, II, III 
        
Inhibitors of integrin activity  
 Vitaxin MedImmune Integrin αVβ3 Phase I, II 
 Medi-522 MedImmune Integrin αVβ3 Phase I 
 Cilengitide Merck KgaA Integrin αVβ3 Phase I 
        
Vascular targeting agents  
 Combretastatin A4 Oxigene Endothelial tubulin Phase I 
 AVE8062A Aventis Endothelial tubulin Phase I 
 ZD6126 Astra Zeneca Endothelial tubulin Phase I 
 DMXAA   Induction of TNF-   Phase I 
 
Table 1.4. Angiogenesis inhibitors in clinical trials 
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The list below includes cancers that are being studied in active Phase 3 
treatment clinical trials using angiogenesis inhibitors. The clinical trials are in 
the National Cancer Institute’s (NCI) clinical trials database at 
http://www.cancer.gov/clinicaltrials/search. 
• Breast cancer 
• Oesophageal cancer 
• Gastrointestinal Stromal Tumors (GIST) 
• Kidney (renal cell) cancer 
• Leukaemia 
• Liver (adult primary) cancer 
• Lymphoma 
• Melanoma 
• Multiple myeloma 
• Non-small cell lung cancer (NSCLC) 
• Ovarian epithelial cancer 
• Pancreatic cancer 
• Prostate cancer 
• Stomach (gastric) cancer 
 
VEGFR is a typical tyrosine kinase; various small chemicals that block kinase 
activity have been tested in the clinical field and so far two such inhibitors, 
Sorafenib (Raf and VEGFR inhibitor) and Sunitinib (VEGFR and other 
tyrosine kinase inhibitors), have been approved for the treatment of renal cell 
carcinoma. These inhibitors significantly improve the survival of renal cell 
cancer patients. Furthermore, in late 2007 the FDA approved Sorafenib for 
the treatment of hepatocellular carcinoma patients based on a clinical study. 
Anti-angiogenic therapy has recently been reported to significantly increase 
survival in lung cancer, breast cancer in addition to colorectal cancer (Roy 
Herbst Lecture ASCO May 2005). Another example is Thalidomide which 
suppresses the production of endothelial cell precursors and down regulates 
VEGF; it was approved in Australia in 2003 for the treatment of advanced 
multiple myeloma and is now used as first line therapy for carcinoma of the 
breast, ovary, bladder, vulva, uterus and cervix 38 45 87 88.  
 
Anti-VEGF therapy has been used in clinical trials to inhibit angiogenesis and 
its use is showing promising results in cancer treatment therapies. Preclinical 
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models of solid tumours have shown anti-VEGF therapy to cause a slowing of 
tumour progression, resolution of malignant effusions, and synergy with 
cytotoxic agents 39. Bevacizumab (Avastin), a humanised anti human VEGF-A 
neutralizing antibody was the first drug developed solely as an angiogenesis 
inhibitor, and the first to demonstrate prolongation of survival in patients with 
advanced cancer. It significantly improved the disease free survival rate as 
well as the overall survival rate in late stage colorectal cancer patients in a 
Phase 3 clinical trial and has been FDA approved in 2004 for its use for 
colorectal cancer 89. Bevacizumab has also approved for the treatment of 
non-squamous non-small cell lung cancers, the major type of which is 
pulmonary adenocarcinoma 90. The main reason that it has not been applied 
to squamous-type lung cancer is because of the risk of severe thrombosis and 
haemorrhage 91. The Gynecologic Oncology Group (GOG) 170-D study is a 
proof of the principle that bevacizumab is active in platinum and taxane 
resistant ovarian cancer 92. Other ongoing trials including GOG-218 and 
ICON-7 are studying the addition of bevacizumab to standard frontline 
chemotherapy. Other agents that target the VEGF pathway include VEGF 
Trap, a soluble decoy receptor that causes fusion of the IgG1-Fc ligand 
binding domains of VEGFR-1 and VEGFR-2 42. It has been shown to 
suppress tumour angiogenesis and growth in multiple preclinical models 49 50. 
It is currently undergoing phase I evaluation.  
The increasing availability of approved angiogenesis inhibitors, their relatively 
low side effect profile and their low incidence of drug resistance, will enable a 
new approach to cancer based therapy. The evolution and discovery of 
angiogenesis biomarkers are under development of include  
 
1) Quantification of urinary metallinoprotineases 93  
2) Analysis of the platelet angiogenic proteome 94  
3) Measurement of blood levels of circulating endothelial cell precursors 
(CEPS) 95 
4) Measurement of mature endothelial cells (CECS) 95 
 
These methods can detect human tumours in mice at sizes of millimeters or 
less. In the future, it may be possible to detect recurrent cancer by these and 
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other biomarkers and to use them to guide anti-angiogenic therapy prior to the 
onset of recurrent disease or before imaging can detect and or the 
visualisation of macroscopic tumour is possible.  
 
 
1.2.4   Angiogenesis and Cancer 
 
 
Cancer is defined in Wikipedia as  ‘a class of diseases in which a group of 
cells display uncontrolled growth (division beyond the normal limits), invasion 
(intrusion on and destruction of adjacent tissues), and sometimes metastasis 
(spread to other locations in the body via lymph or blood). These three 
malignant properties of cancers differentiate them from benign tumours, which 
are self-limited, and do not invade or metastasize.’ 
  
In a seminal paper based on his own work as well as a number of other 
studies, Judah Folkman in 1971 proposed that angiogenesis was an important 
process in tumour growth and metastases 3,  and that the inhibition of 
angiogenesis might be exploited as a means for treating cancer (Folkman 
1972 anti-angiogenesis: new concept for therapy). The central point of the 
hypotheses was that most tumours go through a prolonged state of avascular 
dormant growth attaining a maximum size of 1-2mm in diameter, the 
maximum size that tumour cells can obtain the necessary nutrient supplies 
and oxygen that they require for growth by passive diffusion. These cells, in 
response to stimulating factors, switch on angiogenesis by recruiting 
surrounding blood vessels to sprout new vessels which grow toward and 
infiltrate the tumour mass thus setting the potential for growth and metastases 
96-99. Folkman hypothesized that by blocking angiogenesis, established solid 
tumours could regress to a size of 1-2mm where survival is possible without a 
blood supply. Therefore the development of tumours is associated with two 
phases of tumour growth: the pre-vascular phase and the vascular or the 
angiogenic phase 8 97 100. The pre-vascular phase is seen with various 
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intraepithelial neoplasia and can persist for many years and is not capable of 
metastases 96. The angiogenic phase occurs when a tumour possesses the 
innate ability to potentiate its own growth. Oncogenesis of this type whereby 
the extent of neovascularisation is directly correlated with metastases has 
been demonstrated in several cancers, for example breast cancer 96  and in 
cutaneous melanoma 6. Thus angiogenesis is a crucial factor in the 
progression of solid tumours and metastases 3 101. 
 
 
 
 
Figure 1.5. Angiogenesis is a hallmark of tumour development: To grow 
beyond 1 to 2 mm in diameter, a tumour needs an independent blood supply, 
which is acquired by expressing growth factors that recruit new vasculature from 
existing blood vessels. This process continues even as the tumour matures. 
Reproduced from http://www.biooncology.com/research-education/vegf/multimedia/ 
index.html#resourcePlayer/SlideDecks 
 
 
A series of elegant experiments where tumours were transplanted into an 
avascular environment proved that angiogenesis was a control point in tumour 
growth: the tumour cells remained dormant indefinitely. However the 
acquisition of a blood supply resulted in a rapid logarithmic growth 102. 
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The normal regulation of angiogenesis is governed by a fine balance between 
factors that induce the formation of blood vessels and those that halt or inhibit 
the process. The list of known angiogenic stimulators and inhibitors grows 
yearly. There are now over 35 activators and 18 suppressants of 
angiogenesis. While numerous pro-angiogenic factors have been 
characterised, the VEGF ligand identified by Dvorak et al in 1979 has been 
identified as the predominant regulator of tumour angiogenesis 103.  
 
 
 
Figure 1.6. The classical angiogenic switch. The angiogenic switch is a 
discrete step in tumour development that can occur at different stages in the 
tumour-progression pathway, depending on the nature of the tumour and its 
microenvironment. Most tumours start growing as avascular nodules 
(dormant) (a) until they reach a steady-state level of proliferating and 
apoptosing cells. The initiation of angiogenesis, or the ‘angiogenic switch’, 
has to occur to ensure exponential tumour growth. The switch begins with 
perivascular detachment and vessel dilation (b), followed by angiogenic 
sprouting (c), new vessel formation and maturation, and the recruitment of 
perivascular cells (d). Blood-vessel formation will continue as long as the 
tumour grows, and the blood vessels specifically feed hypoxic and necrotic 
areas of the tumour to provide it with essential nutrients and oxygen (e) 104.  
VEGF is expressed in a wide variety of human malignancies. The VEGF 
ligand may affect tumour vasculature in 3 essential ways. Early in tumour 
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development, VEGF may help new vasculature establish. Specifically, VEGF 
has been shown to stimulate tumour growth at both primary and metastatic 
sites through the recruitment of bone-marrow−derived progenitor cells that 
form the building blocks of a new vascular network. As this network develops, 
VEGF may continue to help new vasculature grow, providing the blood supply 
needed to drive further tumour growth and metastasis. Throughout tumour 
development, VEGF may also help existing vasculature survive, allowing 
tumours to sustain their metabolic requirements over their entire life cycle 105. 
 
 
 
 Helps tumour 
vessels 
ESTABLISH 
Helps tumour 
vessels 
GROW 
Helps tumour 
vessels 
SURVIVE 
Proposed 
mechanism 
Recruitment of 
progenitor 
cells to primary and 
metastatic sites 
 
Stimulation of 
endothelial cell 
proliferation, 
migration, and 
invasion 
Inhibition of 
endothelial 
cell apoptosis 
Effect on 
tumour 
growth 
Helps tumour cells 
seed and form 
pre-metastatic 
niches 
Provides the blood 
supply needed for 
tumours to grow 
beyond 1 to 2 mm 
Maintains a 
vascular network 
that fuels 
continued tumour 
growth and survival 
 
 
Table 1.5. Proposed effects of the VEGF ligand 
 
 
The VEGF ligand is the only angiogenic factor known to be present 
throughout the entire tumour life cycle. As the tumour develops, it may begin 
to activate secondary angiogenic pathways, such as basic fibroblast growth 
factor (bFGF), transforming growth factor beta (TGFß), placental growth factor 
(PlGF), and platelet-derived endothelial cell growth factor (PD-ECGF). As 
these secondary pathways emerge, the VEGF ligand continues to be 
overexpressed and remains one of the critical mediators of angiogenesis 106-
109. 
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Figure 1.7 VEGF is expressed throughout the tumour life cycle. As the tumour 
matures, secondary angiogenic factors may be increasingly produced110. Reproduced 
from http://www.biooncology.com/research-education/vegf/multimedia/index.html#resourcePlayer/SlideDecks  
 
 
The observation that tumours are highly dependent on VEGF early in 
development and are continuously dependent on VEGF throughout their life 
cycle is reflected by preclinical research with VEGF inhibitors. In these 
experiments, VEGF inhibition has demonstrated significant antitumour effects 
when administered throughout tumour development 111 112.  
Inhibition of VEGF causes regression of immature vessels but does not 
disturb normal mature blood vessels. There are physiological differences 
between mature blood vessels and the immature blood vessels seen in 
tumour 113. There is extensive endothelial membrane remodeling, leading to 
tubule and loop vessel formation. The maturation of new vasculature is 
accomplished by the recruitment of pericytes, which stabilise the new vessels. 
During normal maturation, growth factors are not needed for endothelium 
survival. Maturation of the vessels is usually not complete in neoplastic 
growth; there is constant vascular remodeling leading to microvessel invasion 
into the tumour stroma, which feeds tumour growth. Endothelial cells of 
immature blood vessels need growth signals for survival to avoid programmed 
cell death (apoptosis).  
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Figure 1.8 By inhibiting the VEGF protein, the blood supply to a tumour may be gradually 
reduced. Reproduced from http://www.avastin.com/hcp/overview/resources/moa/index.html 
 
Physiologically VEGF gene expression is regulated by mutations in the 
tumour suppressor gene p53 and transient tissue hypoxia, such as that 
occurring in poorly vascularised areas of tumours 114-116. 
 
NORMAL VASCULATURE TUMOUR VASCULATURE 
Organised Disorganised 
Evenly distributed and non 
permeable 
Serpentine and leaky 
Properly maintained Immature 
Supporting  cells present (pericytes) Supporting cells deficient 
Appropriate expression of                         
membrane proteins 
Inappropriate expression of membrane 
proteins eg integrins 
 
Table 1.6. Histological differences between normal and tumour vasculature 
 
Over-expression of VEGF has been observed across a range of tumour types 
including colon, lung, breast, renal, ovarian, prostate and other cancers and 
has been widely associated with tumour development and/ or poor prognosis 
117-119. Because it drives tumour growth through multiple stages of 
development, direct and indirect continuous inhibition of the VEGF ligand is a 
rational anti-tumour strategy. 
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There are two primary strategies for inhibiting the VEGF pathway; these 
include inhibiting either the VEGF ligand or the VEGF receptor 118. Anti-VEGF 
strategies that directly target the VEGF ligand include ligand-binding 
antibodies and soluble receptors. These agents work extracellularly to provide 
specific inhibition of the VEGF pathway without disrupting other non-
VEGF−related targets. Therefore, they may inhibit angiogenesis without 
affecting other secondary—or “off-target”—pathways 107 120 121. Anti-VEGF 
strategies that target the VEGF receptor include tyrosine kinase inhibitors 
(TKIs) and receptor antibodies. Agents that target the VEGF receptor 
intracellularly, such as TKIs, have a wider range of inhibitory effects and may 
disrupt other secondary pathways that are also mediated through receptor 
kinases 107 120 122. 
Finally, although the amount of VEGF that is produced and released may 
change in response to certain stimuli within the tumour environment, VEGF is 
thought to be a genetically stable protein that may be relatively unsusceptible 
to mutation 118 123.,This genetic stability may make continued targeting of the 
VEGF ligand a rational antitumour strategy.It is envisaged that a better 
understanding of these aspects of tumour biology will provide insight into the 
factors involved in tumour progression and potentially lead us to new 
therapeutic strategies.  
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Figure 1.9 Strategies for inhibiting the VEGF pathway 118. Reproduced from 
http://www.biooncology.com/research-education/vegf/multimedia/index.html#resourcePlayer/SlideDecks 
1. Some anti-VEGF strategies specifically target the ligand, allowing for 
controlled inhibition of the VEGF pathway. 
2. Other strategies target the receptor. Some of these approaches (e.g., TKIs) 
have a wider range of inhibitory effects and may also disrupt other non-
VEGF–mediated pathways. 
 
 
1.3    OVARIAN CANCER 
 
Ovarian cancer is the fourth most common cancer amongst women in the 
United Kingdom and the leading cause of gynaecological cancer deaths. In 
addition, ovarian cancer is the fifth most common cause of deaths in women 
with over approximately 4400 deaths from the disease every year ( Cancer 
Research UK 2008 Cancer Statistics Registrations 2008).  
The natural history of ovarian cancer development, including the nature of the 
precursor cell type is poorly understood. Approximately 90% of malignant 
ovarian tumours are epithelial in origin, the remainder are germ cell tumours. 
Various theories have been suggested alluding to the development of ovarian 
cancer, including: 
 
 38 
1. Incessant ovulation theory 124 suggests that the risk of ovarian cancer 
increases as a result of the recurrent minor trauma to the ovarian 
surface epithelium that occurs during ovulation. The suggestion is that 
the greater the number of times the ovarian surface epithelium 
undergoes repair and regeneration, the greater the chance will be that 
aberrations leading to a malignant transformation will occur.   
 
2. The gonadotrophin theory125 suggests that high levels of 
gonadotrophins, especially in the early menopausal years, are 
associated with an increased risk of ovarian cancer as a result of 
oestrogen or oestrogen precursors stimulating the ovarian surface 
epithelial lining of ovarian inclusion cysts. Inclusion cysts are benign 
vacuoles that can form and imbed in the ovarian stroma following 
repair to the ovarian surface epithelium. Histologically, the epithelial 
lining of these cyst appear normal.  
 
3. Retrograde transportation hypothesis 126 suggests that certain 
carcinogenic factors, e.g. talc, gain access from the uterus through the 
fallopian tubes to the ovaries thereby increasing the risk of ovarian 
cancer.  
 
All of the above theories have been supported by data from epidemiological 
studies; but no single theory seems has been substantiated thus far. Our 
understanding of the molecular and genetic events underlying the basis of 
ovarian cancer development, which may in turn provide support or refute 
these theories are also poorly understood127 . 
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Figure 1.10. Pathways to EOC are influenced by events at ovulation, 
including hormonal stimulation and inflammation. Post-ovulatory re-
epithelialisation involves OSE (blue cells) cell division and possibly 
migration, to cover the ovulatory lesion (black arrows). Hyperplasia and 
transformation of the OSE to adenocarcinoma can occur directly (red arrow 
top left). The pre-ovulatory luteinising hormone surge induces increased 
expression of cytokines and invasion of macrophages and monocytes 
(orange cells), leading to differentiation of follicle cells into luteal cells. 
Ovulation stimulates formation of invaginations and the formation of 
inclusion cysts. Cyst cells may differentiate to take on müllerian 
characteristics under the influence of hormonal or cytokine stimulation and 
become ciliated (yellow cells) or secretory (tan cells), as shown on the right 
hand side of the figure. Rete ovarii tubules at the hilus of the ovary, close to 
the mesothelium to OSE transition (M–E), also contain ciliated and 
secretory cells and can dilate to form cysts, at least in rodents. It is still not 
known whether cells in both cyst types can transform to become 
cancerous. Furthermore, the role of any proposed ovarian stem or 
progenitor cells (purple cells) in epithelial ovarian carcinogenesis remains 
to be elucidated. 128 
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1.3.1 Causes and pathogenesis 
 
Although the subtypes of epithelial ovarian cancer have unique molecular 
alterations and transcriptional signatures, their morphological features 
resemble the specialised epithelia of the reproductive tract that derive from 
the Müllerian ducts. Current research postulates that they might all arise from 
one surface epithelium precursor cell with specific path of differentiation 
regulated by embryonic pathways involving HOX genes 129-131. 
 
HOX genes are not usually expressed in ovarian surface epithelium. 
However, expression of HOXA9, HOXA10, and HOXA11 in cells derived from 
ovarian surface epithelium in tumourigenic mice induces these cells to 
differentiate along distinct Müllerian lineages, giving rise to tumours with 
morphological features that are characteristic of serous, endometrioid, and 
mucinous ovarian tumours, respectively. HOXA7 controls extent of 
differentiation and grade of ovarian tumours. Since sex steroids regulate HOX 
expression throughout the menstrual cycle, protracted exposure of ovarian 
surface epithelium cells to these hormones in adult women might contribute to 
inappropriate HOX activation, perhaps in the context of epithelial inclusion 
cysts and excessive autocrine or paracrine stimulation leading to proliferation 
and genomic instability. 
 
Genomic mutations have a vital role in the development of many forms of 
cancer. High-prevalence somatic (non-germline) mutations (>5%) have been 
reported in only a small number of genes in epithelial ovarian cancer. Like the 
HOX gene changes, these mutations occur in a histological subtype-specific 
and grade-specific manner, and identify genes whose functional perturbation 
probably has a role in ovarian carcinogenesis. These genes include TP53, 
CTNNB1, and PTEN (all inactivated), and KRAS, PIK3CA, and AKT1 (all 
activated) 129 132 133. 
  
Hereditary (germline) BRCA1 and BRCA2 mutation-related epithelial ovarian 
cancers tend to occur at an earlier age than do sporadic tumours and are 
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more often high-grade serous tumours with P53 dysfunction 134. Like many 
solid tumours, epithelial ovarian cancers frequently have a high amount of 
chromosomal instability (gene copy number amplifications and deletions), and 
both total and regional instability are associated with tumour grade and patient 
outcome 135. Although such aberrant areas of DNA frequently carry many 
genes, only a small number of genes are thought to be key drivers of the 
process; these key drivers are the most crucial markers and potential 
treatment targets. Since inhibition of protein function is generally believed to 
be more achievable than is restoration of function, most investigators focus on 
areas of chromosomal gain (amplicons) for identification of novel potential 
targets for therapy. Candidate drivers at areas of copy number gain that have 
been identified in ovarian tumours include RAB25 at 1q22, EVI1 (ecotropic 
viral integration site-1), PRKCi (protein kinase C iota), SKIL, BCL6, the 
initiation factor EIF5A2, and PIK3CA at 3q26·2, MYC and PVT1 at 8q24·2, 
RSF1 (remodeling and spacing factor 1) and PAK1 at 11q13, HER2 (also 
known as ERBB2) at 17q12, AKT2 at 19q13·2, and ZNF217, AURKA (Aurora 
Kinase), PTK6, and EEF1A2 at 20q13·2 86 98 136. 
Some of these genes can be targeted with novel agents that are in preclinical 
or early clinical assessment. Rearrangements, epigenetic changes, and 
imprinting also affect cellular function and identify potentially important 
markers and therapy targets. 
In one model of ovarian carcinogenesis, epithelial ovarian cancers are divided 
into two categories that are designated type I and type II tumours, 
corresponding to two main pathways of tumourigenesis 96 127 130. Type I 
tumours arise in a stepwise manner from borderline tumours and include low-
grade serous carcinomas, mucinous, endometrioid, and clear-cell carcinomas. 
Type II tumours arise de novo and include high-grade serous carcinoma, 
malignant mixed mesodermal tumours, and undifferentiated carcinomas. Type 
II tumours are characterised by frequent TP53 mutations, genomic instability, 
and BRCA mutations in some cases. This model of carcinogenesis reconciles 
the relation of borderline tumours to invasive carcinoma and provides a 
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morphological and molecular framework for studies aimed at elucidating the 
pathogenesis of epithelial ovarian cancer 126. 
Recent evidence, have led to suggest that both type 1 and type 2 tumours develop 
from extraovarian tissue, from the fallopian tube, and the fallopian tube peritoneal 
junction, rather than the ovarian surface epithelium, that was previously believed 137 
138. 
 
 
1.3.2 Epidemiological and Genetic Risk Factors 
1.3.2.1 Age 
The single biggest risk factor for ovarian cancer is age.  There is a 
progressive increase in ovarian cancer incidence with age. For epithelial 
ovarian tumours, the risk of disease in women under the age of 30 is low even 
in families with evidence of a hereditary basis of ovarian cancer. From 30 to 
50 years of age, ovarian cancer incidence increases in a linear fashion. It then 
continues to increase at a lower rate, reaching a maximum incidence of 60.5 
per 100,000 in the 75 to 79 year age group (data from the US Surveillance, 
Epidemiology and End Result. 
 
Figure 1.12 Age-associated incidence of epithelial ovarian cancer (data from 
the Surveillance Epidemiology and End Results Program of the National 
Cancer Institute) 
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1.3.2.2 Geography 
 Ovarian cancer incidence varies widely across different geographic regions 
and ethnic groups (see Figure 3). The highest incidence is in Northern Europe 
(14. cases per 100,000 women in Sweden) and the United States (13.3 cases 
per 100,000 women); the lowest incidence is in Japan (2.7 cases per 100,000 
women). In Pakistan the risk of Ovarian cancer is similar in incidence to the 
West, with an ASR of 10.1 per 100,000. As with other cancers, there are 
obvious increases in risk in populations that migrate from a country with low 
risk to a country of higher risk indicating a possible role for dietary and 
environmental factors. 
 
Figure 1.12: Geographical variation in incidence and mortality rates for 
epithelial ovarian cancer (data from the GLOBOCAN 2002 database 
project hosted by the Descriptive Epidemiology Group at the 
International Agency for Research on Cancer) 
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1.3.2.3 Family history 
The majority of ovarian cancer cases are sporadic, and the lifetime risk of 
developing ovarian cancer is between 1 -2 %. However, 5-10% of cases of all 
ovarian cancer cases have a hereditary basis (i.e. they are familial). Despite 
this, the single greatest ovarian cancer risk factor is a family history of the 
disease; the relative risk of ovarian cancer in a woman with an affected first 
degree relative is 3.1 (95% CI:2.6-3.7). The level of ovarian cancer risk is 
correlated with the number of affected first and second-degree relatives and 
the age at diagnosis- the highest risk is associated with women below the age 
of 50 that have a first degree affected relative under 50.  
There are at least two groups of individuals with a hereditary predisposition to 
ovarian cancer for which pedigree analyses suggest autosomal dominant 
transmission with variable penetrance. Families with the BReast CAncer 1 
and 2 (BRCA1 and BRCA2) mutations are responsible for approximately 90 % 
of families with strong history of ovarian cancer (more than 3 cases in first 
degree relatives) or multiple cases of ovarian and breast cancer. The lifetime 
risk of developing ovarian cancer for BRCA1 carriers is 16-44% and for 
BRCA2 carriers 27% 139-142. 
The BRCA1 gene is located on chromosome 17q21; it consists of 22 coding 
exons distributed over 100kb of genomic DNA. It has 5592bp of coding 
sequence and encodes a protein of 1863 amino acids. Approximately 80% of 
the mutations are frame shift or nonsense mutations causing truncation of the 
protein 143. In 1994 Wooster et al localised the second breast ovarian cancer 
gene at chromosome 13q12-13 144. The BRCA2 gene consists of 26 coding 
exons distributed over approximately 70kb of genomic DNA. It has 10254bp of 
coding sequence and encodes a protein of 3418 amino acids. There are 
approximately 100 separate mutations described thus far, and as is for 
BRCA1, these are scattered throughout the coding sequence and, apart from 
several distinct founder mutations 145. 
BRCA1 and BRCA2 both function as tumour suppressor genes, and are 
involved in specific pathways of DNA repair and are likely to be involved in 
specific carcinogenic pathways in conjunction with other genes 146. Therefore 
the inactivation of BRCA1 or BRCA2 may lead to an increased frequency of 
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DNA breaks, leading to alteration of other genes involved in growth regulation 
and transformation and thus predisposing to an increased susceptibility to 
cancer 147.  
Ovarian cancer is also part of the phenotype of hereditary non-polyposis 
colorectal cancer (HNPCC) syndrome (alternatively known as the Lynch 
syndrome), which is commonly associated with inherited susceptibility to 
colorectal, gastric and endometrial cancers. The lifetime risk of ovarian cancer 
for a carrier in a HNPCC family is about 10%148. HNPCC families are caused 
by mutations in one of several genes that function in DNA mismatch repair 
pathway. 
High-risk genes that cause ovarian cancer are rare and are responsible for 
only 30% of the excess familial ovarian cancer risk. It is likely that the 
remaining familial risks are the result of more common but less penetrant 
genetic variation (moderate risk genes); but these genes await identification 
 
1.3.2.4 Reproductive And Hormonal Factors 
Early menarche and late menopause, have been implicated as risk factors in 
the development of ovarian cancer, however there have been several 
epidemiological studies that have looked at age at menarche as a risk factor 
for ovarian cancer. In general, these have found no association 149-153.  
Although no association has been found between age at menopause ovarian 
cancer risk for most studies 151-154, a small number of studies have suggested 
that late menopause may increase risk with estimates ranging from 1.5 to 2.9 
fold increased risks in oldest menopause groups compared with younger 
referents 150 153 155. 
  
1.3.2.5 Parity 
Low parity is a risk factor for ovarian cancer. The association between the 
number of pregnancies and a decreased risk of ovarian cancer is well 
established. Epidemiological studies have continually shown that parity is 
protective against ovarian cancer. Whittemore et al 151 reviewed 12 case-
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control studies and showed that parity was significantly protective effect 
against ovarian cancer; there was an approximately 40% reduction in risk with 
first birth and a further reduction of 10% with each subsequent birth.  
There may also be an association with the age at first birth, although this is 
less clear. Some hospital-based studies suggest that an older rather than 
younger age at first birth is associated with greater risk, but case-control 
studies with population based controls indicate the reverse is true 150 156 157. 
Whilst the impact of term pregnancies on the ovarian cancer risk is clear, the 
effect of miscarriages, terminations and ectopics is not. A case-control study 
from Denmark found no relationship between ovarian cancer and pregnancies 
that fail to go to term 158. However, other studies, suggest that incomplete 
pregnancies confer some risk reduction, albeit a weaker protective effect than 
for full term pregnancies 152 153 157.   
 
1.3.2.6 Lactation 
 Most studies that have separated the effects of breast-feeding from 
pregnancy have demonstrated a small protective effect from lactation. Risk 
estimates range from between 0.6 and 0.9 in parous women who have 
breastfed their children compared with those who have never breastfed 151 157 
159 160.  
 
1.3.2.7 Oral contraceptive pill 
 Based on a large body of epidemiological studies, it is now accepted that the 
oral contraceptive pill (OC) protects against ovarian cancer. The cause of this 
protective effect has been put down to the cessation of ovulation and/or the 
decrease in gonadotrophin levels in mid-cycle. In case-control and 
prospective studies, ‘ever’ users of OCs have been shown to have a lower 
risk compared to never-users 150-152 155 161. 
The protective effect increases with duration of OC use; there is a 10-12% 
decrease in risk associated with a one year OC use 162 and an approximate 
50% decrease after 5 years of use 163. The risk reduction associated with OC 
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use continues for a long time after cessation of the OC; several studies 
showed a 40-70% risk reduction even 10 years after cessation of OC use 150 
151 155 164.   
One recent study even suggested a risk reduction after 25 years of OC use 
150.  OCs confer a protective effect regardless of other known risk factors such 
as parity or age 161 164. However, there does appear to be an additive effect for 
parity and OC use combined; Franceschi et al found that women who have 
two children and have taken the oral contraceptive pill for ≥5 years had a 70% 
risk reduction for ovarian cancer 165.  
The risk reduction for OC use may also be associated with different 
histological sub-type of ovarian cancer. In a case-control study that examined 
the effect of OC use on the risk of mucinous and non-mucinous ovarian 
cancer, by Risch et al found that the risk of mucinous ovarian cancer was not 
reduced in women on the combined oral contraceptive pill 166.   
There are a wide variety of oral contraceptives with differing content of 
oestrogens and progestins. The initial OCs of the 1960s were high dose 
monophasic formulations. Hormonal doses were then reduced in the 1970s 
and in the 1980s biphasic and triphasic formulations were introduced. The 
majority of studies showing the protective role of OCs were based on women 
using the early monophasic formulations. The protective effect appears to be 
present in newer formulations as well; use of one of two types of low dose OC 
formulations (≤35µg of ethinyl oestradiol) compared to never-users was 
associated with a reduced relative risk of ovarian cancer of 0.7 and 0.4 
respectively and there was a risk reduction with multiphasic OCs as well. In 
another study, in which both high and low dose OCs reduced the risk of 
ovarian cancer, the high-dose regimen appeared slightly more effective 167.  
A few studies that have evaluated the effect of progesterone only 
contraceptives on ovarian cancer suggest a protective effect. In a study of 
5000 women receiving medroxyprogesterone injections with a 4-13 years 
follow-up, there was an insignificant decrease in ovarian cancer risk (RR 0.8, 
95%CI 0.1-4.6)168.    
The association between oral contraceptive use and ovarian cancer risk in 
women who are BRCA carriers has also been studied. In a population-based 
study, no association was observed between oral contraceptive use and risk 
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reduction in high-risk women 169. However, in a family based study, a 60% risk 
reduction was observed in women with BRCA mutations who had been on the 
pill for 6 or more years 170. More recently, in a study of 451 BRCA1/2 mutation 
carriers, the odds-ratio for ovarian cancer associated with the use of oral 
contraceptives for 6 or more years was 0.62 (95% CI 0.35-1.09) after 
adjusting for parity 171. 
 
1.3.2.8 Infertility 
In 1992, a collaborative analysis of 12 US case control studies reported that 
the risk of ovarian cancer in nulliparous women who received fertility 
treatment was increased 27 fold. However, this finding should be treated with 
caution for two reasons. Firstly the confidence intervals for this study were 
wide (95% CI 2.3-315.6) 171. Secondly, the individual studies that make-up the 
collaborative differ vastly in the depth with which the relevant information was 
collected; only 3 of the 12 studies contained results regarding infertility 
therapy. Since this report, a further two case-control studies have failed to find 
an association between fertility drug use and ovarian cancer 171 172. 
A number of cohort studies of women undergoing fertility treatment have also 
failed to show an increased ovarian cancer risk associated with infertility 173 
In the largest of these studies, the excess risk of ovarian cancer was 
observed in women with unexplained fertility that had not had any fertility 
drugs 173.  
There are several difficulties in study design that make this a difficult question 
to address, and this may be responsible for some of the disparity observed 
between studies. For example, it is unclear whether the risk of ovarian cancer 
increases as women come to an age where ovarian cancer is more common, 
which coincides with the timing of infertility treatment. In addition, for case-
control studies, there are problems associated with defining the ‘infertility 
type’, the different types of fertility drugs used and in the selection of an 
appropriate control group.  
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1.3.2.9 Hormone replacement therapy 
Issues relating to the use of hormone replacement therapy (HRT) and its 
safety continue to challenge clinicians. 
HRT initially contained oestradiol or conjugated oestrogens only. It then 
became apparent in the 1970s that the use of oestrogen therapy (ET) was 
associated with an increased risk in endometrial cancer. As a result, 
progestins were added to the ET in women with an intact uterus. ET, 
however, continues to be used in women who have undergone a 
hysterectomy. 
Studies on the effect of ET/HRT on the risk of ovarian cancer are 
contradictory. In a recent cohort study that followed 44,241 menopausal 
women for approximately 20 years, a relative risk of 1.6 (95% CI 1.2-2.0) was 
observed among ever-users compared with never users of ET 174. The largest 
risk observed in this study was for women who used ET for 20 years or more: 
the relative risk was 3.2 (95% CI 1.7-5.7). In another study, there was an 
increased risk of ovarian cancer associated with ET of 10 or more years 175.   
Until recently many of the studies that examined the effect of combined HRT 
on ovarian cancer risk have been too small to draw firm conclusions. One 
such study suggested that HRT did not increase the risk of ovarian cancer if 
progestin was used for more than 15 days per month 176. The largest trial so 
far on the effect of HRT on ovarian cancer risk is the Women’s Health 
Initiative (WHI) 177. In this double blind randomised control trial approximately 
17,000 women were randomised to either combined HRT or placebo. After an 
average 5.6 years of follow-up, there was a non-statistically significant 
increase in ovarian cancer risk in users of HRT compared to the placebo 
group (hazard ratio 1.58, 95% CI 0.77-3.24).  
 
1.3.2.10 Talc powder 
There is some evidence to suggest that agents that irritate and inflame the 
ovarian epithelium promote ovarian carcinogenesis. This theory arose from 
observations that asbestos was associated with mesotheliomas in animals 178  
and that particle passage from the vagina to the ovary was possible 179. Talc 
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powder use in the genital area has been postulated to increase the risk of 
ovarian cancer by ascending the genital tract. This theory has been supported 
in a case control study 179 180 that gave an OR of 1.6 (95% CI of 1.18-2.15) 
and that talc use was associated with serous and undifferentiated tumours. 
 
1.3.2.11 Pelvic surgery  
The association between pelvic surgery such as tubal ligation and 
hysterectomy and ovarian cancer has been reported in a number of 
epidemiological studies. Although the Oxford Family Planning Association 
study showed no association between sterilisation and ovarian cancer, (OR 
1.5 [95% CI 0.7-3.1]) 181, the majority of studies support a protective effect 
with observed risk reductions from 10-80% 182-185. 
A similar protective effect was observed in women who underwent 
hysterectomy, although the magnitude of protection appears to be lower than 
that of tubal ligation 182-185. 
Both these operations provide closure of the ovaries to the external genital 
tract and it has been suggested that these operations reduce the risk of 
ovarian cancer by preventing carcinogens from ascending the genital tract. It 
is however interesting that the protective effect has been reported only up to 
20 years after surgery. 
 
1.3.2.12 Endometriosis  
Pathology and epidemiological studies have consistently shown an 
association between endometriosis and ovarian cancer, particularly of the 
endometrioid  186 187 and clear cell  subtypes of ovarian cancer. 
Histopathology studies analysing large series of ovarian tumours have 
identified ovarian endometriotic lesions in 5-10% of cases. These were most 
commonly found in tumours of the endometrioid (up to 60%) and clear cell (up 
to 15%) sub-types, which is disproportionate to the expected frequencies of 
these sub-types of ovarian cancer (10-20% and 3-10% respectively). In 
another study, endometriosis was found in 40% of women with stage I 
 51 
endometrioid or clear cell carcinoma, one third of which were carcinomas 
arising out of the endometriotic lesions. Two theories have been proposed for 
the transformation of endometriosis to ovarian cancer. Firstly, aberrant 
inflammation may serve to promote the growth and invasion of ectopic 
endometrium. Secondly, it has been postulated that the same balance of 
steroid hormones that has been shown to increase the severity of 
endometriosis may also enhance the occurrence of ovarian cancer. 
 
1.3.2.13 Polycystic ovarian syndrome (PCOS) 
Clinical features of PCOS commonly include obesity, infertility, menstrual 
abnormalities and hirsutism. In addition PCOS is also characterised by a 
raised luteinising hormone (LH) to follicle stimulating hormone (FSH), 
increased androgen production and abnormal oestrogen secretion. There is a 
well-established relationship between PCOS and endometrial cancer risk but 
the risks associated with ovarian cancer are less clear. In a case-control 
study188, the risk of ovarian cancer was increased in women with PCOS (OR 
2.5; 95% CI 1.1-5.9) and the risk was greater in women who had not used the 
OC (OR 10.5; 95% CI 2.5-44.2). Other studies, however, found no association 
between PCOS and ovarian cancer 189. 
 
1.3.2.14 Pelvic inflammatory disease 
Pelvic inflammatory disease (PID) can arise as a complication of sexually 
transmitted diseases or after childbirth, terminations and gynaecological 
procedures. Whilst some studies have found a positive association between 
PID and the risk of ovarian cancer 190 others have not 152 183 191. In a Canadian 
study, there was an increased risk of ovarian cancer with one episode of PID 
compared to those with none (OR 1.5, 95% CI 1.0-2.1). Risks were also 
greater if PID had occurred at an earlier age, if the women were nulliparous, 
infertile or had repeated episodes of PID 190. Despite the association between 
human papilloma virus (HPV) and cervical cancer, no association has been 
found with ovarian cancer 192 193. 
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1.3.2.15 Diet 
Diet may affect ovarian cancer risk but there appears to be no consensus 
about which dietary factors may be causative or protective. Several studies 
have suggested a link between one or more of lactose, animal fat, meat, egg 
and cholesterol intake with an increased risk of ovarian cancer 194 195. 
A high consumption of vegetables and olive oil on the other hand may 
decrease risk 195-197. A systematic review of 11 population based case-control 
studies and 5 cohort studies 198 showed a positive association between body 
size and ovarian cancer risk, which is of course associated with dietary and 
calorific intake. These findings have been confirmed in more recent studies 
199-203. 
 
 
1.3.3 Clinical Features of Ovarian Cancer 
 
The clinical manifestations of this malignancy are non-specific and show great 
variability. Pain and abdominal distention provide the most obvious complaints 
either because of the primary ovarian mass, ascites or epigastric omental 
plaque. The gastrointestinal manifestations of ovarian malignancy include 
dyspepsia, vomiting and alteration of bowel habit. Irregular periods, shortness 
of breath and urinary problems are also symptoms of the disease. Owing to 
the silent nature of the initial stages of the disease, there is little correlation 
between symptoms and the stage of the disease. In most cases the disease 
presents at an advanced stage (FIGO stage III and IV). 
Manifestations of extra abdominal disease can include nodal metastases 
(especially inguinal or supraclavicular), pleural effusions and uncommon 
deposits in breast, lung, bone, or skin, including the umbilicus (Sister Joseph’s 
nodule). Pleural effusions alone does not allocate a patient to stage IV 
disease unless malignancy is confirmed by exfoliative cytology. Rarely 
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respiratory symptoms may dominate the clinical picture and an ovarian 
primary source may be occult or even undetectable. 
Bilateral involvement of the ovaries is common, but it is unclear whether this is 
due to metastatic spread or multicentric origin. Possible routes of spread to 
the opposite ovary include transperitoneal seeding, cell migration through the 
tubes and endometrial cavity and lymphatic spread via anastomoses between 
ovarian and uterine lymphatic vessels. The uterus is frequently involved with 
tumour. Extension to the endometrium may be via the lymphatics or by 
luminal migration of tumour cells through the tube. In advanced stages of 
ovarian cancer the peritoneal wall, diaphragm and omental structures are 
seeded with micro and macrometastases of tumour cells (transcoelomic 
spread). Lymphatic dissemination to the pelvic (48-80%) and para-aortic 
lymph nodes (58-78%) 204  are also common especially in advanced disease. 
Ascites is associated with ovarian cancer of stages III and IV. Ascitic fluid 
arises as a plasma exudates, its formation resulting from an imbalance 
between the influx and efflux of fluid from the peritoneal compartment (Nage 
1993).  
Ovarian cancer patients show increased plasma levels of CA 125, a low 
molecular weight glycoprotein found in tissues derived from fetal embryonic 
coelomic epithelium 205. Serum levels up to 35U/ml are considered normal. 
Normal ovarian epithelium does not express CA 125. Elevated level are found 
in 85% of women presenting with ovarian cancer, but this is reduced to 50% 
when only those with stage I disease are considered 206. Unfortunately it is 
also elevated in a number of other conditions including fibroids, 
endometriosis, inflammatory conditions involving the pleura and peritoneum, 
and cirrhosis, which can lead to false positive results 207. 
 
  
 
1.3.3.1 Histopathology of Ovarian Tumours 
Epithelial ovarian cancers are classified by histopathological grade (grade 1–
3) and appearance (serous being the most common, mucinous, endometrioid, 
and, less commonly, clear cell, transitional, squamous, mixed, and 
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undifferentiated subtypes). Additionally, fallopian tube and primary peritoneal 
cancers occur that morphologically and clinically resemble epithelial ovarian 
cancers, possibly because the same embryonic precursor is shared by the 
ovarian surface epithelium and the peritoneal and fallopian tube epithelia. 
There is some evidence that suggests that some ovarian cancers might 
originate from the distal tubes (fimbria) 208.  
In a series of more than 8000 cases, mucinous and endometrioid carcinomas 
were associated with a favourable prognosis, serous carcinomas less so, and 
undifferentiated carcinoma was the most aggressive subtype 209. Data for 
clear-cell carcinoma were conflicting. Grade has consistently been of 
prognostic significance. 
 
 
1.3.3.2 Grading of ovarian cancers and prognostic 
significance 
The grade of the ovarian cancer refers to the cells themselves. The most 
important features in assessment of grade are mitotic activity, nuclear size 
and pleomorphism, and differentiation from the original cells 210. Grading is 
not entirely objective, and different pathologists may disagree on the grade of 
a particular ovarian cancer, as there are different systems for grading ovarian 
cancers211. Pathologists usually use a combination of the pattern system and 
Broder’s grading system. 
There are three different grades; grade 1 (well differentiated), grade 2 
(moderately differentiated), and grade 3 (poorly differentiated) 212. Tumours 
are often heterogeneous, and the grading is normally performed on what 
appears to be the least differentiated area211. However in view of the extent of 
variation it is usually based on the worst features. Overall low-grade (grade 1) 
tumours grow more slowly, and have a better prognosis than high-grade 
(grade 3) tumours 210. However, determining prognosis is multi-factorial 212.  
 
 55 
1.3.3.3 Histological subtypes of ovarian cancers 
Ovarian tumours may be divided into five broad categories (Underwood, 
2000) according to the World Health Organisation : 
• Epithelial 
• Germ-cell 
• Sex-cord stromal 
• Metastatic 
• Miscellaneous 
 
1.3.3.4 Epithelial Ovarian Cancer 
Malignant epithelial tumours of the ovary are adenocarcinomas and account 
for over 90% of malignant tumours. They are thought to originate from the 
epithelium on the surface of the ovary, which is coelomic in origin 213 214.More 
recent evidence suggests that epithelial tumours arise from the fallopian tube 
and tubo peritoneal junction 138 Epithelial ovarian cancer is subdivided into six 
categories.  
 
a) Serous carcinoma is the most common type of epithelial ovarian 
cancer, accounting for 40-50% of all cases. Tumours consist of cuboid 
epithelial cells. Well-differentiated serous adenocarcinomas have a 
predominately papillary pattern. Often some areas show an irregular 
acinar pattern. Poorly differentiated serous adenocarcinomas have a 
predominately solid histological appearance, with sheets of small 
relatively uniform cells and poorly formed glandular acini. Tumours are 
often bilateral and multicystic.  
 
b) Endometrioid Carcinomas account for 20% of epithelial ovarian 
cancers. Typically oval, columnar cells form tubular gland-like structures 
similar to those seen in endometrial cancer. Papillae are blunter and 
broader than in serous adenocarcinoma. Stromal invasion is usually 
apparent.  
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c) Mucinous Carcinomas account for 10% of all epithelial ovarian 
cancers. They are characterised by tall columnar mucus secreting cells 
which tend to have large multiloculated cystic structures filled with thick 
viscous fluid. Tumour cells can appear to be floating in large cells of 
mucous.  
 
d) Clear Cell Carcinomas account for 5-10% of epithelial ovarian 
cancers. Architectural patterns vary considerably. Tumours may be 
papillary, acinar or solid, with polyhedral cells containing clear cytoplasm 
and angular nuclei. Tubules and cysts are common.  
 
e) Brenner tumours are the rarest ovarian epithelial cancers, accounting 
for only 1-2% of all epithelial ovarian tumours. Areas of squamous 
differentiation are common. Nests of urothelial-like epithelial cells with a 
dense collagenous stroma are typically seen.  
 
f) Unclassifiable/ Undifferentiated:17% of epithelial ovarian cancer are 
undifferentiated and behave in an aggressive fashion.  
 
 
1.3.4 Management of Ovarian Cancer  
 
Primary debulking surgery for advanced ovarian cancer followed by platinum 
based chemotherapy has been the standard of care for the last 3 decades. 
Subsequently, in the 1990s, taxanes were added to platinum based 
chemotherapy.  
 
The International Federation of Gynaecology and Obstetrics (FIGO) staging 
system is given below. It is based on the concept that ovarian cancer spreads 
first to sites within the pelvis and then to the peritoneal cavity, only 
metastasizing outside the peritoneal cavity in advanced disease.  
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Table 1.7 Staging Of Ovarian Cancer. International Federation of 
Gynecology and Obstetrics criteria (2002) 
 
 
 
FIGO STAGE  DISEASE EXTENT 
I  Tumour limited to ovaries 
 IA Tumour limited to one ovary; capsule intact; no tumour on 
ovarian surface; no malignant cells in ascites or peritoneal 
washes.  
 IB Tumour limited to both ovaries, capsule intact, no tumour 
seen on ovarian surface; no malignant cells in ascites or 
peritoneal washings 
 IC Tumour limited to one or both ovaries, malignant cells in 
ascites or peritoneal washings with any of the following; 
capsule ruptured, tumour 
 
 
II  Tumour involves one or two ovaries with pelvic extension . 
 IIA Extension and/or implants on the uterus and/or tube(s). No 
malignant cells seen in ascites/peritoneal washings 
 IIB Extension to other pelvic tissue; No malignant cells in 
ascites/ peritoneal washings. 
 
 IIC Pelvic extension (IIa and IIb); malignant cells seen in ascites 
/peritoneal washes. 
 
 
III  Tumour limited to one or both ovaries with microscopically 
confirmed peritoneal metastasis outside the pelvis and/or 
regional lymph node metastasis. 
 IIIA Microscopic peritoneal metastases beyond the pelvis 
 IIIB Macroscopic peritoneal metastasis beyond the pelvis 2cm or 
less in greatest dimension. 
 IIIC Peritoneal metastasis beyond the pelvis more than 
2cm in greatest dimension and/or lymph node metastasis 
 
 
IV  Distant Metastases (excludes peritoneal metastases) 
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1.3.4.1 Surgical Management 
Primary surgery has for many years been the mainstay of the initial 
management of advanced ovarian cancer. This has been based on the work 
of Griffiths identifying the completeness of cytoreductive surgery as a 
prognostic factor for outcome 215 216 217. Peritoneal washings are usually taken 
immediately on entering for cytology. A thorough exploration of the abdomen 
and pelvis is performed to assess the extent of spread. The surface of the 
liver, diaphragm, and spleen are examined, as well as the small and large 
bowel, omentum, para-aortic and pelvic lymph nodes. A total abdominal 
hysterectomy, bilateral salpingo-oophorectomy, omentectomy, para-aortic and 
pelvic lymph node sampling, peritoneal biopsies, and peritoneal cytology 
(peritoneal washings) are usually performed if ovarian cancer is confirmed. In 
advanced disease cytoreduction or debulking surgery (where as much tumour 
tissue as possible is removed) is performed, which will then offer the best 
response to subsequent chemotherapy. It is recommended to achieve a 
residual disease of less than 1cm 218 219. 
The survival advantage of surgical debulking or cytoreduction for advanced-
stage disease has been shown retrospectively in studies as early as 1934 219 
220. In a meta-analysis of 53 studies including 6885 patients with stage III or IV 
disease, Bristow and colleagues reported that every 10% increase in 
cytoreduction was associated with a 5·5% increase in median survival. The 
parameter that defines an optimum cytoreduction and allows maximum 
survival advantage remains debatable, although the most widely accepted 
definition is residual disease less than 1 cm 219-221. Optimum cytoreduction is 
often established as no visible residual disease because prognosis is directly 
related to the number of residual implants and to the size of residual disease 
219 222 223. The role of a systematic dissection of retroperitoneal lymph nodes 
remains debatable and might be appropriate in patients for whom maximum 
cytoreduction is possible 224 225. Although most experts agree that optimum 
cytoreduction improves survival, whether aggressive or ultra-radical surgery 
(e.g., diaphragm or hepatic resection, splenectomy, cholecystectomy, distal 
pancreatectomy, peritonectomy, modified posterior exenteration) increases 
survival in patients with extensive tumour is unknown 226.   
 59 
 
Retrospective data suggest that aggressive surgical resections can increase 
rate of optimum debulking and thereby correlate with improved outcomes, 
albeit at the expense of increased complication rates 227 228; for example, 
pneumothoraces and symptomatic pleural effusions occur in roughly 20% of 
women after diaphragmatic resection 228. A 2004 consensus statement from 
the Third International Gynecologic Cancer Intergroup Ovarian Cancer 
Consensus Conference (GCIG-OCCC-2004) unanimously recommended an 
initial maximum surgical effort at cytoreduction, with the goal of no residual 
disease 229. Specialist gynaecological oncologists at high-volume centres are 
best suited to debulk tumours in patients with advanced disease 220 230. 
Surgery done by a gynaecological oncologist resulted in a 5-8 month survival 
advantage for these patients 231. The GCIG-OCCC-2004 unanimously 
recommended that surgery in cases of advanced disease be done by an 
appropriately trained surgeon skilled in management of epithelial ovarian 
cancer 229. 
 
1.3.5 Prognostic Factors 
The surgical management of patients with epithelial ovarian cancer facilitates 
accurate staging and in turn allows the evaluation of a series of 
clinicopathological variables that are often used to select postoperative 
therapy. The established clinicopathological prognostic factors are described 
below. 
1.3.5.1 Tumour Stage  
The 5-year survival of patients with epithelial ovarian cancer is directly 
correlated with the tumour stage at diagnosis (Cancer Research UK):  
 
Stage 1 – 90% 5 year survival 
Stage 2 – 70% 5 year survival 
Stage 3 – 21% 5 year survival 
Stage 4 – 6% 5 year survival  
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1.3.5.2 Volume of Residual Disease 
The volume of residual disease following cytoreductive surgery directly 
correlates with survival 232 233, Delgado 1984). Patients who have been 
optimally cytoreduced have a 22 month improvement in median survival 
compared to those patients undergoing less than optimal debulking. In studies 
outlining the importance of residual volume upon survival, the size of the 
largest residual tumour mass 234and not the total number of lesions has been 
thought to be the primary factor correlating with prognosis. Yet the number of 
residual masses may be an important prognostic factor as well 235 236; Patients 
who have only a single residual mass following cytoreductive surgery have a 
significantly greater chance of achieving a surgically confirmed complete 
remission compared with those patients with multiple small nodules even 
though each nodule is less than 2cm in size. In addition to the volume of 
disease other unknown biological factors influence survival in patients with 
advanced disease, as patients with bulky disease versus small volume 
disease at the outset prior to cytoreduction have a worse overall survival. To 
accommodate this, the FIGO stage III disease is subdivided into three groups 
based upon the volume of disease. This permits a comparison of survival for 
patients who have small volume disease prior to cytoreductive surgery (IIIA –
IIIB) with that of patients who present with bulky disease (IIIC).  
 
1.3.5.3 Histological Subtype and Grade  
In general, the histological type has less prognostic significance than the other 
clinical factors, such as stage, volume of disease and histological grade. In 
some series, patients with mucinous adenocarcinoma have an overall better 
survival in comparison to endometrioid or serous adenocarcinomas. These 
findings reflect the rarity with which high-grade mucinous adenocarcinoma of 
the ovary is diagnosed. Endometrioid carcinoma also has been suggested to 
have a better prognosis than serous adenocarcinoma, as well as presenting 
with a lower histological grade and clinical stage. Some studies have shown 
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that ovarian clear cell adenocarcinoma may be more aggressive than the 
other common epithelial malignancies on a stage for stage basis 234 
The histological grade of the tumour is a particularly important prognostic 
factor in patients with early stage disease Stage I patients with well or 
moderately well differentiated tumours have a greater than 90% 5 year 
survival when treated with surgery alone 237. In contrast, patients with stage I 
disease with poorly differentiated or clear cell tumours have a significantly 
worse survival, and postoperative adjuvant chemotherapy is indicated. In 
advanced stage patients treated with platinum based chemotherapy, most 
studies have failed to demonstrate a significant correlation between 
histological grade and survival (Pettersson F Annual Report on the results of 
treatment in gynaecological cancer vol 20 1988). This may reflect variable 
degrees of intra-observational and inter-observational variation in grading of 
ovarian tumours 238 239 
 
1.3.5.4 Surgical Prognostic Factors 
Surgical factors such as tumour size, bilateralism and ascites without 
cytologically positive cells are not thought to be of prognostic significance in 
patients with early stage disease. However tumour spillage, capsular 
penetration and cytologically malignant ascites (FIGO stage IC) are 
associated with a worse prognosis. 
 
1.3.5.5 CA 125 Levels  
The prognostic significance of preoperative and postoperative CA 125 levels 
has been established 240 241. Serum levels of CA 125 generally reflect the 
volume of disease. Pre-chemotherapy CA 125 levels have been shown in 
univariate analysis to be of prognostic significance. In multivariate analysis, 
they are usually not an independent prognostic factor owing to their 
association with volume of disease 241. In addition preoperative high CA 125 
levels may confer worse overall survival. Postoperative CA 125 levels appear 
to have greater prognostic significance. In a multivariate analysis, 
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postoperative CA125 levels were of independent prognostic significance in 
patients with or without residual disease 242 
Furthermore CA 125 levels are useful for predicting disease response to 
chemotherapy. Criteria have been proposed to define response to treatment 
based on serum CA 125 levels 243-245. An elevated CA 125 has also been 
increasingly used as an indicator of progression following completion of 
chemotherapy Clinical trial groups have established criteria for the 
progression of the disease based on elevations of CA 125 levels or the 
observance of physical or radiographic evidence of disease.  
 
 
Table 1.8 Prognostic and predictive factors in early-stage and advanced 
stage epithelial ovarian cancer 
 
Early-stage (stages I and II) 
• Stage (IA‒IB vs. IC vs. II) 
• Rupture of the ovarian capsule (when considering stage II disease) 
• Grade 
• Histotype 
• Age 
• Pelvic fluid cytology (positive vs negative) 
 
Advanced-stage (stages III and IV) 
• Residual tumour size after surgical debulking (≤1 cm vs >1 cm) 
• Stage (III vs IV) 
• Histological subtype 
• Age 
• Grade 
• Lymph-node involvement 
* 
 
1.3.6 Chemotherapy for epithelial ovarian 
cancer 
 
 
The majority of patients with ovarian cancer present with advanced disease 
and although response rates to chemotherapy are high, many patients 
eventually develop drug resistant tumours and the 5-year mortality from 
ovarian cancer remains at 60-70%. 
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There are many chemotherapeutic agents used to treat ovarian cancer, 
depending on the type, grade, stage of the disease, and the health of the 
patient. Meta analyses of randomised clinical trials have shown that platinum 
compounds (cisplatin/carboplatin), anthracyclines (doxorubicin/epirubicin), 
alkylating agents (cyclophosphamide/ melphalan), spindle poisons 
(paclitaxel/docetaxel), anti-metabolites such as gemcitabine, and the 
topoisomerase I inhibitor topotecan are the most active agents in ovarian 
cancer 246. 
 
1.3.6.1 Spindle Poisons 
Spindle poisons include taxanes such as paclitaxel and docetaxel, and 
promote the assembly of microtubules by binding to β-tubulin, which inhibits 
depolymerisation 247. This action disturbs mitosis in normal and malignant 
cells 248.The taxanes were originally derived from the bark of the Pacific Yew 
tree, Taxus brevifolia, and paclitaxel was identified as the active constituent in 
1971249 (McGuire et al., 2003). Docetaxel is a semi-synthetic taxoid derived 
from the needles of T. baccata 250 and has been shown to be less neurotoxic 
than paclitaxel 251. The introduction of paclitaxel in the 1990’s to treat ovarian 
cancer increased the survival rates of women with the disease 252. 
 
1.3.6.2 Anthracyclines 
Anthracyclines such as doxorubicin and epirubicin, have several cytotoxic 
actions. Their main mechanism of action appears to be mediated by their 
effect on topoisomerase II, whose activity is markedly increased in dividing 
cells 253. Topoisomerase II binds to the double stranded DNA, cleaves both 
strands of duplex DNA and passes a second duplex through this transient 
cleavage, involving hydrolysis of ATP, and enzyme recycling 254. The 
intermediate form is termed the ‘cleavable complex’. As a result of its double-
stranded DNA passage mechanism, topoisomerase II is able to remove 
negative or positive superhelical twists (i.e., under- or overwinds) from the 
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genetic material and resolve intramolecular DNA knots as well as 
intermolecular tangles 255. 
Doxorubicin poisons the cleavable complex, inhibiting religation of the cleaved 
complex, resulting in double strand breaks of the DNA. Doxorubicin 
intercalates into the DNA and becomes trapped 256. Apoptosis results if the 
cell is unable to repair these DNA double-strand breaks. However, these 
drugs have additional modes of action such as production of oxygen free 
radicals, and formation of covalent adducts which may contribute to its toxicity 
257. 
 
1.3.6.3 Topoisomerase inhibitors 
Topoisomerase I inserts a nick into one strand of the DNA to relax supercoiled 
DNA that occurs when DNA replicates itself. It also re-ligates the cleaved 
DNA. Irinotecan and topotecan (9-dimethylaminoethyl-10-hydroxycamto-
thecin) are potent inhibitors of topoisomerase I  258. 
In patients with platinum-resistant ovarian cancer, there was a low probability 
of responding to single agent Topotecan 259. Unfortunately Topotecan in 
combination with gemcitabine in the treatment of platinum refractory ovarian 
cancer in a phase I/II trial and has shown disappointing results 260. 
 
1.3.6.4 Antimetabolites 
Antimetabolites such as gemcitabine, interfere with nucleic acid production, 
either by mimicking nucleotide structure, enabling them to be incorporated 
into nucleic acids, thus terminating their production, or by preventing 
synthesis of nucleotides directly.  
Gemcitabine (2’, 2’-difluorodeoxycytidine dFdC) is a fluorinated deoxycytidine 
derivative, which can be used in a variety of solid tumours including ovarian 
cancer (usually in combination with carboplatin), non-small cell lung cancer, 
head and neck cancer, and genitourinary cancer 261. Gemcitabine enters the 
cell through a membrane nucleoside transporter 262, and it is activated by 
phosphorylation to gemcitabine monophosphate, which is subsequently 
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phosphorylated to the 5’-diphosphate (dFdCDP) and triphosphate (dFdCTP), 
which represent the active forms of gemcitabine. dFdCTP is incorporated into 
DNA instead of cytosine, followed by one or more deoxynucleotides, thus 
blocking DNA synthesis and preventing repair by 3’-5’-exonuclease activity. 
Gemcitabine triphosphate is also incorporated into RNA, thus terminating 
RNA synthesis. Only a proportion of gemcitabine is converted into the di- or 
triphosphate forms. The majority of gemcitabine is rapidly inactivated in the 
blood, liver and kidneys by deamination into 2’, 2’-diflurodeoxyuridine in a 
reaction catalysed by deoxycytidine deaminase (CDD) (Fruscella et al. 2003). 
 
1.3.6.5 Platinum compounds cisplatin and carboplatin 
Cisplatin (cis-dichlorodiammine platinum II) was discovered serendipitously by 
Rosenberg in the 1950’s while investigating inhibition of bacterial growth by 
electric currents 263. The resulting inhibitory complexes were produced by the 
reaction of platinum electrodes with growth media. Cisplatin (a neutral 
complex) was the most active of these, and was tested in clinical trials 264. 
 
1.3.6.6 Current First Line Therapy  
The main stay of first line therapy for ovarian cancer is platinum based 
chemotherapy combined with paclitaxel. The value of adjuvant therapy for 
advanced disease is well established (NHS Executive 1999). Platinum drugs 
are the most active agents in untreated ovarian cancer and form the mainstay 
of any regimen for this disease. The survival benefit for platinum therapy is 
particularly impressive in population based studies although the effect of 
platinum on overall survival in individual randomised trials is not large 265-268.  
When cisplatin was introduced into first line trials in ovarian cancer there was 
little difficulty in recognising its impact on progression free survival (PFS). The 
FDA approved cisplatin in its approval indication for ovarian cancer in 1979. 
Although its impact became increasingly clear, its initial use was hampered by 
complex combinations. Later on with the development of anti-emetics and 
simplification of treatment regimes, cisplatin became the treatment if choice 
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following surgery for all stages of ovarian cancer. Studies by the 
Gynecological Oncology Group (GOG) employed it in combination with 
cyclophosphamide and this became first line treatment until GOG 111 showed 
the PFS and overall survival (OS) superiority of cisplatin and paclitaxel 269. 
Eventually in terms of reduced toxicity, GOG 158 showed that carboplatin and 
paclitaxel was preferred because of less toxicity with at least equal efficacy to 
cisplatin 223. 
The current standard treatment is to give cisplatin or carboplatin in 
combination with paclitaxel 269 270. Women with stage III or IV ovarian cancer 
have between 6-8 cycles of intravenous platinum-paclitaxel chemotherapy 
after primary surgery If the patient was not optimally debulked at primary 
surgery, interval debulking after 3- 4 courses of chemotherapy may be of use. 
Failure of Ca 125 levels to return to normal after primary surgery and initial 
chemotherapy has been associated with the degree of residual disease 
remaining and a likely adverse disease course. The interval between the end 
of first line therapy and first relapse, or the treatment free interval between 
subsequent relapses is an important determining factor for response.  
The role of other cytotoxic drugs in current use for ovarian cancer in 
complementing the effects of the platinum drugs is less clear. After exposure 
to cisplatin various alkylating agents had disappointing activity 271, and 
Doxorubicin’s acute and chronic toxicities led to diminishing use until the 
advent of liposomal formulations. Upon the introduction of Paclitaxel, followed 
by topotecan, gemcitabine, and pegylated liposomal doxorubicin (PLD) drugs 
with reproducible activity and reasonable therapeutic index came into use 272. 
However the addition of the latter three drugs in five arm GOG 182 did not 
prove advantageous over the combination of carboplatin and paclitaxel 273.  
Radiotherapy has very limited use in ovarian cancer.  
 
1.3.7 Anti-angiogenic and new ‘targeted’ agents 
These drugs are a major focus of current therapeutic research. The anti-
tumour activity of bevacizumab in ovarian cancer has led to the study of this 
agent in the first line and recurrence strategies for ovarian cancer 274 275. 
 67 
 Activity has been shown with anti-angiogenic approaches other than 
bevacizumab and the efforts to establish their role is ongoing. Sorafenib 
added to bevacizumab has shown promise in a phase I study, but at a cost of 
enhanced toxicity 276. Efforts to combine them with first line platinum based 
regimes or to test a strategy of maintenance following initial surgical and 
platinum based cytoreduction are undergoing evaluation in studies currently.     
 
 
1.4 Angiogenesis in Ovarian Cancer 
 
 
Recurrent VEGF-mediated angiogenesis followed by vascular regression is 
unique to the ovulatory cycle and is highly regulated 277. New vessel 
generation is essential for the whole reproductive cycle, and the role of 
vascular growth factors involved in regulating this process, particularly VEGF, 
has been demonstrated by highly regulated changes in expression throughout 
an ovulatory cycle 278.  
Early in tumourigenesis, the previously highly maintained balance of pro-
angiogenic and anti-angiogenic factors that regulate normal ovarian function 
is tipped, with the down regulation of anti-angiogenic signalling and the up 
regulation of pro-angiogenic growth factors 278.  Although VEGF is expressed 
in healthy ovaries, it is overexpressed in ovarian hyperstimulation syndrome 
and ovarian cancer 277 279.  VEGF expression is hypothesized to mediate 
multiple functional and structural characteristics of the disease and 
angiogenesis plays an important part in the growth and metastasis of ovarian 
cancer 280 and several studies have shown that VEGF regulated angiogenesis 
is an important component of EOC growth.  
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Figure1.13 Hormonal profiles and 
angiogenic responses during a human 
ovulatory cycle. Intrafollicular levels of 
VEGF, in particular VEGF-A, increase 
during the initial part of the ovulatory cycle, 
peaking just before the start of the luteal 
phase.2 Subsequent vascular regression 
during follicular atresia is promoted by 
elevated levels of angiogenic inhibitors and 
reduced VEGF levels toward the end of the 
luteal phase and the ovulation cycle. 
LH=luteinising hormone; FSH=follicle-
stimulating hormone; EG-
VEGF=endocrine–gland derived-vascular 
endothelial growth factor (Ramakrishnan et 
al. 2005, Kumaran, Jayson and Clamp 
2009). 
 
The degree of angiogenesis of a tumour, as assessed by microvessel density 
(MVD), has emerged as a powerful candidate for prognosis and as a 
predictive tool 281. In a multivariate analysis, MVD was found to be the most 
accurate prognostic indicator in breast carcinoma for disease free survival; 
better than size, grade, or oestrogen receptor status 282. In other studies, 
VEGF expression has been demonstrated in a variety of tumours and has 
been correlated with increased MVD and poor prognosis 283-285. 
MVD and degree of expression of VEGF and its receptors in ovarian tumours 
are directly correlated with poor prognosis suggesting that angiogenesis 
influences disease progression in EOC286-288. The role of angiogenesis in 
ovarian carcinoma was uncertain until Hollingsworth et al. conducted a 
retrospective study on 43 advanced-stage epithelial ovarian cancer patients 
289. Their results suggested that the degree of neovascularization was 
associated with overall and disease-free survival and may be a useful 
prognostic factor. Using a Cox proportional hazards model, Hollingsworth 
concluded that stage was the best predictor of overall survival. Tumour 
angiogenesis, however, was found to be the best predictor of disease-free 
survival. This study did not include women with early-stage disease and 
contained a small number of study subjects.  
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An investigation by Abulafia et al. evaluated angiogenesis in 42 consecutive 
patients with primary epithelial ovarian cancer. In 19 patients with advanced 
disease, the degree of neovascularisation was assessed in both the primary 
tumour as well as metastatic omental implants 135. Overall, the microvessel 
counts of the primary tumour were not significantly related to patient age, 
preoperative CA 125 level, tumour stage, tumour grade, or patient survival. In 
contrast, in women with advanced stage disease, the microvessel counts of 
the omental metastases were significantly correlated with preoperative CA 
125 level and were significantly predictive of survival. This study also 
contained a small number of subjects, and only 12 patients had early-stage 
disease.  
Ovarian cancer is characterized by the rapid growth of solid intraperitoneal 
tumour cells creating large areas of hypoxia and large volumes of ascitic fluid 
290.  The growth of ovarian tumour cells is supplied by ascites, and ascites 
accumulation is associated with progression 291. Experimental models have 
demonstrated a positive correlation between ascites volume and VEGF 
expression 292.  
 
Figure 1.15. Correlation between ascites volume and VEGF 
expression. In a murine model, a positive correlation was observed 
between ascites volume and VEGF levels in ascitic fluid. In this same 
study, a correlation was also observed between ascites volume and 
tumour burden 292. 
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Ovarian malignancies are presumed to metastasize through the process of 
exfoliation of tumour cells from the primary tumour, followed by dissemination 
of cells throughout the peritoneal cavity, implantation, and subsequent growth. 
Most patients who succumb to this disease ultimately die from starvation and 
inanition due to bowel obstruction caused by intraperitoneal metastases. In 
this regard, the degree of angiogenesis of ovarian cancers may directly 
influence the clinical course of the disease. Highly angiogenic tumours may: 
(a) facilitate a rapidly increasing volume of tumour cells, thereby facilitating 
the dissemination of the cells within the abdominal cavity and accelerating the 
clinical development of bowel obstruction; (b) provide access to the circulatory 
system; and (c) promote the development of lymphatic channels. Conversely, 
a lack of angiogenic capability in ovarian tumours may serve to prevent the 
rapid development of a large intraperitoneal tumour burden, which is a 
prerequisite for bowel obstruction, thereby resulting in improved median 
survival for women with ovarian carcinoma, and angiogenesis has been 
correlated with poor prognosis In patients with advanced ovarian cancer289. 
 
 
1.4.1 VEGF expression in ovarian cancer 
 
VEGF is expressed in a wide variety of human malignancies and is 
considered to be an important mediator of angiogenesis especially in ovarian 
cancer 293. In ovarian cancer, VEGF appears to be a prognostic factor as well 
as helping monitor the clinical course of the disease 294. Patients with 
disseminated cancer have higher serum levels of VEGF compared to patients 
with localised disease and healthy controls 295. Mesiano et al have shown 
higher levels of VEGF in the ascitic fluid of patients with high stage 
tumours290. Barton et al reported an increased concentration of VEGF in the 
ascitic fluid and serum296. The formation of ascites in ovarian cancer seems to 
be directly associated with VEGF expression 297. VEGF mRNA has been 
found in the majority of epithelial ovarian cancers in the malignant cells but 
not in the normal stroma, although the protein does accumulate in the stromal 
 71 
matrix 298. In xenograft models of human EOC, the expression of VEGF is 
associated with the formation of ascites and the tumour growth rate is 
proportional to the MVD, which correlates to VEGF297. As seen with other 
tumours, human EOC overexpress VEGF, and its expression is directly 
correlated to MVD293. 
Wong te Fong et al showed that VEGF expression was significantly more 
pronounced in malignant vs. benign tumours, and borderline tumour and 
normal ovary 299 300. There was a significant difference in VEGF expression 
between the histological subtypes; serous subtypes of benign and malignant 
tumours expressed higher amounts of VEGF. Serous adenocarcinomas had 
significantly higher VEGF expression compared with endometrioid 
carcinomas. It was also shown in this study that the degree of VEGF 
expression was related to the stage of EOC, late stage EOC, having higher 
VEGF expression when compared with early stage EOC. This may indicate 
that VEGF is involved in the process of invasion and angiogenesis in serous 
tumours.  
 
1.4.2 VEGF Expression and its relationship to 
prognosis in ovarian cancer 
 
Overall, VEGF expression and high degrees of tumour angiogenesis in 
ovarian cancer have been associated with poor survival outcomes 291. 
 
Expression of VEGF in ovarian carcinomas has also been associated with 
tumour growth and proliferation within the peritoneal space, and intense 
VEGF staining is more often found in peritoneal metastases than in primary 
tumours 277. 
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Figure 1.16. Microvessel density (MVD) and overall survival in 
ovarian cancer. The degree of angiogenesis, as measured by 
MVD, is associated with prognosis (as measured by the 
proportion of patients surviving). In this experiment, survival in 
patients with high MVD (>10 vessels/field) was significantly 
lower than in patients with low MVD (3 to 10 vessels/field) 291. 
 
 
There have been many studies examining the prognostic value of  VEGF in 
EOC; Paley et al illustrated that VEGF expression was a significant and 
independent predictor for shorter relapse free survival and overall survival301 . 
Wong te Fong et al showed that survival rates of patients with EOC whose 
tumour was positive for VEGF were significantly worse than those of patients 
with VEGF negative tumours 302 303. In a recent study by Engels et al, it was 
shown that the expression of VEGF-A is a prognostic marker for clinical 
outcome in serous ovarian cancer patients with microscopic complete tumour 
resection (R0)304. These studies illustrate that VEGF may have an important 
role to play in the prognosis of EOC, as a negative predictor for patients with 
early and late stage cancer.  
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1.4.3 PDEGF/TP in ovarian cancer 
 
 
It has been shown that angiogenesis is associated with normal ovarian, 
follicular and corpus luteal development. Studies have shown that PDEGF/TP 
expression increased from normal, benign, borderline and malignant ovarian 
tumours and high PDEGF/TP expression is correlated with poor 
survival61.importance in the progression of early ovarian carcinomas and may 
also have some prognostic relevance. Nakanishi et al found that the patients 
with advanced ovarian cancer showed an increase of PDEGF/TP expression 
in stromal cells293. Similarly Hata et al showed that PDEGF/TP was 
significantly higher in EOC specimens than in normal ovary specimens305.  
 
1.4.4 The Role of MVD assessment in ovarian 
cancer 
 
 
Several techniques have been applied to assess the extent of angiogenesis in 
clinical samples. Simple measurements of microvessel number and or density 
have been done using immunohistochemical methods135 306-308. Endothelial 
cells can be identified by antibodies to von Willebrand’s factor, factor viii, CD 
31 and CD 3. High microvessel counts have been correlated with relapse of 
disease in all stages of ovarian cancer289.  
The extent of angiogenesis has been shown to correlate with progression free 
survival and overall survival in ovarian cancers. Holllingsworth et al studied 
advanced stage ovarian cancer and identified CD 34 as the most useful 
discriminant of microvessel density; MVD counts and stage of disease were 
associated with overall survival and disease free survival, respectively289.  
The expression of VEGF has been used to complement microvessel density 
in the clinical assessment of angiogenesis. Paley and colleagues first 
demonstrated that higher expression of VEGF correlated with poor outcome in 
early stage EOC and LMP ovarian tumours 301. Although variability in methods 
exists, neoangiogenesis is a consistent clinical predictor of poor progression 
 74 
free survival in EOC, in univariate and multivariate analysis. However 
measures of angiogenesis have not proven consistently as an independent 
variable for overall survival. 
Using anti-vWF, Orre et al showed that average microvessel counts in 
malignant serous and benign ovarian tumours were similar and significantly 
less compared with other markers309. This was thought to result from the 
reduced or even absent expression of vWF factor antigen in the smaller less 
mature microvessel of many tumours, therefore giving conflicting results as to 
the importance of MVD in EOC tumourigenesis310.  
It has been found that in EOC, angiogenesis was equally stimulated 
regardless of the stage of the disease 293; Nakanishi et al suggested that 
angiogenesis might be induced differently, depending on the organ involved 
and the histological type of the tumour. It is postulated that angiogenesis is 
necessary for cancer cell growth and allows tumours to increase in volume; 
other mechanisms also play a crucial role in tumour progression in EOC. It 
was suggested that degree and control of angiogenesis may differ between 
ovarian tumour types289 311. Following on from this observation, angiogenesis 
in EOC has also been shown to be intensified with invasive capability and 
tumour vascularity. This was shown in a study by Abufalia et al and it was felt 
that the assessment of tumour vascularity by immunohistochemical 
techniques of MVD quantification, may help the gynaecologist, and 
pathologists to differentiate between borderline and invasive tumours312. 
In solid tumours, including EOC there is a significant correlation between the 
incidence of metastasis and MVD289 293 312. These areas are thought to 
represent ongoing tumour angiogenesis, in addition to the site of tumour entry 
into the circulation313. It is however postulated that ovarian tumours spread via 
peritoneal dissemination rather than through the vasculature96, tumour 
angiogenesis is unlikely to play a role in this type of spread. Weidner et al 
showed that MVD as assessed by immunohistochemical staining for 
endothelial cells was an independent prognostic factor in breast cancer MVD 
has since been reported as a possible prognostic indicator/factor in numerous 
human solid tumours including breast314, prostrate129, non-small cell lung 
cancer315, gastric316 and colorectal cancers317. The reports and studies 
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assessing the role and prognostic value of MVD in advanced EOC are 
conflicting as studies have shown that angiogenesis may not be as pertinent, 
as that seen in other types of carcinomas in which angiogenesis is an 
independent prognostic factor. In a recent study by Rubatt et al 318 which 
looked at the expression of cd105 (Endoglin), this is expressed almost 
exclusively on proliferating endothelial cells, as opposed to CD31 and CD34 
which are pan endothelial markers and stain nearly all blood vessels including 
the established mature vessels. As CD105, recognises proliferating vessels it 
may be a better prognostic marker319. The study showed that high MVD as 
assessed using CD 105, a marker of proliferating endothelial cells and 
neoangiogenesis but not CD 31, a pan endothelial marker, appeared to be an 
independent prognostic factor for worse progression-free survival in women 
with advanced EOC, after adjusting for prognostic clinical covariates.  
Others have reported that MVD a marker of tumour angiogenesis has 
prognostic significance in ovarian cancer, with most studies reporting that a 
high degree of tumour angiogenesis conferred a worse survival289 291 320-322. 
Only one study found that high MVD was a prognostic factor for improved 
survival in advanced ovarian cancer323 and one study did not find any 
evidence of an association between MVD and survival324 in EOC. 
 
 
1.5 Genetic Variation and Cancer 
 
1.5.1 DNA Sequence Variation 
 
All humans would be a clone if the nucleotide sequences of their genomes 
were exactly identical. The only known human clones are identical twins. All 
other humans have nearly 99.9% identical genomic sequence 325. The 
remaining 0.1% variation (i.e. one base in every 1000 bases) is medically very 
important. It is this DNA sequence variation or polymorphism that is 
responsible for the phenotypic differences among individuals and races e.g. 
skin colour, facial features, height etc. Even in the same individual, 
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corresponding loci on homologous chromosomes have variations. The variant 
DNA sequences on corresponding loci of homologous chromosomes are 
commonly known as alleles. The most common type of genetic variation is 
single nucleotide polymorphism (SNP). There are more than ten million SNPs 
in the human genome. Other less frequent polymorphisms are variable 
number of tandem repeats (VNTRs), deletion / insertion polymorphisms (DIPs 
or indels), and inversions. Genetic variations are usually present in the non-
coding regions of the genomes / genes. The non-coding regions could be 
regulatory or of unknown function. However, if SNPs are present in the exons 
of genes, they may or may not alter the amino acid sequence, and hence 
function, of the peptide or protein (synonymous or non-synonymous SNPs) 326 
327. Increasing evidence suggests that polymorphisms in the flanking regions 
of genes, the non-coding regulatory regions, influence the level of gene 
expression, or the location or timing of expression 328. 
 
1.5.2 DNA Sequence Variation and Diseases 
 
An estimated 10,000+ human diseases are known to be monogenic 329. 
These diseases are rare, highly heritable “Mendelian” disorders in which 
variation in a single gene is both necessary and sufficient. It is now 
increasingly apparent that these genes are further modified by other genes 
known as modifier genes, that cause intra-familial variations, altered 
penetrance, and altered severity of disease 330. The nature of disease 
depends on the functions performed by the modified gene. Monogenic 
diseases result from modifications in a single gene occurring in all cells of the 
body. Though relatively rare, they affect millions of people worldwide. The 
single-gene or monogenic diseases can be classified into three main 
categories: 
Dominant  
Recessive  
X-linked  
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1.5.3 Gene Polymorphisms and Cancer 
 
Most of the gene polymorphisms identified so far in cancer epidemiology are 
located in genes encoding for metabolic enzymes involved in phases I and II 
of chemical metabolism and those responsible for the DNA repair, 
inflammatory response, cell adhesion and vascular growth 331.  
Cancers arise from the accumulation of inherited polymorphisms (i.e. SNPs 
and mutations) and sporadic somatic polymorphisms in cell cycle, DNA repair, 
and growth signalling genes 332. For instance members of certain ethnic 
groups have a higher risk of carrying SNPs in cancer genes such as BRCA-1, 
BRCA-2, or APC (adenomatous polyposis coli). These SNPs confer an 
increased risk of developing breast, ovarian, prostate, or colon cancers 333.  
Somatic polymorphisms such as those in the p53 gene, influence both clinical 
outcome and response to therapy 334. 
 
1.5.4 The HapMap Project 
 
The identification of the haplotype on which the mutation is located and then 
subsequent identification of the mutation is a common research approach. 
This has been shown for several diseases e.g. in cystic fibrosis and 
diastrophic dysplasia 335 336. Sequence analysis of the human genome has 
yielded numerous SNPs, raising the expectation that new low-penetrance 
tumour susceptibility genes will be identified that can be used to estimate an 
individual”s cancer risk 337. Several groups have worked to create a SNP map 
of the whole human genome 338. Notable among these are the U.S. Human 
Genome Project (HGP) and SNP consortium. The International HapMap 
Project was launched in October 2002 to create a public, genome-wide 
database of common human sequence variation, providing information 
needed as a guide to genetic studies of clinical phenotypes The HapMap data 
have generated a genome wide variation resource that will have a huge 
impact on the investigation of evolutionary forces that have shaped variations 
in natural populations. The HapMap should be valuable in reducing the 
number of SNPs required to examine the entire genome for association with a 
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phenotype from the 10 million SNPs that exist to roughly 500,000 tag SNPs. 
This will make genome scan approaches to finding regions with genes that 
affect cancers much more efficient and comprehensive; since effort will not be 
wasted typing more SNPs than necessary and all regions of the genome can 
be included. 
 
1.5.5 Early detection of cancers 
 
Cancer is caused by both external factors (chemical compounds, infectious 
organisms etc.) and internal factors (inherited predispositions and hormones). 
Some of the factors that lead to development of cancer are avoidable for 
example smoking, nutritional deficiencies, obesity, and physical inactivity. 
However, the inherent risks contributed by genetic variation cannot be 
eliminated and may enhance the effects of prevalent environmental factors 
thus leading to different outcomes in individuals sharing the same 
environment. For common cancers such as breast, cervix, prostate, and 
colorectal cancers, screening examinations are available for early detection 
but no cost effective screening examinations are available for ovarian cancer. 
Most of patients are diagnosed at a late stage and hence the 5 year survival 
rate of ovarian cancer remains poor 339. A continuing search for biomarkers 
and risk factors to facilitate early diagnosis is essential to improve the dismal 
outlook for the patients with ovarian cancers.  
 
 
1.6 The VEGF Gene and Polymorphisms 
 
Angiogenesis has been established as a major factor in carcinogenesis 
influencing tumour growth, invasion, and the formation of metastases 340 341 
VEGF is believed to play a central role in angiogenesis through a variety of 
mechainisms, including effects on endothelial cell proliferation, survival and 
migration342. In ovarian cancer, studies have shown that VEGF is critically 
involved in various steps of ovarian tumour progression286 298 343. 
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The gene encoding VEGF is located on chromosome 6 and comprises a 14-
kilobase coding region with 8 exons and 7 introns and its coding region spans 
approximately 14Kb 344 345. The VEGF gene is reported to be regulated by 
oestrogen, hypoxia, growth factors including epidermal growth factor and 
cytokines including interleukin 6 346-349  There is considerable variation 
between individuals in VEGF expression and analysis of the 5’ untranslated 
region of the gene has shown many polymorphisms 110 350 351. The VEGF gene 
is highly polymorphic with some of the polymorphisms occurring at high 
frequency. Significant associations have been noted genotype and both 
VEGF secretion and disease. (Watson CJ 2000, 352-354. At least 30 SNPS in 
this gene have been described in the literature. The promoter region and the 
5’ untranslated region of the VEGF gene were first screened for 
polymorphisms by Watson et al 429. Fifteen polymorphisms were identified, 
and +405 GG genotype of 405 G/C polymorphism was significantly 
associated with increased peripheral blood mononuclear cell VEGF protein 
production.  
 
Several studies have investigated the association of the VEGF gene 
polymorphisms with diseases in which angiogenesis plays a major role in 
pathogenesis such as diabetic retinopathy 352, renal cell carcinoma 355,acute 
renal allograft rejection 353 and  melanoma 356. The polymorphisms described 
thus far that are associated with an increased VEGF production in vivo, 
include VEGF 405G/C, VEGF 460C/T, VEGF 936C/T /C  and VEGF 1154 
G/A. 
 
 
1.7 CONCLUSION 
 
The high mortality rate of ovarian cancer results mainly from the occult 
progression of the tumour within the peritoneal cavity, with the initial diagnosis 
usually only being made at an advanced stage. Understanding the biology 
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regulation, and implications of the process of invasion and angiogenesis has 
and will continue to drive new biomarker and therapeutic target identification 
and intervention. Future studies are needed to determine what biomarkers are 
predictive of response to therapy or survival in women who receive treatment 
with an anti-angiogenic treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.17. Angiopoietin 1 (ANGPT1), expressed by many cells, binds to the endothelial TIE2 
(also known as TEK) receptor and helps maintain a normalized state in blood vessels. 
Vascular endothelial growth factor (VEGF) is secreted by tumour cells and binds to its 
receptor (VEGFR2) and to neuropilin on endothelial cells. It is the most common of at least 
six other pro-angiogenic proteins from tumours. Matrix metalloproteinases (MMPs) are 
released from tumour cells, but also by VEGF-stimulated endothelial cells. MMPs mobilize 
pro-angiogenic proteins from stroma, but can also cleave endostatin from collagen 18 in the 
vessel wall and participate in the cleavage of angiostatin from circulating plasminogen. 
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Tumour cells secrete angiopoietin 2 (ANGPT2), which competes with ANGPT1 for binding to 
the endothelial TIE2 receptor. ANGPT2 increases the degradation of vascular basement 
membrane and migration of endothelial cells, therefore facilitating sprout formation. Platelet-
derived growth factor (PDGF), an angiogenic protein secreted  by some tumours, can up 
regulate its own receptor (PDGFR) on endothelial cells. Basic fibroblast growth factor (bFGF; 
also known as FGF2) is secreted by other tumours. Integrins on endothelial cells carry signals 
in both directions. Integrins facilitate endothelial cell binding to extracellular membranes, a 
requirement for the cells to maintain viability and responsiveness to growth regulatory 
proteins. Endothelial cells are among the most anchorage-dependent cells. Certain pro-
angiogenic proteins up regulate endothelial integrins and are thought to sustain endothelial 
cell viability during the intermittent detachments that are required to migrate towards a tumour 
and to simultaneously increase their sensitivity to growth regulators — both mitogenic (VEGF 
or bFGF) and anti-mitogenic (endostatin). New endothelial cells do not all originate from 
neighbouring vessels. A few arrive as precursor bone-marrow-derived endothelial cells. 
Endothelial growth factors are not all delivered to the local endothelium directly from tumour 
cells. Some angiogenic regulatory proteins (both pro- and anti-angiogenic) are scavenged by 
platelets, stored in alpha granules and seem to be released within the tumour vasculature. It 
was recently discovered that pro- and anti-angiogenic proteins are stored in different sets of 
alpha granules (depicted in green and red respectively). 
 
Adapted from Folkman J2.  
              
 
1.8 AIMS AND OBJECTIVES 
 
1) To examine the role of angiogenesis in EOC 
2) To examine the association between intra-tumoural VEGF expression 
as a marker of angiogenesis and correlate its expression with 
established clinicopathological variables and overall patient survival.  
3) To understand and illustrate the role of VEGF-A expression and its 
correlation with disease response to platinum based chemotherapy 
4) To look at the correlation of a polymorphism in the VEGF gene- VEGF 
1154 A/G, known to be associated with the increased production of 
VEGF protein, to risk of epithelial ovarian cancer in a population based 
case control study.  
 
 
 
 82 
 
CHAPTER 2: MATERIALS & METHODS 
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2.1 MATERIALS 
 
 
2.1.1 Reagents 
 
All laboratory reagents are listed along with the manufacturer. The grade of 
reagents, where applicable, is also given. Molecular biology grade reagents 
were used in methods involving PCR, e.g. PCR, quantitative real-time RT-
PCR and gel electrophoresis. 
 
2.1.2 Clinical samples 
 
The immunohistochemical part of the study was conducted at the Royal Free 
Hospital and ethical approval from the Local Research Ethics Committee 
(LREC) was obtained for tissue collection prior to conducting the study. 
Tissue was removed during routine surgery and placed in formalin and 
processed routinely through the Department of Histopathology, where the 
tissue was paraffin wax-embedded, or frozen and stored in the tumour bank. 
Depending on the availability of the samples, the number examined differed 
for each part of this study. These samples are described in the respective 
chapters of the thesis. 
 
2.1.3 Archival tissue 
 
There are a number of methods for fixing tissue to preserve its morphology, 
depending on the tissue type and which techniques will be used after 
sectioning. The most widely used fixatives in diagnostic hospital histology 
laboratories are formalin based, as formalin is a neutral salt employed to 
maintain tonicity. In this study, either 10% formol saline or 10% neutral 
buffered formalin (10% w/v formaldehyde in water) was used. After fixation 
was complete, the fixative was poured off and the tissue was processed using 
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an enclosed automatic processing system (VIP 2000F/300E) programmed 
with the following schedule: 10% neutral buffered formalin, 2 hours at 40°C; 
70% industrial methylated spirit (IMS), 1 hour at 40°C; 90% IMS, 1 hour, 
40°C; absolute IMS, 3 hours, 40°C; xylene, 4 hours, 40°C; paraffin wax, 3 
hours 60°C. Tissues were embedded in paraffin wax utilising the Tissue-Tek 
III. The cast blocks were then left at room temperature to allow the wax to 
become hard. After the wax hardened, the cast blocks were removed from 
embedding mould and stored in a dry place at room temperature until 
required. 
The blocks were sectioned at 5µm using a microtome at room temperature. 
The sections were floated on warmed distilled water (45°C) to prevent 
creasing, mounted onto 2% 3-aminopropyltriethoxysilane (APES) coated 
slides (see Appendix I), and dried at 42°C for 30 minutes. The slides were 
placed in the incubator at 37°C for 2 days to firmly attach the sections to the 
slides and were stored in a slide box and placed at 4°C until required. Each 
block also had a corresponding Haematoxylin and Eosin (H&E) stained slide 
taken for comparison, and histological correlation of tumour and non tumour 
tissue. 
 
2.1.4 Clinicopathological parameters 
 
The clinico-pathological data such as age at diagnosis, tumour type, grade 
and stage were obtained from the hospital records. 
 
 
2.2 METHODS 
 
All procedures were performed using strict laboratory protocols that adhered 
to Control of Substances Hazardous to Health (COSHH) guidelines (October 
1984). 
 
 85 
2.2.1 Immunohistochemistry (IHC) 
 
H&E sections were examined by a consultant gynaecological pathologist 
(JCC) and myself to review the histopathological features. 
 
IHC is the demonstration of antigens in tissue sections by the use of specific 
antigen-antibody interactions, which culminate in the attachment of a marker 
to the antigen. Through a series of steps, an enzyme that forms a coloured or 
fluorescent reaction product (visible with a microscope) is attached to the 
antibody ‘probe,’ allowing the presence or absence of the antigen in the cells 
to be determined as well as enabling an assessment of its distribution and 
variability within a given specimen to be made (Figure 2.1). This can be 
accomplished by viewing the stained slide with a standard or specialised 
microscope. IHC provides a permanent record with excellent preservation of 
cell morphology and can be performed on formalin-fixed paraffin wax-
embedded tissue or on frozen tissue. IHC allows direct visualisation of the 
cells bearing or lacking the marker of interest, so allowing direct correlation 
with histopathological features of the diagnostic material. 
 
 
2.2.2 Immunolabelling with streptavidin-biotin 
complex 
 
Originally, the glycoprotein avidin was used to conjugate with biotin, however, 
avidin may bind non-specifically to negatively charged structures such as the 
nucleus, and as it is a glycoprotein, it can react with molecules such as 
lectins. In this study, the formation of streptavidin-biotin complex was chosen 
as the immunolabelling method of highest sensitivity because it uses its high 
affinity of streptavidin for biotin. Streptavidin is a protein (molecular weight 60 
kDa) isolated from the bacterium Streptomyces avidinii, and has 4 high affinity 
binding sites for biotin although not all are used due to molecular orientation. 
Streptavidin has an isoelectric point close to neutral pH and therefore 
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possesses few strongly charged groups at the near neutral pH used in IHC 
detection systems. The physical properties of streptavidin make this protein 
much more desirable for use in IHC detection, compared to avidin. 
Streptavidin and biotinylated enzyme are simply mixed at appropriate 
concentrations and allowed to stand for at least 30 minutes at room 
temperature for the complex to form. This pre-formed complex is attached to 
the biotinylated secondary antibody. Careful stoichiometric control ensures 
that some binding sites remain free to bind with the biotinylated secondary 
antibody. This allows the pre-formed complex to bind and provides a very high 
signal at the antigen-binding site (Figure 2.1). 
 
 
 
 
Abbreviations: B-Biotin; S-Streptavidin; P-horseradish peroxidase 
 
 
 
Figure 2.1 The Streptavidin-Biotin method for IHC. 
 
 
P 
P 
P 
S 
B B 
B 
B 
B 
B 
S 
B 
  P 
B 
B 
Antigen 
Primary antibody 
Biotinylated 
secondary 
antibody 
Peroxidase-streptavidin-biotin 
complex 
Streptavidin / biotin complex 
          Tissue 
 87 
2.2.3 Standard IHC protocol 
 
Immunohistochemical analysis for the expression of all the proteins in this 
work was performed using an indirect peroxidase-based labeling procedure 
with a streptavidin-biotin-horseradish peroxidase detection system (Dako, 
U.K, Appendix I). IHC was optimised to ensure reduction of non-specific 
background staining using a suitable positive control for each respective 
antibody. For IHC, sections were from formalin-fixed paraffin wax-
embedded tissue.  
 
The sections were deparaffinised in xylene and rehydrated in different 
grades of ethanol up to distilled water. Endogeneous peroxidase activity 
was quenched with a 3% v/v fresh solution of hydrogen peroxide followed 
by a wash in phosphate buffered saline (PBS; see Appendix I). To optimise 
immunoreactivity, antigen retrieval was performed using different methods 
for each protein: 
 Heat-induced epitope retrieval (HIER) – this method is used to 
increase the sensitivity of reactions directed to paraffin resistant 
antigens, especially those found in the nucleus. The most common 
HIER methods use pressure cookers, microwave ovens or autoclaves 
as the heat source and low molarity buffers with acid or alkaline pH 
357,358 359,360. In this project, several attempts using different conditions 
such as low to full power of the microwave or pressure cooker, heating 
incubation time of 2, 5, 10 and 15 minutes and different buffers (sodium 
citrate or EDTA buffer) were used to enhance the retrieval of the 
antigens. As a result, microwaving in sodium citrate buffer (pH 6.0, 
Appendix I) for 10 minutes at full power or pressure cooking in sodium 
citrate buffer (pH 6.0, Appendix I) for 2 minutes were the established 
optimum conditions. 
 
 Protease digestion or protease induced epitope retrieval (PIER) – 
Initially, this method was commonly used to counteract the antigen 
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masking effects of formalin fixation. It involves the use of numerous 
enzymes such as proteinase K, trypsin, DNAse and pepsin which is 
required for the cleavage of the molecular cross-linking, allowing the 
epitope to return to its normal configuration, hence enabling more 
binding of the antibody; however, the cleavage is not specific and some 
antigens might be negatively affected by this treatment 361. By trial and 
error, using different times incubation of 5, 10 and 15 minutes, as well 
as various concentrations of protease solution of 6, 10, 12.5 and 15 
mg, the optimised conditions were found to be the use of protease 
digestion (Bacterial protease Type 24, Sigma) 12.5 mg in 100 ml of 
PBS at 37˚C for 10 minutes (Appendix I). 
 
 No antigen retrieval step – this method is performed for antibodies 
which are easily detected, without causing any background that may 
result in non-specific staining. 
 
The sections were then placed in a humidity chamber and a solution of 
serum (normal rabbit or goat) was added to prevent non-specific staining 
(10% v/v in PBS, left for 15-30 minutes at room temperature). This serum 
was then removed by tapping off the excess and the primary antibody was 
placed on top of the section using the optimum dilution (Table 2.1). All 
dilutions were performed in bovine serum albumin (BSA) diluted in PBS 
(see Appendix I) unless specified.  
 
Optimisation of antibody dilutions was performed for all primary antibodies 
on control tissue sections, initially using the dilution range recommended 
by the manufacturer and then performing other dilutions to optimise 
conditions. The sections from the control tissue were then assessed for 
intensity of staining and absence of non-specific staining. The optimal 
dilution chosen for each antibody was the one in which there was good 
quality brown staining which disappeared if the dilution was increased. 
Incubation times were also optimised for all antibodies, along with the 
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incubation temperature, allowing specific staining with the lowest 
concentration of antibody but still providing intense specific staining. Table 
2.1 shows the optimum antigen retrieval step used for each protein. 
 
Following incubation, the primary antibody was washed off in two 3-minute 
washes with PBS. The secondary antibody, was then applied in PBS-BSA 
containing a 10% dilution of normal human serum (see Appendix I). The 
secondary antibody uses the primary antibody as its antigen; hence a 
mouse monoclonal primary would have a secondary antibody raised 
against the mouse. This secondary antibody had been biotinylated; i.e. 
biotin had been added chemically. It was added at a dilution of 1:200 and 
was left at room temperature for 30 minutes. The secondary antibody was 
then removed by two 3-minute washes with PBS and then reacted with 
peroxidase-conjugated streptavidin-biotin (Appendix I) at a dilution of 1:200 
for 30 min. Excess peroxidase was washed off in 2-3 washes of PBS and 
peroxidase activity was detected by incubating the sections in a solution of 
3, 3'-diaminobenzidine tetra hydrochloride (Appendix I) for 5-8 min until a 
brown colour had developed. Placing the slides in tap water then 
terminated the reaction. The slides were counterstained in Mayer’s 
haematoxylin, which is used to define nuclear structures, washed and 
finally rehydrated with grades of ethanol. They were then cleared in xylene 
to allow the refractive index to come to 1, mounted in DPX and a cover slip 
was then added. 
 
 
2.2.4 Controls 
 
A known positive control was added to each staining batch to ensure that the 
staining was successful. The same control specimen was used for each run 
for a given antigen to evaluate the intensity of the stain. The control used was 
placental tissue in all cases. Negative controls were also included in each 
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staining run. They were the tissue under investigation with omission of the 
primary antibody (replaced by PBS) in order to ensure that other reagents do 
not stain non-specifically. In the negative control for VEGF staining, the 
primary antibody was replaced by IgG2B. 
To ensure staining consistency and reproducibility, a number of 
precautions were taken:  
i. Sections from different blocks were stained as a batch on the same 
day and the process was repeated 3-4 times for each protein to assess 
the uniformity of the intensity of the staining. 
ii. If available, different blocks (approximately 2-3) from the same 
specimen were analysed separately and the most representative block 
was used. 
iii. Results were analysed independently by three observers (Dr Anne 
Christine Wong te Fong, Dr Julie Crow and me).  
In all cases, there was <5% variation in results between sections, blocks 
and observers. A consensus score was then achieved. 
 
 
2.2.5 Immunohistochemical staining with VEGF-
A antibody.  
 
Sections were deparaffinised in xylene and rehydrated in different 
percentages of ethanol up to distilled water for 10mins.3% hydrogen peroxide 
was placed on the sections to block endogenous peroxidase for 10mins. They 
were then placed in distilled water for 10min at 37 ºC.  
 
Optimisation of the protocol was performed for the primary antibody as above.  
Optimisation of the antigen retrieval method was performed using 3 different 
methods; microwaving in sodium citrate buffer(pH 6.0) for 10 minutes at 
750watts; protease digestion( bacterial protease Type 24, Sigma) using 
12.5mg in 100ml of PBS at 37C for 10mins, and finally using no antigen 
retrieval. Different protease digestion times (using different time intervals of 5, 
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7.5, 10 and 15mins) and protease concentrations (6, 10, 12.5 and 15mg) as 
well as different incubation times and temperatures were also tried. The 
optimal incubation time and temperature was identified when specific staining 
was achieved with the lowest concentration of antibody but still providing 
intense staining.  
 
Sections were stained on three separate occasions to ensure reproducibility. 
Results were analysed by three independent observers (GKS, JCC, LFWTF). 
In all cases there was < 5% variation in results sections and observers.  
 
 
Table 2.1 :   Antibodies and Optimum conditions used for 
Immunohistochemistry. 
 
Antigen Source Clone Working 
dilution 
Antigen 
Retrieval    
Positive 
control 
Negative 
control 
Incubation 
time 
Incubation 
temperature 
Human 
VEGF 
R&D  
Systems, 
Abington, 
UK 
26503.1 
IgG2B 
1:40 Protease 
digestion 
Placenta IgG2B Overnight 4ºC 
 
 
Biotinylated rabbit antimouse serum (Dao, Cambs, UK) dilution 1: 400 in TBS, 
PBS was used as the secondary antibody in all cases.  
 
 
 
2.2.6 VEGF Quantification 
 
For the assessment of VEGF, regions of interest containing tumour cells and 
no connective tissue stroma were defined by two independent observers (JCC 
& GKS). Each slide that contained tumour was analysed by using a eye-piece 
graticule that defined an area of 1cm x 1cm at a magnification of 200 times 
(i.e with x20 objective). That graticule comprised 100 individual squares (each 
1mm  x 1mm) and was placed over all fields of the slide that contained tumour 
(minus large areas of connective tissue), All areas that contained tumour were 
analysed. The identification of at least 1 VEGF-positive cell within the confines 
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of an individual square defined that square as a positive focal area. The 
number of VEGF-positive focal areas was added up for each slide and then 
an average number of focal areas for that case were obtained. Using the tariff 
shown in Table 1 (scoring system devised by GKS and JCC), the average 
number of focal areas per case was converted into a score for VEGF, on an 
increasing linear scale of 0 – 5, (where 0 = 1 - 4 focal areas, and 5  >50 focal 
areas). 
 
 
Table 2.2. VEGF score by IHC as a function of the number of focally positive VEGF 
areas 
 
 
 Number of focal areas per cm2 of tissue section 
 1-4 5-9 10-14 15-19 20-24 25-20 30-34 35-39 40-44 45-50 >50 
Score 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 
 
 
 
2.2.7 Statistical Analysis 
 
The correlation between VEGF-A levels and other prognostic variables was 
statistically analysed by means of Pearson’s chi squared test, Spearman rank 
correlation analysis and univariate analysis. Survival rates were examined 
using Kaplan-Meier plots of analysis. The statistical significance of differences 
between the survival rates of groups with different VEGF expression ie high or 
low expression was assessed by the log-rank test. The independent 
prognostic significance of variables was assessed by multivariate analysis, by 
means of a multivariate Cox regression model. P values of <0.05 were 
considered statistically significant. All statistical analysis was carried out using 
SPSS version 15.0.  
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Expression of the intratumoural VEGF-A protein was correlated with platinum 
sensitivity (using Mann-Whitney U Test and a Fisher’s Exact Test). Spearman 
Rank correlations were calculated to test for association between VEGF-A 
expression and, patient age, tumour stage, grade and survival. Survival times 
were estimated in months from the date of operation to the date of death (or 
date of last follow-up). Kaplan Meier survival plots and a log rank test were 
used for the univariate analysis. The Cox Proportional Hazard Model was 
used for multivariate analysis.  
 
Univariate and Multivariate Logistic regression was used to investigate the 
association with clinical response to platinum based chemotherapy of each of 
the variables described above. Response to therapy was defined as for the 
2003 revision of the ‘Gynaecologic Oncology Group’ criteria. 362. Patients who 
had progressed on chemotherapy or who relapsed within 6 months of 
completing of completing their primary therapy were defined as platinum 
resistant. All other patients were categorised as responders to platinum-based 
therapy. Recurrence of tumour was defined by imaging modalities (MRI and 
MRI modalities) and/or by the demonstration of increasing levels of CA-125 in 
the serum.  
 
Patients were divided into two groups based upon the intra-tumoural VEGF 
expression, the median value of the VEGF score, which was 3, was taken as 
the cut off point. Therefore the groups were: 
1) High VEGF expression; score of 3 or > 3.  
2) Low VEGF expression score of <3.  
These two data sets were used to analyze the data statistically. 
 
A cut-off point for scoring of VEGF as high expression (≥3) and low 
expression (<3) was used to analyse some of the data statistically. 
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2.3 CASE CONTROL STUDY 
 
2.3.1 Study Design 
 
Genetic studies for common diseases fall into many broad categories: family-
based linkage studies across the entire genome, linkage disequilibrium 
mapping studies, and population-based association studies of individual 
candidate genes. Genetic association studies in cancer are complex because 
of the multi-stage process of cancer and difficulties in analysing genetic 
variants in population and family studies. This study fell under the last 
category and the basic question this study was designed to answer was 
“whether the suspected genetic factor was associated with the outcome of 
interest ie development of cancer?” Prospective studies are considered to be 
the most powerful and reliable because by randomisation they are able to 
balance the unknown prognostic factors. However, since ovarian cancer is 
comparatively a less frequent cancer and given the time and logistical 
constraints of this study, it was not possible in this study setting to achieve a 
sufficient sample size or proper follow up required in a prospective study. A 
case-control study was therefore designed to assess the relationship between 
the described genotype and the presence of cancer, the outcome event. The 
exposure of primary interest was the presence or absence of the genotypes or 
haplotypes determined by the chosen set of angiogenesis related genes. The 
outcome events in this study were the development of epithelial type of 
ovarian cancer. The objective was to compare exposure history between the 
case and the control groups. 
 
The strengths of this case-control study were: 
• It was less constrained by the natural frequency of the disease. 
• It greatly shortened the waiting time generally required by cohort 
studies. 
• It was low cost and it had fewer practical problems. 
• It was ideal for the assessment of the chosen disease aetiology. 
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• The chosen population are known to have a high rate of consanguinity; 
therefore the sample size could be smaller. 
 
The drawbacks of this retrospective case-control study were: 
• Randomisation was not possible and population at risk was undefined 
• Selection biases were unavoidable and causal interpretation was 
unattainable due to presence of confounding factors 
• Since a baseline had not been defined there was no absolute measure 
of many confounding variables.  
 
 
2.3.2 Target population 
 
The aim of the study was to obtain the information about and apply the result 
to the Pakistani population. For both the study groups (cases and controls) 
the target population was individuals of Pakistani ancestry who had been 
resident in Pakistan for most of their lives.  
 
 
2.3.3 Patients 
 
This case-control study was undertaken in a population based ovarian cancer 
collection from four tertiary referral centres and hospitals in Karachi (Liaquat 
National Hospital, Aga Khan University Hospital, and Ziauddin University 
Hospital) and Lahore (Shaukat Khanum Memorial Cancer Hospital and 
Research Centre).These centres were selected, due to the fact that most of 
the ovarian cancer patients were known to attend the centres selected. The 
study was conducted between September 2005 and June 2007. A total of 400 
cases of epithelial ovarian cancer (EOC) were identified and recruited from 
the above named centres. During the same period 438 controls were recruited 
and interviewed. The controls consisted of women attending hospital based 
outpatient clinics.  
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2.3.4 Case definition 
 
A case was defined as: 
An individual of Pakistani ancestry diagnosed with histologically 
proven epithelial ovarian cancer and undergoing treatment at any 
four of the participating centres as mentioned previously and 
having relevant patient information available in the hospital 
records either in electronic or paper form in the Department of 
Oncology and/or Department of Obstetrics and Gynaecology. 
 
 
2.3.5 Outcome of Interest  
 
Primary Epithelial Ovarian Cancer 
 
2.3.6 Bias considerations 
 
In designing the study the following sources of bias were considered. 
 
• Recall bias: It did not affect this study because the main variable under 
study did not depend upon the memory of the cases under study. Most 
of the data were obtained from the epidemiological questionnaire 
• Confounding bias: This is an inherent bias of case-control study, and 
could not be avoided because ovarian cancer patients are diagnosed 
at a late stage in life when co-morbidities are generally present, and 
there is no available technique at present to measure the stepwise 
DNA damage that occurs with advancing age. However, care was 
taken at analysis stage to handle this issue wherever possible. 
• Berkson’s Bias: A Berkson’s bias is introduced if subjects who are both 
exposed and diseased are more likely to be admitted to the hospital. 
The proportion of exposed in the disease groups can be inflated 
artificially. E.g. in a study for an association between low birth weight 
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and cerebral palsy, infants having both low birth weight plus palsy are 
more likely to be admitted as compared with cerebral palsy alone. This 
would distort the real effect of exposure when cases are selected only 
from the hospital. Berkson’s bias did not affect this study because the 
exposure under study did not by itself increase the chances of 
admission to a tertiary care hospital. 
• Neyman’s Bias: A Neyman’s bias is introduced when the study base 
does not capture all the cases it is supposed to capture, thus distorts 
the true prevalence of the disease e.g. if the disease is very transient 
(or leads to early death) or this could also happen to studies of 
asymptomatic diseases (HPV). Neyman’s bias could not be avoided 
although the study was done in four centres and missed the cases that 
were representative of other centres. However, the results of the study 
ware not affected by this bias because an exact measure of prevalence 
was not required.  
 
 
2.3.7 Selection of Controls 
 
The controls consisted of women attending hospital based outpatient clinics. 
Hospital matched controls were selected to balance the hospital related 
confounding factors, additionally it helps in excluding the possibility that the 
exposure itself is a cause of admission to hospital (please refer to definition of 
Berkson’s bias in previous section). It also reduces the cost of the study. 
However, the inferences drawn from the hospital controls would not be valid if 
the distribution of exposures are significantly different from population 
controls. The controls in this study were selected from the fracture clinics and 
obstetric and gynaecology outpatient clinics. The inclusion criteria for controls 
were women not to have a personal or family history of ovarian or breast 
cancer. 
 
 
 98 
2.3.8 Study setting 
 
The study was part of the Pakistani Ovarian Cancer Study carried out in the 
departments of oncology and Obstetrics and Gynaecology at four tertiary 
referral centres in Pakistan, in two cities in Pakistan, Lahore and Karachi. The 
participating centres although tertiary centres covered a wide geographical 
area and had a catchment population that covered all socioeconomic and 
ethnic groups, within the Pakistani population. 
 
2.3.9 Inclusion Criteria 
 
• Proven cases of primary epithelial  ovarian  cancer 
• Pakistani ancestry for both cases and controls 
• Availability of medical records of cases 
• Controls free from any malignancies both without personal history and 
family history. 
 
2.3.10 Exclusion Criteria 
 
• Presence of DNA from tumour tissue 
• Personal or family history of breast or ovarian cancer in the controls 
• Non amplification in PCR 
• Non-reproducibility of genotyping result 
 
2.3.11 List of Variables 
 
2.3.11.1 Dependent Variables 
• Tumour histology: All cases were epithelial ovarian cancer. 
• Post operative outcome: This was measured from the date of 
operation to death or recurrence of the disease. 
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2.3.11.2 Independent Variables 
 
2.3.11.3 Variables of Primary Interest              
• VEGF 1154 A/G  polymorphism; (SNP rs ID 3024997 number; 
Individual sequences can be referred to by their refSNP cluster ID 
numbers). 
• Postoperative outcome 
 
2.3.11.4 Other Variables 
• Age 
• Tumour size: This was both of the primary and metastatic tumour. 
• Tumour Grade 
• Tumour stage: based on the International Histological Classification 
of Ovarian Tumours recommended by FIGO. 
 
 
2.3.12 Sample Size Calculation  
 
The aim of sample size calculation for this study was to enable a judgement 
that is accurate and reliable, to get a precise estimate of proportions in the 
two groups and at the same time not waste resources and time by choosing a 
larger than required sample size. The sample size calculation related to final 
achieved sample allowing for response rates and loss to follow up. The 
calculation was based on a power of 80%, an effect size of 20 percent. 
Since this is the first study in the Pakistani population that undertook to 
examine the distribution of genotypes in ovarian cancer patients, no previous 
data were available to presume a proportion of outcome in a particular 
genotype or haplotype or vice versa. For the purpose of calculating sample 
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size proportions p1 and p2 of 60% and 40%, respectively, were assumed and 
an effect size of 20 % was taken as clinically significant difference in 
outcomes (http://www.sgul.ac.uk/index.cfm?DD25D103-C079-6609-F78D-
BC005970DCD9).  
 
n = required sample size for each group 
A = depends on desired significance level. 1.96 for 5% significance level 
B = depends on desired power. 0.84 for a power of 80%. 
p1 = High risk allele frequency in cases (primary outcome variable in this study 
was either presence or absence of ovarian cancer 
p2  =  High risk allele frequency in controls. 
 
n = 294 in each group 
 
 
2.3.13 Ethical Considerations 
 
In designing this study, it was recognised that genetic susceptibility 
biomarkers could have an impact not only on the study subjects but also on 
their families. Biomarkers that are obtained from the individual person have 
the potential for providing important information about exposures, biological 
effects of exposures, and susceptibility for disease for that individual and her 
family. No medical interpretation of the genotyping result was provided to the 
patients or any other individual. However, it is recognised that study subjects 
have rights to appropriate information before, during and after the study. It 
was explained to the participants of this study that the results obtained were 
part of a research study, and the clinical interpretation and importance of the 
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presence of the polymorphism in question was not known and that any results 
would have to be verified in a larger population based study. 
 
Ethical approval was obtained from the Ethics committee of each individual 
participating centre prior to the start of the study. The individual hospital 
based Committees operate according to the general principles of medical 
ethics including the Declaration of Helsinki.  
 
Written assurance was provided to the Ethical committee in each individual 
institution that the leftover genetic material would not be used in any other 
study without fulfilling legal and ethical requirements. The stored genetic and 
biological material is neither identifiable nor traceable back to the donor. Care 
was taken to inform the participants of their freedom to refuse participation in 
the study. The information leaflet, was translated into the local language Urdu, 
and was provided to each participant and given enough opportunity to 
carefully peruse the leaflet. Informed consent form was approved by the 
ethical committee. Written informed consent was obtained from participants. 
Use of patient’s records/histological records has been explained elsewhere in 
the material and methods section. Confidentiality of data was ensured and 
access was limited to directly concerned researchers only. The data were 
stored and reported in a way that did not identify the study participants to a 
third party. After obtaining relevant information about the study subjects they 
were coded and anonymised and could not be traced back to subject 
identification. 
 
 
2.3.14 Data collection 
 
 A comprehensive clinicopathological database of all patients was constructed 
in an Obstetric and Gynaecology Department of each institution, clinical 
information from the patients’ charts was entered into the electronic database 
by the research officer assigned to the study at each centre. 
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Genotyping and haplotyping data were entered into SPSS, as and when it 
became available, throughout the duration of the study. 
 
 
2.3.15 Sample collection and storage 
 
Data collection and sample collection was started in September of 2005 and 
continued up to June 2007. This study was running in parallel with the 
Pakistani Ovarian Cancer Study (POCS), which is looking at the 
epidemiological factors associated with ovarian cancer in the Pakistani 
population. To date this study has over 2000 ovarian cancer cases and 3000 
controls, with both DNA from study subjects and epidemiological data. This 
has been collected over a period of 5years and is part of the International 
Ovarian Cancer Consortium, examining genetic and lifestyle factors 
predisposing to the development of ovarian cancer. 
 
The blood samples for both cases and controls were collected by the research 
officers assigned to the study at each participating centre. A total of 10 ml of 
venous blood was drawn in a purple top tube (vacutainer) containing EDTA 
(ethylenediaminetetraacetic acid) as an anticoagulant. All tubes were labelled 
with a sample ID. Blood samples were either refrigerated or frozen until 
extraction of DNA. 
 
Patient names and other information linking the samples to the patients’ 
identification were removed and replaced by sample ID numbers. The 
researchers involved in the PCR analysis of these samples were blinded to 
clinicopathological data, of the samples. 
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2.3.16 Selection of polymorphism in the VEGF 
gene and Primer Design 
 
2.3.16.1 DNA extraction 
1. REQUIREMENTS 
a. CONSUMABLES 
1. 50 ml polypropylene centrifuge tube  
2. 15 ml polypropylene centrifuge tube 
3. 1.5 ml centrifuge tube 
4. Blue (100-1000 microlitres) and yellow (10-200 microlitres) 
tips for pipettes. 
 
b. REAGENTS 
1. Solution A 
2. Solution B 
3. Sodium per chlorate (5M) 
4. Chloroform 
5. Absolute Ethanol / Isopropanol 
6. 70% Ethanol 
7. Autoclaved-deionized water / TE ( Tris EDTA ) 
 
c. EQUIPMENT 
• Water Bath 
• Centrifuge 
• Micro Centrifuge 
• Vortex 
• Incubator 
• Refrigerator 
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d. RECIPES OF SOLUTIONS 
 
SOLUTION A (1 Litre)     SOLUTION B (1 Litre) 
 
Tris  = 1.21 gm   Tris = 48.5 gm 
Sucrose  = 109.5 gm   EDTA = 22.3 gm 
MgCl2  = 1.02 gm (Hexahydrate) NaCl = 8.77 gm  
Triton (100%) = 10 ml    Autoclave 
Adjust the ph at 8              Add 10 gm SDS 
Autoclave 
 
 
2. PROCEDURE 
i. PREPARATION 
• Prepare solution A and solution B. 
• Set a water bath at 65ºC. 
• Label a 50 ml polypropylene centrifuge tube. 
• Add 5-10 ml of blood to the tube. 
• Fill the tube with 40 ml of solution A. 
• Spin for 20 minutes at 2500 rpm. 
• Dump the blood out into the appropriate waste container, 
leaving behind a cell pellet. 
 
ii. CELL LYSES 
• Add 2 ml of solution B and vortex briefly to re-suspend the cell 
pellet. 
  
 
iii. DEPROTEINISATION 
• Add 500 µl of Sodium per chlorate (5M) to the cell suspension 
and mix manually. 
• Incubate the tubes in a 65ºC water bath for 25 minutes. 
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iv. DNA EXTRACTION 
• Add 2 ml of Chloroform to the cell suspension, vortex and spin 
at 2500 rpm for 15 minutes. 
• Pipette out the top (DNA) layer into a fresh 15 ml centrifuge 
tube. 
 
 
v. DNA PRECIPITATION 
• Add 2 volumes of Absolute Ethanol / Isopropanol. 
• Invert gently to precipitate the DNA. 
• Keep the tube inverted for 5 minutes. 
• When DNA is settled at bottom then decant Isopropanol. 
• Add 1 ml of 70% Ethanol. 
• Transfer it in 1.5 ml centrifuge tube. 
• Spin Eppendorf tubes at 10,000 rpm for 15 minutes. 
• Decant 70% Ethanol and allow DNA to air dry to remove excess 
alcohol. 
 
 
vi. DNA RESUSPENSION 
• Re-suspend the DNA in water / TE (Tris EDTA). 
• Incubate it at 37ºC for 12 hours. 
• Then place at 4ºC for storage. 
 
 
vii. READ O.D AT RATIO 260/280 nm BY 
SPECTROPHOTOMETER 
• First make dilution (100 percent) of dissolved DNA sample. 
• Fill 1.5 ml centrifuge tube with 495 ul Autoclaved deionized 
water. 
• Add 5 ul DNA into above tube, mix it and than take O.D. 
• Note down the quantity and quality of the DNA. 
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2.3.16.2 Selection of Polymorphism in VEGF Gene, 
Primer Design and SNP Genotyping 
Tetra-Primer ARMS-PCR 
It is known that single nucleotide polymorphisms (SNP’S) occur approximately 
once per 250-1000bp and account for approximately ~90% of DNA sequence 
variation in the human genetic structure 363. Analysis of SNP’S has been 
increasingly used in studying genetic determinants of complex diseases. The 
stability and large numbers of SNPs within the genome, make them especially 
useful DNA markers 364. 
 
Population genetics and genetics association studies require the analysis of 
large numbers of subjects, it would be beneficial if techniques were employed 
for SNP genotyping that were, simple, low cost, and high throughput, such as 
Tetra-Primer ARMS-PCR. This technique was chosen for this study, as it is 
known to be simple and economical, especially relevant for research in low 
resource setting such as Pakistan. It involves employing two primer pairs to 
amplify, respectively, the two different alleles of a SNP, in a single PCR 
reaction, followed by gel electrophoresis, it utilises some of the certain 
principles of the tetra-primer PCR method 365, and the amplification refractory 
mutation system (ARMS) 366. The main advantage of this method is that it only 
requires a single PCR reaction and does not need post PCR manipulation, 
making it rapid, simple and cheap. The initial planning of primers, is a critical 
step of this technique but is often time consuming. To circumvent this problem 
a primer design computer programme, which has made this task automated 
and accessible through the Internet, at http://cedar.genetics.soton.ac.uk/-
publiic/html/primer1.html. Users need to input the target DNA sequence, 
specify the polymorphic site and define criteria for the primers (Tm, %GC, 
length and complementarities) and product sizes 365. 
 
Single nucleotide polymorphism (SNP) was selected in the VEGF gene (Table 
2.3). This polymorphism is non coding and is intronic. Flanking sequence was 
retrieved from ENSEMBL. The tetra primers ARMS-PCR procedure365 was 
used to genotype the SNP (rs3024997). The method employs four primers to 
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amplify a larger fragment from DNA containing the SNP and amplicons 
representing each of the two allelic forms (Table 2.3). Primers were designed 
using web based software made accessible by Ye.et.al 
(http://cedar.genetics.soton.ac.uk/public_html/primer1.html). 
 
Optimisation of tetra-primer ARMS PCR for detection of rs3024997 
polymorphism was performed empirically. For outer-inner primer pair Mg2+ 
concentrations was tested from 1.5 mM to 4 mM. Searching for the optimal 
one, annealing temperatures were tested from 53°C to 67°C by using the 
gradient function of thermal cycler (Eppendorf). The usually suggested outer–
inner primer ratio (1:10) for tetra-primer ARMS PCR (Ye.et al 2001) was used. 
Finally optimised PCR was performed in a total volume of 10 µl containing 
200-300 ng of template DNA, 1 pmol of each inner primer, 0.1 pmol of each 
outer primers, 200 µM dNTP, 2 mM MgCl2, 1Xbuffer and 0.5 U of Taq DNA 
Polymerase (Promega). 
 
PCR conditions were: initial denaturation at 94°C for 7 minutes followed by 34 
amplification cycles each consisting of denaturation at 94°C for 45 seconds 
annealing at -66.2°C for 45 seconds and extension at 72°C for 45 seconds 
and final extension at 72°C for 7 min.  
 
Agarose gel electrophoresis was used to separate and analyse DNA. The 
DNA was visualised in the gel by addition of ethidium bromide (EtBr). EtBr 
binds strongly to DNA by intercalating between the bases and is fluorescent. 
2% agarose gels were made in all cases. Different sizes of gels (with varying 
numbers of wells) and gel tanks were used. 10 µl of PCR product along with 2 
µl of loading dye was used to load the wells. Since the size of the DNA 
fragments ranged between 100 and 500 bps, a 100 bp ladder was used to 
identify the sizes of fragments.  
 
The amplified products were electrophoresed in a 2.5 % agarose gels made 
by adding 2.5gm of agarose to 100ml of 0.5X TBE at pH 8, the solution was 
then carefully brought to boil in a microwave oven to dissolve agarose. 0.7 ul 
of ethidium bromide (stock 10mg/ml) was added and solution was stirred to 
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disperse ethidium bromide and then poured into the gel casting tray . Combs 
were inserted into the gel and were taken out on solidification of the gel. The 
gel together with the tray was put in an electrophoresis chamber and TBE of 
same concentration was poured to completely cover the gel. 10ul of amplified 
products were loaded in to the wells, the lid of the electrophoresis chamber 
was closed and current (100 V) for 45 minutes was applied. DNA moved 
towards the anode due to negative charges on its phosphate backbone. After 
45 minutes gel was visualised under UV trans-illumination (GelDoc®, Biorad, 
Hercules, Ca, USA). 
 
 
 
Table 2.3.SNP ID and Primer Sequences 
 
 
refSNP  
ID      
Polymorphis
m 
              Primer Sequence(5'-3')  Tm 
( °C ) 
Amplicon 
size  
        ( bp )      
rs302499
7 
       G/A 
 
Forward inner primer(A allele): 
GATTTTGGAAGGACTTGCCTGATGCA 
Reverse inner primer(G allele): 
CTGTAATGCCACTCTTTGGAGCTGCC 
Forward outer primer: 
GTGTGATCTCTGGAATGAAAACAGGCC
T 
Reverse outer primer: 
ATCAGGGTACTCCTGGAAGATGTCCAC
C 
63.2 
 
 
66.4 
 
65.1 
 
68.0 
 
208(A allele) 
 
 
 
144(G allele) 
 
300(from two 
outer primers) 
 
 
2.3.17 Statistical Analysis 
 
The statistical analysis was carried out by Professor Philippe Frossard and Dr 
Danish Salaheen, at the Centre for Non Communicable Diseases Pakistan 
and Strangeways Labaroratory Cambridge University UK. 
2.3.7.1 Statistical software and Data entry 
STATA version 10 was used for all data entry purposes. The original data 
were obtained in Excel format. The data were transferred to STATA data 
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editor from excel and variables were labelled in the variable view of the 
STATA data editor.  
 
2.3.17.2 Descriptive Statistics 
Tables were made using C tables in SPSS. Summary of data e.g frequency 
counts, percentages, was obtained using the descriptive and graphs menu in 
SPSS. Means, Medians, Standard deviations, and Ranges were given in case 
of continuous variables. Characteristics of groups have been described in 
appropriate sections. 
 
2.3.17.3 Data Analysis 
The association between VEGF rs 1570360 and EOC was modelled through 
multivariate logistic regression analysis. Odd ratios and confidence intervals 
were used to assess the occurrence of VEGF -1154G>A genotypes in 
patients with EOC cases compared with the control group. Significance 
testing was carried out by combining chi-square tests and then comparing the 
two independent proportions. Adjusted OR’s for the epidemiological covariant 
such as history of gynaecological cancer and/or other cancer types in the 
family, tumour stage and grade, age and ethnicity, were determined by using 
a multivariate logistic regression method. Survival associated with each of the 
three genotypes was estimated by Kaplan-Meier survival analysis. We 
considered results with P<0.05 as statistically significant.  STATA 10.0 was 
used to carry out the statistical analyses. 
 
The measure of Hardy-Weinberg disequilibrium was calculated as the function of the 
difference between the observed and expected genotype frequencies. Estimation of 
departure from Hardy-Weinberg proportions was evaluated with the help of DA 
statistic and tests of statistical significance were applied as reported by Haviland. 367. 
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CHAPTER 3:   PROGNOSTIC 
SIGNIFICANCE OF INTRA-TUMOURAL 
VEGF AS A MARKER OF TUMOUR 
ANGIOGENESIS IN EPITHELIAL 
OVARIAN CANCER 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publication: 
Prognostic significance of intra-tumoral Vascular Endothelial Growth Factor 
(VEGF) as a marker of tumour angiogenesis in epithelial ovarian cancer. 
Siddiqui GK, Elmasry K, Wong Te Fong AC, Perrett C, Morris R, Crow JC, 
Maclean AB. Eur J. Gynecol Oncology 2010; 3(2): 156-9. 
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3.1 INTRODUCTION 
 
3.1.1 ANGIOGENESIS  
 
Angiogenesis is the formation of new capillary blood vessels from pre existing 
microvessels. Vasculogenesis is the process whereby the early vascular 
plexus forms from the mesoderm by the differentiation of angioblasts 
(vascular endothelial cells that have not yet formed a lumen), which 
subsequently generate primitive blood vessels. Mesoderm-inducing factors of 
the fibroblast growth factor are crucial in inducing paraxial and lateral plate 
mesoderm to form angioblasts and haematopoietic cells. Angiogenesis 
precedes and sustains tissue growth and therefore plays a critical role in 
normal tissue physiological processes such as reproduction, wound healing or 
bone remodelling368 369. 
 
Angiogenesis involves the migration of endothelial cells from the parent 
vessel towards a chemo-attractant. As well as the ability to promote 
endothelial cell migration, angiogenic factors must also degrade the matrix 
through which the cells move. Endothelial cell invasion, as part of the 
angiogenic process, involves secretion of urokinase-type plasminogen 
activator and its inhibitor (PAI-1). Fine maintenance of the proteolysis balance 
seems to be crucial for the correct development of new blood vessels. Having 
migrated, the endothelial cells must proliferate, lay down their own basement 
membrane and form a lumen, which is the basis of the new capillary. This 
sequence of events: cell migration, matrix degradation and proliferation, is the 
basis of angiogenesis. Many different factors have been identified that 
promote angiogenesis; the most extensively studied is vascular endothelial 
growth factor (VEGF)370.  
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3.1.1.1 TUMOUR ANGIOGENESIS and its role in 
ovarian cancer 
It is recognised that tumour angiogenesis is critical for tumour growth beyond 
2mm and is associated with prognostic significance in a variety of solid 
malignancies such as breast, prostate, gastric and non–small cell lung 
cancer129 371.  
In theory, the development of tumours is associated with two phases of 
tumour growth8 97 372. First is the pre vascular phase which is seen with various 
intraepithelial neoplastic lesions, can persist for many years and are not 
capable of metastasis96. In contrast the “vascular phase” is characterised by 
rapid tumour growth and potential for metastasis. However results from 
studies in EOC are conflicting and the clinicopathological significance has 
been debated129 315 316 373. Vascular endothelial growth factor (VEGF) is a 
homodimeric glycoprotein expressed in a wide variety of normal and 
transformed cell types55. VEGF is a key angiogenic factor and acts as a highly 
specific mitogen promoting endothelial cell migration and inhibiting 
apoptosis12. Studies have suggested a specific role for VEGF in various 
phases of ovarian carcinogenesis with effects on tumour growth and 
neovascularisation illustrated in animal models and in humans298 343. 
Angiogenesis was suggested as a prognostic factor in various solid tumours 
but its clinicopathological significance in ovarian cancer and its exact role is 
unclear. In xenograft models of human EOC, the expression of VEGF is 
associated with the formation of ascites and the tumour growth rate is 
proportional to the Microvessel density MVD, which correlates with VEGF, 
and indirectly with angiogenesis297.   
Previous research has shown an association with the high expression of 
VEGF in EOC and worse overall prognosis in EOC and others have 
attempted to explore the role of VEGF on the development and progression of 
EOC289.  
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3.1.1.2 VEGF 
Vascular Endothelial Growth Factor (VEGF), a heparin binding glycoprotein 
was originally identified in the media conditioned by normal bovine pituitary 
folliculostellate cells10 and by a variety of transformed cell lines11 13 374. It is a 
multifunctional cytokine with potent angiogenic activity. VEGF stimulates 
angiogenesis through its action as an endothelial mitogen and its ability to 
increase vascular permeability.  
The VEGF family belongs to the platelet-derived growth factor (PDGF)/ VEGF 
supergene family. Having a homodimeric structure with 8 conserved cytokine 
residues in a monomer peptide. The VEGF family has at least 7 members, 
VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, PIGF and snake venom-
derived VEGFs. VEGF-A is a key player in vasculogenesis, as well as 
angiogenesis21 22 375.  
VEGF-A binds and activates VEGFR1 and VEGFR2 but not VEGFR3.The 
major subtypes of VEGF-A in humans are the 121,165, and 189-aminoacid 
types (18). VEGF-A165 is the dominant subtype protein among VEGF-A 
proteins in terms of amount and biological activity. VEGF-A165 binds with 
neuropilin-1 (Nrp1) and heparin, which contributes, to a gradient of VEGF-
A165 surrounding VEGF-A expressing cells. This gradient is known to be 
important for the stimulation of vascular endothelial cells, and for strong 
angiogenesis23. 
The biological effects of VEGF are mediated through the activation of specific 
tyrosine kinase receptors expressed mainly on angioblasts and endothelial 
cells34. VEGF acts selectively on endothelial cells by binding to specific class 
III receptor kinases. The receptor VEGFR-2 binds VEGF, VEGF-C and VEGF-
D and promotes the proliferation and motility of endothelial cells. VEGFR-1 
shows a 10fold lower kinase activity than VEGFR-2 and has been proposed to 
act as a negative regulator of VEGF-induced endothelial cell proliferation376; 
VEGF-R3 which in adults is exclusively expressed in lymph node endothelial 
cells, binds VEGF-C and VEGF-D34. 
Anti-VEGF therapy has been used in clinical trials to inhibit angiogenesis and 
is showing promising results in cancer therapies. Bevacizumab is a 
humanized recombinant antibody that binds to all isoforms of VEGF-A and 
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inhibits VEGF-A induced endothelial cell proliferation in vitro models111. It has 
shown promising results in several non-gynaecological tumours, especially in 
colorectal cancers377. Its application in the treatment of ovarian cancer is 
currently being tested39.  
 
 
3.1.2 Prognostic Factors in Epithelial Ovarian 
Cancer 
 
Surgery accurately stages the disease and allows the evaluation of a series of 
clinicopathological variables that are predictive of the prognosis of the patient 
and are often used to guide and select postoperative therapy. Established 
prognostic factors include: 
• Tumour Stage and Distribution  
• Volume of Residual Disease  
• Histological Subtype and Grade. 
 
 
3.2 AIMS  
 
Our study aims to determine intra-tumoural VEGF status in patients with EOC, 
and to investigate its relation to prognosis. The elucidation of the prognostic 
role of VEGF in patients with EOC may enable us to stratify patients with EOC 
into groups based upon the expression of VEGF, and to tailor treatment 
schedules, developing novel therapies to inhibit angiogenesis. These 
therapies are more likely to be most effective in tumours expressing high 
levels of VEGF.  
 
 
 
 115 
 
3.3 MATERIALS AND METHODS 
 
3.3.1 Patients  
 
VEGF expression was studied in 105 primary EOC samples, in patients who 
underwent surgical staging and tumour debulking at the Royal Free NHS 
Trust, London, UK between 1995 and 2000. Information on tumour grade, 
stage, presence or absence of residual disease after staging, and age at 
diagnosis was extracted from the case notes. Only patients considered to 
have primary EOC were included in this study. Survival was calculated from 
the operation date until death or December 2005 when any survivors were 
censored.  
 
 
3.3.2 Sample Collection and Preparation 
  
Clinical data and patient information were collected from the patient’s clinical 
records. Ethical approval was obtained for this retrospective analysis from the 
Royal Free Hospital and Medical School Research Ethics Committee (code 
number 09/H0720/87). Informed consent was obtained as per local 
guidelines. 
 
 
3.3.3 Tissue Specimens 
 
One hundred and five specimens were retrieved from the Histopathology 
department at the Royal Free Hospital UK. The archival cases had all been 
formalin fixed and paraffin embedded. In patients who underwent surgical 
staging and tumour debulking for primary epithelial ovarian carcinoma at the 
Royal Free NHS Trust London, between 1995 and 2000. Stage was 
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determined according to International Federation of Gynecology and 
Obstetrics (FIGO 1986). Only patients considered to have primary EOC were 
included in the study.  
A single consultant histopathologist (JCC) at the Royal Free Hospital originally 
diagnosed all cases. JCC reviewed all of the haematoxylin and eosin (H&E) 
stained slides of the cases to confirm the original diagnosis. Wax embedded 
sections of ovarian and omental tissues, 5um thick were cut using a 
microtome and mounted on 3- aminopropyltriethoxysilone (APES) coated 
glass slides to aid adherence. Slides were stored at 4°C if they not used 
immediately as there have been reports of loss of antigen when left at room 
temperature. These were placed onto 2% 3-aminopropyl-triethoxysilane 
(APES) coated slides (see Appendix I), and dried at 42°C for 30 minutes. The 
slides were placed in the incubator at 37°C for 2 days to firmly attach the 
sections to the slides and were stored in a slide box and placed at 4°C until 
required. Each block also had a corresponding Haematoxylin and Eosin 
(H&E) stained slide taken for comparison. 
 
 
3.3.4 Optimisation of the immunohistochemical 
protocol 
  
Immunohistochemistry was optimised to ensure reduction of non-specific 
background staining, using suitable positive controls for each respective 
antibody.  
 
Optimising of antibody dilutions was performed for the primary antibody 
starting with the recommended manufacturer’s dilution and then using a range 
either side of this. Incubation time was also optimised for the antibody along 
with incubation temperature allowing for specific staining with the lowest 
concentration of antibody, but still providing intense specific staining. 
 
Various antigen retrieval steps e.g. none, microwaving, pressure-cooking and 
protease digestion were also optimised using various concentrations and 
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incubation times. A known positive control was used in each staining 
procedure to ensure optimal quality of reagents and methods and to ensure 
that restaining was successful.  
 
The same control specimen was used for each run for a given antigen to 
assess the intensity of the stain. Negative controls (same specimen as 
positive control) were also included in each staining run (Table 3). In the 
negative controls the primary antibody was omitted and replaced by 
Phosphate Buffered Saline (PBS) in one reaction, and the secondary antibody 
replaced by PBS in another.  
 
 
3.3.5 Specific Immunohistochemical Staining 
with VEGF-A Antibodies 
 
See Materials and Mehod Section 2.25 p86-87.Tissue sections were 
deparaffinised in xylene (3x5min) and then rehydrated in different 
percentages of ethanol up to distilled water (3x5min). 3% hydrogen peroxide 
was placed on the sections to block endogenous peroxidase for 10mins. They 
were then placed in distilled water for 10min at 37 ºC.  
 
 
3.3.6 VEGF Quantification  
 
See Materials and Methods Section 2.26 p87-88 
 
 
 
Table 3.1 VEGF score by IHC as a function of the number of focally positive VEGF areas 
 
 Number of focal areas per cm2 of tissue section 
 1-4 5-9 10-14 15-19 20-24 25-20 30-34 35-39 40-44 45-50 >50 
Score 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 
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3.3.7 Statistical Analysis 
 
The correlation between VEGF-A levels and other prognostic variables was 
statistically analysed by means of Pearson’s x2 test, Spearman rank 
correlation analysis and invariable analysis. Survival rates were examined 
using Kaplan-Meier plots of analysis. The statistical significance of differences 
between the survival rates of groups with different VEGF expression i.e. high 
or low expression was assessed by the log-rank test. The independent 
prognostic significance of variables was assessed by multivariate analysis, by 
means of a multivariate Cox regression model. P values of <0.05 were 
considered statistically significant. All statistical analysis was carried out using 
SPSS version 15.0.  
 
 
3.4 RESULTS 
 
3.4.1 Clinicopathological Characteristics 
 
The mean age of the patients at diagnosis was 58 years (range 22-82years). 
Serous cystadenocarcinoma was the commonest histological subtype (55%) 
followed by undifferentiated (10%), endometrioid (11%), mucinous (14%), 
clear cell (10%). All patients were treated surgically in the first instance. Of 
these 70% had their tumour optimally debulked (< 2cm residual disease). 
Clinicopathological staging showed that the majority of patients had advanced 
stage disease (66% and 18% for stage 3 and 4 respectively) whereas 16% 
had early stage disease (10% and 6% for stage 2 and 1 respectively). 70% of 
the tumours were poorly differentiated (grade 3), 22% were moderately 
differentiated grade 2, and 8% were well differentiated (grade 1). The results 
are summarised in Table 3.3 
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Table 3.2. Patient characteristics 
 
 
Patient characteristic  Number 
 n=105 
Age Mean age 58 
 Range 22-82 
   
FIGO stage 1 6 (6%) 
 2 10 (10%) 
 3 70 (67%) 
 4 19 (17%) 
   
   
Histological grade 1 8 (7%) 
 2 23 (22%) 
 3 74 (71%) 
   
Level of debulking Residual tumour >2cm 31 (30%) 
 Optimal debulking<2cm 74 (70%) 
 
 
 
3.4.2 VEGF Analysis 
 
Patients were divided into two groups based upon the intra-tumoural VEGF 
expression, the median value of the VEGF score, which was 3, was taken as 
the cut off point. Therefore the groups were: 
1) High VEGF expression; score of 3 or > 3.  
2) Low VEGF expression score of <3.  
 
No relationship was observed between intra-tumoural VEGF levels to the age 
of the patient (p= 0.936) or to the postoperative residual tumour (p= 0.142), 
the histological grade (p= 0.15) the histological subtype (p=0.371) or the FIGO 
stage of tumour (p=0.18). Association between these factors was measured 
with the spearman rank correlation coeffient, p values less than 0.05 were 
considered to be significant.  The results are summarised in Table 3.4. 
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Table 3.3. Association of the degree of immunostaining for VEGF and clinico-
pathological variables. 
 
 
  Low VEGF 
expression (%) 
High VEGF 
expression (%). 
FIGO stage Stage 1 (n=6) 48 52 
 Stage 2 (n=10) 57 43 
 Stage 3 (n=70) 39 61 
 Stage 4 (n=19) 32 68 
    
Tumour grade Grade 1 (n=8) 47 53 
 Grade 2 (n=23) 34 76 
 Grade 3 (n=74) 59 41 
    
    
Histological subtype Serous (n=58) 37 63 
 Endometrioid (n=12) 69 31 
 Clear cell (n=11) 41 59 
 Mucinous (n=8) 55 45 
 Undifferentiated 
(n=11) 
33 67 
    
Level of debulking <2cm (n=74) 62 38 
 >2cm (n=31) 44 56 
 
p> 0.05 for all above subgroup comparisons 
 
 
Survival analysis revealed that patients that had low intra-tumoural VEGF 
expression had a median survival time of 36.7 months (SD 21.7) whereas the 
median survival of patients with a high VEGF expression was 10.8 months 
(SD 7.8). This difference in survival was shown to be statistically significant by 
Cox Proportional Hazards model after tumour stage was accounted for (p< 
0.001). A Kaplan Meier survival plot is shown in Figure 3.1.  
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Figure 3.1: Differences in survival between high and low VEGF scoring 
ovarian tumours. 
 
 
 
 
3.6 DISCUSSION 
 
The central concept that tumour growth is angiogenesis dependent is widely 
accepted today. Every increment of tumour growth requires an increment of 
vascular growth 1 97 378.   
 
Angiogenesis was suggested as a prognostic factor in various solid tumours 
but its clinicopathological significance in ovarian cancer and its exact role is 
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still unclear. The results of various studies are contradictory. Hollingsworth et 
al assessed tumour vascularity in 43 patients with advanced stage EOC, by 
using microvessel counts. It was reported that microvessel counts and stage 
were associated with disease free survival and overall survival by Kaplan 
Meier analysis. In this study, with Cox Proportional Hazards model, stage was 
the best predictor of overall survival, however the average microvessel count, 
which is a surrogate measure of the degree of angiogenesis, was found to be 
the best predictor of disease free survival. 289.In a study by Alvarez et al 
overall, median survival was 2.7 years in women with cancers containing high 
microvessel counts versus 7.9 years in those with low microvessel counts (P 
= 0.03).  A low microvessel count was associated with better 5-year survival in 
both early stage (I and II) and advanced stage (III and IV) disease. However  
in a study by Obermair et al, MVD failed to show prognostic significance in 
EOC, in multivariate analysis. 291 379. 
  
Our results indicate that patients with tumours that express high levels of 
VEGF have a worse overall survival rate compared to those with low VEGF or 
no VEGF expression. A median survival advantage of approximately 25 
months is seen with the patients who have low VEGF expression (p<0.001). 
This result was further substantiated when a multivariate Cox regression 
model was constructed in which established prognostic factors were 
accounted for. VEGF expression maintained statistical significance with 
regards to patient survival (p<0.001). These results exhibit that 
immunohistochemical assessment of VEGF expression within a tumour can 
display further information about the potential for anti-angiogenic activity, and 
its effect on tumour behaviour and subsequent prognosis for the patient. The 
literature to date has been unclear as to the role of VEGF expression within 
ovarian tumours. Some studies have shown that it is a significant independent 
prognostic factor. Paley et al found that patients with early stage disease 
(FIGO stage 1 and 2) showed poorer prognosis with increased VEGF 
expression within the tumour 301. Shen et al showed that survival of patients 
with high VEGF expression was significantly worse than those with a low 
VEGF expression, and in multivariable analysis VEGF expression together 
with stage was an independent prognostic indicator for overall survival 380. 
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Interestingly there was no correlation with microvessel density contradicting 
previous work. Raspollini et al showed that VEGF and MVD were both 
independent predictors of survival in advanced disease (FIGO stages 3 and 
4), and also correlated with the likelihood of response to chemotherapy 381. In 
contrast, some authors showed no independent relationship with prognosis 293 
382. 
 
In our study we showed that the prognostic effects of VEGF, which are seen 
in all disease stages, are independent of established clinicopathological 
variables, such as stage, grade and residual tumour status.  
 
From our work we have illustrated that there were no associations between 
VEGF and any of the clinicopathological variables, including stage and grade 
of the tumour. This is in agreement with other published work289 293 383-385. 
Some studies have suggested that stage and grade are associated with 
VEGF expression, although these studies had a large proportion of early 
stage disease380. Heterogeneous expression of VEGF, difficulties in 
maintaining a standardised scoring system for the quantitative assessment of 
VEGF, and small sample size, may be the factors accounting for the 
inconsistent results among the studies thus far386.  
 
Due to the central role of angiogenesis in cancer progression, inhibition of 
tumour angiogenesis could be a therapeutic tool to arrest tumour progression. 
Bevacizumab, is a monoclonal antibody against VEGF-A and is the first anti- 
angiogenic drug in oncology, having been approved by the FDA for that 
purpose. Previous studies have shown that in tumours VEGF is over-
expressed in solid tumours including breast and colorectal cancer. In EOC 
over-expression is associated with ascites formation, malignant progression 
and poor prognosis. Preclinical models of solid tumours show that anti-VEGF 
therapy causes slowing of tumour progression, resolution of malignant 
effusions, and synergy with cytotoxic agents92 121. Randomized trials of 
bevacizumab have established its efficacy in colon, breast, lung and renal 
cancer121. Monk et al have shown some clinical benefit from using 
bevacizumab in recurrent ovarian cancer387. There are currently ongoing trials 
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with bevacizumab, VEGF Trap (VEGF receptor decoy), and other agents 
targeting the VEGF pathway388.  The GOG 218 and ICON 7 trials are ongoing 
at present and are studying the addition of bevacizumab to front line 
chemotherapy.  
 
Further evaluation and research is required in prospective studies to 
substantiate the finding that the intra-tumoural expression of VEGF in patients 
is of clinical relevance,and in our work has shown to provide a survival 
advantage of 25months in those patients with low VEGF expression. This can 
play a role in predicting a subgroup of patients who are amenable to anti-
angiogenic targeted therapy and may help to stratify patients into those who 
would benefit from first line anti-angiogenic therapy, in addition to standard 
chemotherapy.  
 
In conclusion the expression of VEGF-A is an independent prognostic 
indicator in our series of patients, with all stages of ovarian cancer. The 
angiogenic evaluation of the tumour, by means of VEGF expression may help 
to identify a group of patients in which anti-angiogenic therapy is more 
effective, and could be used as a first line agent, either alone or in 
combination with standard platinum based chemotherapy. This observation in 
turn leads to the question that whether 
 the assessment of VEGF-A, is something that should be performed prior to 
introducing chemotherapy?  
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4.1 INTRODUCTION 
 
 
Epithelial Ovarian cancer EOC is the leading cause of death among the 
female genital tract malignancies 389. The high mortality of ovarian cancer is 
due partly to the fact that most patients are detected when the disease is at 
an advanced stage (III and IV).  
 
Developments in chemotherapy and surgical technique have had minimal 
effect on patient survival over the last few decades 389. Cytoreduction together 
with a combination of taxane and carboplatin is the standard treatment for 
EOC. However approximately 50% of patients with advanced disease will 
relapse despite this form of management. Moreover 15-20% is resistant to 
platinum based treatment 390.  
 
Tumour stage and residual tumour mass following primary cytoreductive 
surgery has shown to reliably predict outcomes in patients with EOC, however 
this offers no information with regard to the potential sensitivity to molecular 
targeted therapies or indeed standard platinum based chemotherapy. 
Investigation of novel prognostic markers offers an insight into the 
mechanisms of tumour development and suggests potential avenues for the 
development of new therapeutic agents particularly through the use of 
monoclonal antibody therapies targeted against antigens that are 
overexpressed in disseminated cancer cells 391. 
 
Angiogenesis has a vital role in tumour growth, invasion and metastases 392-
394. This process is tightly regulated in normal tissues for maintenance and 
repair, and in wound healing, by the VEGF signalling pathway. VEGF, 
originally identified as a vascular permeability factor 383, is a homodimeric 
glycoprotein that is expressed in a wide variety of normal and transformed cell 
types 395.  
 
The VEGF signaling pathway plays a crucial role in angiogenesis in both 
normal and disease settings, triggering multiple signaling pathways that can 
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profoundly affect the function of endothelial cells leading to cell survival 396, 
migration 397, mitogenesis 398 and differentiation 399. The VEGF-related gene 
family of angiogenic and lymphangiogenic factors (VEGF-A, VEGF-B, VEGF-
C, VEGF-D, VEGF-E and placental growth factor - PlGF) are secreted as 
glycoproteins and mediate their effects by selectively interacting with one of 
the three known VEGF tyrosine kinase receptors (VEGF-R). VEGF-A (made 
up of 5 isoforms of varying molecular weight – kDa 121; 145; 165; 189; 206:), 
VEGF-B (made up of 2 isoforms of 167 kDa and 186 kDa) and PlGF, all bind 
to VEGFR-1.  VEGF-A, VEGF-C; VEGF-D and VEGF-E bind to VEGFR-2, 
and VEGF-C and VEGF-D to VEGFR-3 340. 
 
Angiogenesis is vital for the growth and progression of tumours for their 
development from a small-localised lesion to a tumour with the ability to 
metastasise 400, and its expression has been shown to occur in response to 
up regulation of hypoxia-inducing factor (HIF-1α)382. VEGF expression has 
been shown to predict for metastases and has prognostic significance in 
various solid tumours. Several clinicopathological studies have shown a direct 
association between expression of VEGF and it’s receptors (VEGFR1 - 3) and 
microvascular density (MVD), demonstrating the importance of studying 
intratumoural angiogenesis 286 401.  
 
Thus, demonstration of over-expression of VEGF in patients’ tumours by 
immunohistochemistry (IHC) not only provides the basis for a biomarker 
assay for assessing disease progression, but also identifies rationally those 
patients who might benefit from anti-angiogenic therapy. 
 
 
4.1.1 Chemotherapy for epithelial ovarian 
cancer 
 
The majority of patients with EOC present with advanced stage disease, and 
although response rates are high, many patients eventually develop drug-
resistant tumours and the 5-year mortality remains at 60-70%. 
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Platinum drugs are the most active agents in EOC and form the mainstay of 
any regimen for this disease. Cisplatin and carboplatin have dominated the 
drug therapy of ovarian cancer during the past three decades. In 1978, a 
conference sponsored by the Division of Cancer treatment, National Cancer 
Institute (NCI), clinically evaluated the heavy metal derivative cis-
diammineddichloroplatinum (DDP). Following thorough laboratory studies the 
National Cancer institute introduced it clinical practice in 1971 402.  
 
Cisplatin was discovered in the late 1960’s by Barnett Rosenberg, who went 
onto to interest the NCI to test DDP in it preclinical mouse models and to 
foster its development 403. In 1979 FDA approval was obtained for the 
treatment of ovarian, testicular and head and neck cancers. 
 
 
4.1.1.1 Mechanism of Action  
Three platinums are in common use, and include cisplatin, carboplatin and 
oxaliplatin. It is generally accepted that DNA is the most important intracellular 
target of platinum based compounds.  However DNA is not the only target; 
binding to protein and RNA also occurs, as has been shown by various 
studies 404 405. In addition it can also not be excluded that damage to cell 
membranes is also relevant. Even though there are various studies supporting 
the notion that binding of platinum compounds to DNA leads to the killing of 
the tumour cell and the observed side effects seen in patients treated with 
cisplatin, this does not exclude other modes of action to achieve cytotoxicity 
406-409.  
 
It is evident that on route to the tumour cells, the platinum compounds can 
interact with blood products and with cell wall components. These reactions 
might also contribute to the toxic side effects observed during the treatment of 
patients with platinum compounds. Apart from binding of platinum compounds 
to DNA in the tumour cell-which is generally believed to be the origin of anti-
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neoplastic activity-several other events will take place after the administration 
of the drug into the body. The circulating platinum species is transported-most 
likely as a neutral species-into both tumour cells and normal cells, and then 
undergoes hydrolysis inside the cells. Subsequently the hydrolysed platinum 
species can react with all kinds of cell components, such as peptides, 
proteins, DNA and RNA. Although the binding of the DNA appears to be 
responsible for the ultimate cell killing, it cannot be excluded that reactions of 
the platinum species with other molecules are leading to toxic side effects. 
The repair of DNA may lead to platinum resistance. Also the transport of 
platinum into the cell has been increasingly investigated. It has been shown 
that 25% of proteins in the cell are concerned with transport. Considerable 
advances have been made recently in defining the role of transport into the 
cell and export or sequestration of platinum as another determinant of drug 
sensitivity and resistance; it has become clear that platinum utilizes the 
copper transporters and exporters as well as other cation transporters 410. 
Manipulations in transport can alter cell sensitivity.  
 
 
4.1.1.2 Cisplatin and Carboplatin 
Cisplatin (cis-dichlorodiammine platinum(II)) was discovered serendipitously 
by Rosenberg in the 1950’s while investigating inhibition of bacterial growth by 
electric currents 263. The resulting inhibitory complexes were produced by the 
reaction of platinum electrodes with growth media. Cisplatin, a neutral 
complex, was the most active of these, and was tested in clinical trials264.  
 
It is thought that cisplatin enters the cell by both passive diffusion and 
facilitated transport, possibly by a gated channel411. Some of the uptake is 
dependent on energy because pharmacological agents such as ouabain (a 
Na+, K+-ATPase inhibitor) reduce it412.  
 
Cisplatin is a water-soluble complex, which has a central platinum atom 
surrounded by two chlorine atoms and two ammonia groups253 (Figure 4.1). 
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When cisplatin enters the cell, the chloride ions dissociate (due to the low 
concentration of intracellular chloride ions) leaving a reactive diamine-
platinum complex, which reacts with water and then, can interact with DNA253. 
Cisplatin binds preferentially to the N7 atom of guanine and adenine residues 
413, although there are numerous potential reaction sites in all four bases414.  
 
Cisplatin is widely used not only for the treatment of ovarian cancer, but also 
for many other solid tumours such as those arising from the testes, bladder, 
lung, and head and neck. Cisplatin was first introduced in 1973 for treatment 
of ovarian cancer, which improved disease-free survival and response rates 
when compared to the then-standard treatments252. Cisplatin was either used 
alone or in combination with cyclophosphamide. Cisplatin causes very severe 
nausea and vomiting, and is highly nephrotoxic253 . 
 
 
(a)        (b)         (c)                                        
 
 
   
     
 
Figure 4.1: Structure of (a) cisplatin (b) carboplatin (c) oxaliplatin 
 
In the early 1980’s carboplatin, which is a derivative of cisplatin, was 
introduced (Figure 4.1). Carboplatin causes less nephrotoxicity, neurotoxicity, 
and ototoxicity, and less severe nausea and vomiting than cisplatin, but it is 
more myelotoxic253. Tinnitus and hearing loss in the high frequency ranges 
may occur, as may peripheral neuropathies, hyperuricaemia, myelotoxicity 
and nephrotoxicity.  
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The cytotoxicity of cisplatin and carboplatin are believed to result from the 
formation of platinum-DNA adducts. These include monoadducts, intrastrand 
crosslinks, interstrand crosslinks (ICLs), and DNA-protein crosslinks415 (Figure 
4.2). There has been much debate about which adduct is responsible for the 
cytotoxicity of cisplatin. Fischtinger-Schepman et al concluded that 1,2 
intrastrand crosslinks produced by cisplatin were responsible for its 
cytotoxicity because the peak of formation of these lesions co-incided with the 
peak of cytotoxicity in Chinese hamster ovary cells (CHO)415. Zamble et al., 
demonstrated that the 1,2-cisplatin adducts are poorly recognised, adding 
support to the argument that they are a critical cytotoxic lesion416. In contrast 
Zwelling L.A et al found a correlation between cytotoxicity and ICLs in L1210 
cells in vitro using alkaline elution417. Meyn et al demonstrated that an ERCC1 
mutant CHO cell line, UV20, was extremely sensitive to cisplatin and defective 
in the uncoupling of ICLs, which was taken to demonstrate a direct 
relationship between sensitivity and ICL repair418. In the nitrogen mustard 
class, there is a clear correlation between the extent of interstrand crosslinks 
(ICL) and cytotoxicity419. However, the platinum drugs produce a high 
proportion of intrastrand crosslinks that clearly contribute to their activity420. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: The different types of DNA adducts produced by cisplatin, and 
frequencies of occurrence. 
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Carboplatin has a much slower rate of aquation and ICL formation compared 
to cisplatin421, and therefore the time to reach the peak of ICL formation is 
much longer with carboplatin. 
 
4.1.1.3 Oxaliplatin 
Oxaliplatin is an analogue of cisplatin that was developed to try and overcome 
drug resistance (Figure 4.1). It has a different spectrum of anti-tumour activity 
and has shown activity in treatment of advanced colorectal cancer either as a 
single agent or in combination with 5-fluorouracil422. Side effects of Oxaliplatin 
include neurotoxicity, including facial dyaesthesia, which may be provoked by 
cold weather, and peripheral sensory neuropathy412.   
 
 
4.1.2 INDICATIONS FOR CHEMOTHERAPY 
 
4.1.2.1 Early Disease 
The use of chemotherapy in the treatment of advanced epithelial ovarian 
cancer is established (FIGO stages III and IV). The role of therapy in early 
stage disease remains uncertain. It would be useful to predict out a subset of 
patients with early stage disease that are at the highest risk of relapse, in 
order to offer them adjuvant chemotherapy. Patients who have stage IA and 
IB disease are generally managed without chemotherapy, unless there are 
adverse prognostic features, Patients with stage IC disease are given 
adjuvant chemotherapy, as it has been shown that presence of peritoneal fluid 
with cancer cells (Stage IC) reduces survival 237. It has been suggested that 
stage I patients with well-differentiated tumours have a 90% 5-year survival 
rate, and currently chemotherapy is not thought to be of benefit in these 
women.  
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4.1.2.2 Advanced Disease 
The mainstay of treatment of patients with advanced disease (Stage II and 
above) is to undertake optimal cytoreductive surgery followed by platinum 
based chemotherapy. Cytoreductive surgery and volume of residual disease 
post procedure has prognostic significance. If chemotherapy is given, those 
with no macroscopic disease postoperatively have a progression free survival 
of 42 months versus 20 months for those with disease of 1cm diameter or 
less. These had an improved survival over those with disease greater than 
1cm in diameter. A majority of patients with stage III disease will still die from 
their disease although combination chemotherapy has improved their survival 
with 25-40% being alive at 5 years. Stage IV disease has a poor outcome, 
with a median survival of 12 months and only 5-10% alive at 5 years 423. 
When cisplatin was introduced into first line trials in ovarian cancer, there was 
little difficulty in recognizing its impact in progression free survival (PFS). 
Although its impact became increasingly clear, its initial use was initially 
entangled in an array of complex combinations. Studies by the GOG 
employed it in combination with cyclophosphamide and this doublet became 
the reference regimen for subsequent trials until GOG 111 showed the PFS 
and overall survival OS superiority of cisplatin and Paclitaxel 424. Eventually a 
toxicity reduction but similar disease response showed carboplatin and 
paclitaxel was preferred – because of reduced side effects and toxicity with at 
least equal efficacy over cispaltin 223.  
 
The role of other cytotoxic drugs in current use for ovarian cancer in 
complementing the effects of platinum drugs is less clear. After exposure to 
cisplatin, various alkylating agents had disappointing activity,and 
doxorubicin’s acute and chronic toxicities led to reduced use until the advent 
of liposomal formulations. After the introduction of paclitaxel, this was followed 
by Topetecan, gemcitibine, and pegylated liposomal doxorubicin (PLD) drugs 
with reproducible activity and reasonable therapeutic index came into 
common use. However the addition of the latter three in the five-arm GOG 
182 did not prove advantageous over the carboplatin and pacltixel doublet. 
When used as short term consolidation or maintenance after initial platinum-
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based induction, only paclitaxel has shown improvement in PFS (in GOG 178 
that was stopped early. 
 
 
4.1.3 Drug resistance in ovarian cancer 
 
Chemotherapy resistance is clinically defined as the progression of disease 
during therapy, absence of regression during therapy, or recurrence within 6 
months after completed treatment. Progression of disease during therapy is 
defined by the RECIST (response evaluation criteria in solid tumours) 
guidelines as a 20% increase in the sum of the longest diameter of the target 
(i.e. ovary) or non-target lesions425. Absence of regression during therapy is 
defined by the RECIST guidelines as neither disappearance of all target 
lesions (complete response), >30% decrease in the sum of the longest 
diameter of target lesions (partial response), or progressive disease (defined 
above)425. Recurrence of disease is confirmed as a rise of serum Ca-125 
levels to more than twice the upper limit of normal244, and in patients with 
persistently elevated Ca 125 serum levels, recurrence of disease is a doubling 
of Ca 125 above the nadir426. Recurrence of disease can also be confirmed by 
CT scans. 
 
Tumours are considered to be sensitive if they exhibit complete clinical 
response to therapy, or if relapse occurs after remission and treatment has 
not been administered for more than 6 months427. Resistance to cisplatin can 
be intrinsic or acquired. Intrinsic is present at the time of diagnosis, and 
patients fail to respond to first line chemotherapy. Laboratory studies have 
shown that cisplatin resistance is multifactorial, consisting of mechanisms 
such as: (1) decreased drug accumulation (2) increased drug inactivation (3) 
evasion of apoptosis (4) enhanced ability to repair DNA damage. However, 
because cancer cells are heterogeneous, more than one mechanism of drug 
resistance may be present at one time. 
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4.2 AIM 
 
This study was undertaken to examine whether there is an association 
between VEGF-A expression in epithelial ovarian cancer and the tumour’s 
response to platinum based chemotherapy.  
 
 
4.3 MATERIALS AND METHODS 
 
4.3.1 Study Population  
 
The study cohort consisted of 66 cases with advanced Epithelial Ovarian 
Cancer (EOC) (FIGO stages III and IV), who underwent surgical staging and 
tumour debulking between for primary EOC at the royal Free NHS Trust 
between 1995 and 2000. The inclusion criteria for the cases included:  
a) FIGO stage III / IV disease.  
b) Underwent cytoreductive surgery 
c) Completed 6 cycles of adjuvant platinum based chemotherapy.  
d) Did not receive neoadjuvant chemotherapy.  
 
Clinical data and patient information were collected from the patient’s clinical 
records. Ethical approval was obtained for this retrospective analysis from the 
Royal Free Hospital and Medical School Research Ethics Committee (code 
number 09/H0720/87). Informed consent was obtained as per local 
guidelines. 
 
4.3.2 Chemotherapy Treatment 
 
All patients in this study received platinum based primary therapy with 
carboplatin. In the majority of cases this was in combination with taxanes 
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(56/66 patients, 83%). 10 patients received carboplatin alone. All patients 
received 6 cycles of primary therapy. 30 patients were given further 
consolidation therapy after completing primary therapy. Because 
consolidation therapy was not given as standard treatment to all patients, 
completion of primary therapy was used as the end point for determining 
response outcomes.  
 
 
4.3.3 Histology and Immunohistochemistry 
 
The paraffin blocks from each case were reviewed by a pathologist (JCC) and 
representative areas of tumour were chosen after examining the haematoxylin & eosin 
stained slides, by two observers, including one pathologist (JCC and AC). Briefly, 
sections of primary tumour from each case were cut at 3µm and were deparaffinised 
in xylene, rehydrated with graded ethanol, and immersed in 0.3% H202 in methanol 
for 20 minutes to inhibit endogenous peroxidase activity. Sections were then 
incubated with commercially available mouse monoclonal antibody to VEGF-A 
(R&D Systems Abingdon, UK.) for 45 minutes at RT and binding was then visualised 
by sequential incubation with a biotinylated labelled secondary antibody followed by 
streptavidin-biotin peroxidase labelled complexes reagent (Dako Ltd, UK). IHC 
reactivity was then visualised using 0.1% Diaminobenzidine tetrahydrochloride in 
0.03% HCl. Negative controls were prepared by omitting the primary antibody (to 
VEGF) from the procedure and substituting with mouse immunoglobulin (class 
IgG2b). 
 
 
4.3.4 VEGF Quantification  
 
For the assessment of VEGF, regions of interest (ROIs) containing tumour 
cells with minimal or no associated connective tissue stroma were defined by 
two independent observers (JCC & GKS). Each slide that contained tumour 
was analysed by using an eyepiece graticule that defined an area of 1cm x 
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1cm at a magnification of 200 times (with x20 objective). The graticule 
comprising 100 individual squares (each 1mm x 1mm) was placed over three 
representative fields of the slide that contained tumour (minus large areas of 
connective tissue). The identification of at least 1 VEGF-positive cell within the 
confines of an individual square defined that square as a positive focal area. 
The number of VEGF-positive focal areas was totalled for each slide and then 
an average number of focal areas for that case was obtained. Using the tariff 
shown in Table 4.1 (scoring system devised by GKS and JCC), the average 
number of focal areas per case was converted into a score for VEGF, on an 
increasing linear scale of 0 – 5, (where 0 = 1 - 4 focal areas, and 5 =>50 focal 
areas). All observations and analysis was performed by two independent 
observers (GKS and JCC) who were blinded to all clinical data. In all cases 
there was less than 5% inter-observer variation in results. 
 
 
Table 4.1. VEGF score by IHC as a function of the number of focally positive 
VEGF areas 
 
 
 Number of focal areas per cm2 of tissue section 
 1-4 5-9 10-14 15-19 20-24 25-20 30-34 35-39 40-44 44-50 >50 
Score 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 
 
 
4.3.5 Statistical analyses  
 
Statistical analyses were performed using SPSS version 16.0. Expression of 
the intratumoural VEGF-A protein was correlated with platinum sensitivity 
(using a Mann-Whitney U Test and Fishers Exact Test). Spearman Rank 
correlations were calculated to test for association between VEGF-A 
expression and, patient age, tumour stage, grade and survival. Survival times 
were estimated in months from the date of operation to the date of death (or 
date of last follow-up). Kaplan Meier survival plots and a log rank test were 
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used for the univariate analysis of VEGF expression in resistant and sensitive 
groups. The Cox Proportional Hazard Model was used for multivariate 
analysis. Response to therapy was defined as for the 2003 revision of the 
‘Gynecologic Oncology Group’ criteria362. Patients who had progressed on 
chemotherapy or who relapsed within 6 months of completing of completing 
their primary therapy were defined as platinum resistant. All other patients 
were categorised as responders to platinum-based therapy. Recurrence of 
tumour was defined by imaging modalities (CT & Ultrasound) and/or by the 
demonstration of increasing levels of CA-125 in the serum.  
A cut-off point for scoring of VEGF as, high expression (>3) and low 
expression (≤3) was used to statistically analyse the data. A p (probability) 
value of <0.05 was considered to be significant for all statistical tests.  
 
 
 
4.6 RESULTS 
 
All patient characteristics are detailed in Table 4.2. The median age of the 
patients was found to be 53 years (range 22 -82 years). Of all the EOC 
patients in this cohort, 66% were defined by pathology as serous, 15% as 
endometrioid, 13% as mucinous, and 6% as clear cell. Seventy-five percent of 
the patients were optimally debulked at primary surgery with less than 2cm3 
residual disease, whilst  25% had greater than 2cm3 residual disease after 
debulking. Sixty-four percent of the patients were defined pathologically as 
having grade 3 histology. Using Gynecologic Oncology Group (GOG) criteria 
the patients were stratified into two groups based on their response to 
platinum-based chemotherapy (see Materials and Methods). 45 patients were 
found to have platinum-sensitive disease (68%), the remaining 21 patients 
being platinum-resistant (32%).  
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Table 4.2: Patient Demographics. 
 
 
Characteristic  Patients n=66 (%) 
Age Median 53 years 
 Range 22-82 years 
Histological subtype Serous 44 
 Endometrioid 8 
 Mucinous 9 
 Clear cell 4 
Extent of residual tumour >2cm 25% 
 <2cm 75% 
FIGO stage 3 80% 
 4 20% 
Clinical response to platinum 
chemotherapy 
Sensitive 45 (68%) 
 Resistant 21 (32%) 
 
 
4.6.1 VEGF expression and Primary response to 
Chemotherapy  
 
Immunohistochemical reactivity of VEGF in the tumour cells was granular in 
nature and mainly confined to the cytoplasm of cells (Figure 1a and b). 
Binding of antibody to VEGF was observed in a few areas of the connective 
tissue stroma in some cases, and many cases demonstrated heterogeneous 
reactivity for VEGF with only focal areas of the tumour showing positivity 
(Figure 1a). The median VEGF score in the platinum chemoresistant and 
platinum chemosensitive groups was 4 and 2, respectively. The range for the 
number of focal positive areas of VEGF reactivity for the platinum-resistant 
group was 22 - 150, compared to 5 - 34 for the platinum-sensitive one. 
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(a)       (b) 
 
 
Figure 4.3: Microscopy images of sections reacted by 
immunohistochemistry for VEGF in cases of epithelial ovarian cancer 
demonstrating (a) heterogeneous expression of VEGF in a case from 
the group with low levels of reactivity (VEGF score ≤3) and (b) 
homogeneous expression of VEGF in a case from the group with high 
levels of reactivity (VEGF score >3). Magnification x 200. VEGF 
reactivity is brown. Nuclei of cells (haematoxylin-stained) is blue. 
 
 
4.6.2 Statistical Analysis 
 
The VEGF levels were significantly lower in the chemosensitive cases 
compared to those recorded in the chemoresistant patient group (Mann 
Whitney U test, p = < 0.0001). The VEGF score was also tested in a 
multivariate regression model and demonstrated that VEGF expression within 
the tumour was a significant factor for predicting response to platinum-based 
chemotherapy. No relationship was observed between VEGF expression and 
the age of the patient, or the stage or grade of the tumour and they were not 
significant predictors of disease response to chemotherapy, in both univariate 
and multivariate analysis.  
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4.6.3 VEGF-A expression and overall survival 
 
To examine the relationship between the level of VEGF in the tumour and 
overall survival, patients were stratified into two groups based on the extent of 
VEGF expression. Patient survival was recorded as months of survival (with 
or without disease after surgery), or months from surgery to death. Patients 
were further monitored with a median follow-up period of 18 months (range 12 
- 33 months). Overall median survival was 10 months in patients with a high 
tumour VEGF score in the tumour (i.e. >3) versus 36 months in patients with a 
low tumour VEGF score (≤3). 
 
VEGF levels (IHC score) was significantly inversely correlated with survival in 
months, in all patients (using Spearman Rank Correlation Test, p = < 0.01), 
and also higher levels of VEGF were associated with the poor outcome group 
(i.e. died of their disease), p = < 0.01 (Mann Whitney U test). 
Overall, of the 66 patients, 39 patients died of their disease within the length 
of time of the study. Response to platinum treatment (as assessed by CT and 
ultrasound and/or by demonstration of increasing levels of CA125 in serum) 
was significantly correlated with survival (Cox Proportional Hazards model, p 
= < 0.0001). VEGF expression (IHC score) was also found to be significantly 
correlated to overall survival (p< 0.0001) after tumour stage was taken into 
account (Cox Proportional Hazards model, p = < 0.0001). Kaplan-Meier plots 
of survival with reference to platinum sensitivity and VEGF status is shown in 
Figure 4.4.   
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4.7 DISCUSSION 
 
 
EOC is mainly treated by platinum-based chemotherapy and this study has 
evaluated the expression of VEGF as a marker of chemotherapeutic 
responsiveness in such patients. These data strongly suggest that in EOC 
immunohistochemical level of VEGF expression is significantly associated 
with platinum sensitivity and overall patient survival with high tumour VEGF 
Figure 4.5. Kaplan-Meier plots showing the relationship of 
VEGF status (by IHC) with survival, in 66 patients with 
epithelial ovarian cancer.  
 
Tumour VEGF 
(≤3) 
Tumour VEGF 
(>3) 
Survival in months 
months 
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expression predicting for primary resistance to platinum-based chemotherapy. 
This study has also demonstrated by multivariate analysis that VEGF levels is 
an independent predictive factor for response to platinum-based 
chemotherapy. Overall, 86% of patients who were resistant to platinum were 
found to have a high VEGF score, compared to only 2% in the platinum-
sensitive group (p< 0.0001). We have also demonstrated that VEGF 
expression within the tumour significantly correlated with overall patient 
survival (p = < 0.0001). Overall median survival was 10 months in patients 
with a high VEGF score in the tumour versus 36 months in patients with a low 
VEGF score, demonstrating a median survival advantage for the latter group 
of approximately 26 months. Illustration  of the Kaplan-Maier plot (Figure 4) 
illustrates the potential power of using VEGF scoring by IHC as a prognostic 
biomarker for treatment response. We have demonstrated that VEGF 
expression is a surrogate for survival and have shown its ability to predict 
outcome in our cohort of EOC patients. Whilst we understand that within all 
IHC scoring systems, subjectivity may be a problem, and there is an element 
of subjective bias. We were careful to design a robust protocol that took 
account of this by scoring all VEGF positive areas, within all sections of 
tumour per case. 
 
Angiogenesis plays a central role in the clinical behaviour of EOC and 
progression of disease, with VEGF–A being an important mediator in 
promoting and increasing vascularity. VEGF has been shown to be expressed 
in the majority of tumour specimens from patients with EOC, as assessed by 
in situ hybridisation 382 or immunohistochemistry 286. In addition to stimulating 
angiogenesis, VEGF-A increases vascular permeability and is thought to be 
partly responsible for the development of ascites in both animal models and 
patients with EOC 401. Several studies have suggested that high levels of 
VEGF-A in either tumour or patient serum correlate with poor survival in this 
disease 289 291 301 311. These observations suggest that VEGF-A could be an 
important therapeutic target in EOC. Our study illustrated that patients with 
high levels of VEGF expression in the tumour have lower median survival 
rates compared to those patients that have low expression of VEGF. It is 
noteworthy that single agent bevacizumab (Avastin®), a monoclonal antibody 
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against VEGF-A, is active in EOC as well as in renal cancer 428, whereas it 
appears to have relatively low activity when used by it in other tumour types 
such as colorectal or breast cancer 429 430. It is unclear what the mechanism is 
for this phenomenon but it may reflect a greater contribution of VEGF-
dependent angiogenesis to the pathogenesis of relapsed disease and it may 
be related to the way that colorectal cancer and breast cancer metastasise 
versus the peritoneal invasion seen in ovarian cancer 275.  
 
To date there have been no biomarkers established that can predict response 
to platinum-based chemotherapy in EOC. Currently, three biomarker assays 
of angiogenesis are under development, including quantification of urinary 
matrixmetallinoprotineases 93, analysis of the platelet angiogenic proteome 94 
and measurement of blood levels of circulating endothelial cell precursors 
(CEPs) and mature circulating endothelial cells (CECs) 431. These methods 
can detect human tumours in mice at sizes of millimetres or less. In future it 
may be possible to detect recurrence of cancer by these and other 
biomarkers, to predict groups of patients likely to be resistant to platinum 
based chemotherapy, and to guide antiangiogenic therapy in patients with 
occult tumour, before clinical symptoms appear 84.  
 
Others have reported that the elevated expression of VEGF in the tumour of 
EOC patients is associated with poor prognosis 39 275 301 304. Whilst VEGF has 
been shown to be a prognostic factor in EOC, this study adds to the field by 
correlating VEGF status specifically with platinum treatment response.  One 
possible mechanism to explain the prognostic capacity of high tumour VEGF 
expression may be related to its function as a regulator of angiogenesis. 
However, the pathway that might be involved in causing platinum resistance, 
in association with high VEGF levels is at present unknown. In this study, it is 
not surprising perhaps, that poor prognosis (defined by survival) is also 
reflected in the patients’ VEGF status (which others have also shown to be 
independently related to poor outcome). Whether or not VEGF 
overexpression and presumably stimulation of angiogenesis, can be shown to 
directly to modulate platinum sensitivity, in vivo is unclear. But, a recent in 
vitro study by Roberts et al demonstrated that clonogenic survival of colorectal 
 145 
cancer cells after exposure to oxaliplatin, was significantly reduced in 
spheroids grown in hypoxic conditions 432. Moreover, they reported higher 
levels of platinum adducts in aerobic cells treated with the drug.  
 
This study is one of the first we believe, to define pre-treatment intratumoural 
expression of VEGF as a predictor of response to platinum-based 
chemotherapy.  
 
Other recent experimental data also supports an association between VEGF 
and platinum response. It has been reported that an inhibitor of VEGF 
(soluble decoy receptor – VEGF trap) acts synergistically with Paclitaxel in a 
human ovarian cancer model leading to improved survival 50. Therefore, it 
could be inferred that high VEGF levels in the tumour may hamper the 
cytotoxic effect of Paclitaxel (in the peritoneal cavity) and is one potential 
example of how VEGF overexpression may have implications for treatment 
with platinum-based agents. 
 
Our findings suggest that the immunohistochemical assessment of VEGF 
within a tumour section, offers valuable information about progression of 
disease in EOC, and can be a valuable prognostic indicator for both the 
patient and clinician. Data from other groups support these findings including, 
Bamias et al who showed that high VEGF levels in the ascites of patients with 
advanced epithelial ovarian cancer were of prognostic significance. That 
group also reported an association of VEGF expression, within the ascites of 
patients, with platinum resistance 433.  
 
Recent interest has focussed on the use of antiangiogenic drugs in an attempt 
to inhibit the pro-tumour effects of VEGF. Evidence that these targeted 
therapeutics were biologically active came from studies in 2004, using 
bevacizumab (Avastin®) - Genentech Inc. San Francisco, US) and was the 
first agent to target angiogenesis. It was licensed as a recombinant 
humanised monoclonal antibody (administered three-weekly) for the treatment 
of advanced solid cancers, and its mode of action is by targeting the isoforms 
of VEGF, which circulate in the bloodstream, preventing the ligand binding to 
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its cognate receptor. Avastin® has been shown to improve survival in patients 
with advanced disease alone, and in combination with existing chemotherapy. 
More recently, smaller molecular weight tyrosine kinase inhibitors (TKIs) have 
also shown the ability to interfere within the VEGF signaling network. This 
class of agents (aminophthalazines) includes Vatalinib (PTK787/ZK222584, 
Novartis, Basel, Switzerland) which acts by targeting VEGFR-1, -2 and -3, 
PDGFR-β and c-Kit, and has shown to improve progression-free survival of 
colorectal cancer patients when administered in combination with FOLFOX in 
Phase III trials 429. Anti-VEGF therapy causes a slowing of tumour 
progression, resolution of malignant effusions and synergy with cytotoxic 
agents 92 381. It is also being studied as a first line treatment in a US trial (GOG 
218) and a European Trial (ICON 7) in EOC. Currently, there are many 
ongoing efforts to develop biological markers that predict sensitivity/resistance 
to particular strategies in EOC. This study shows that measurement of the 
level of VEGF, determined by IHC in archival material, may be used for 
selection of patients who may benefit from the addition of anti-VEGF therapies 
to front line platinum/ paclitaxel chemotherapy.  
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Chapter 5: POPULATION BASED CASE 
CONTROL STUDY OF A VEGF GENE 
POLYMORPHISM AND OVARIAN 
CANCER RISK AMONG PAKISTANI 
WOMEN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oral presentations: 
1) ‘Ovarian cancer in Pakistan: a different disease entity?’ Presented at the 
International Gynecological Cancer Society meeting, Bangkok, 2008. 
2) ‘Population based case control study of VEGF gene dimorphism and 
ovarian cancer risk among Pakistani women.’ Presented at the International 
Gynecological Cancer Society meeting, Prague, 2010. 
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5.1 INTRODUCTION 
 
 
5.1.1 Ovarian Cancer In Pakistan 
 
Primary carcinoma of the ovary is the fourth most common female cancer in 
the UK and the most common cause of death from a gynaecological 
malignancy.  The incidence of the disease varies widely across different 
geographical regions and ethnic groups with the highest reported incidence 
rates  in Europe and North America and the lowest rates in Asia 434.  Pakistan, 
however, is the exception to these figures from Asia; the age standardised 
rate (ASR) for ovarian cancer  is reported to be 10.2 per 100, 000 which is 
comparable to rates seen in the West 435. In Pakistan ovarian cancer is the 
most common cancer of gynaecological origin 436. This is in direct contrast to 
the developing world where cervical cancer remains the commonest 
gynaecological malignancy 434 436. 
 
Despite the extensive published research literature on the subject, the natural 
history of ovarian cancer development, including the nature of the precursor 
cell type, remains poorly understood. Various theories have been suggested 
for how ovarian cancer develops. These include the incessant ovulation 
theory 124 which proposes that the risk of ovarian cancer increases as a result 
of the recurrent minor trauma to the ovarian surface epithelium that occurs 
during ovulation. The suggestion is that the greater the number of times the 
ovarian surface epithelium undergoes remodelling, the greater the chance will 
be that aberrations leading to a malignant transformation will occur. 
 
Whilst the exact aetiology of ovarian cancer remains relatively unknown, 
epidemiological studies have shown that several hormonal and reproductive 
risk factors have been associated with the disease 437 438.  Based on several  
studies, there is good evidence that increased parity 439 440 , the use of the 
oral contraceptive pill (OCP) 150-152 439, tubal ligation and hysterectomy 182 
reduce the risk of ovarian cancer and are protective factors 182-185.  Other 
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factors such as lactation, age at menarche, and  age of menopause seem to 
have a weaker effects on risk reduction 150 152 185 439. The major (monogenetic) 
risk factors for breast and ovarian cancer are reproductive and dietary factors.    
 
Pakistani women have a low frequency of these traditional risk factors 
(Bhurgri Y 2000) the female population, on average, has high levels of fertility, 
early age at first pregnancy, multiple births, and prolonged breast-feeding. 
Although the age at first marriage has been gradually rising, women in 
consanguineous unions marry at earlier ages and are less likely to use 
modern contraceptive methods than do women from non-consanguineous 
marriages 441. Pakistan is known to have the highest rate of consanguineous 
marriages worldwide, with frequencies of 60-70% being reported  442.  
Pakistani women do not tend to use exogenous hormones ( OCP or hormone 
replacement therapy).  They generally do not smoke tobacco products, 
although some women practice chewing pan and pan tobacco. 
 
We know that the majority of ovarian cancer cases are sporadic. However 5-
10% of cases have a hereditary basis (ie they are familial) and several genes 
that confer high penetrance susceptibility to ovarian cancer have been 
identified. Two of these, BRCA1 and BRCA2, are responsible for 
approximately half of all families with two or more ovarian cases in first degree 
relatives, and most families in which multiple cases of breast and ovarian 
cancer occur together 139 443 444.  
 
Within the Pakistani population, there is a paucity of the known established 
risk factors to explain the observed high incidence, and alternative risk factors 
have not been identified.   It may be that the high rates of both ovarian and 
breast cancer in Pakistan are due to genetic factors.  
 
It has been reported that the offspring of first cousin unions have twice the risk 
of developing breast and ovarian cancers than those of non-consanguineous 
parents and it is widely accepted that consanguinity and inbreeding increases 
the risk of diseases caused by homozygosity of deleterious alleles 441 442 445.  
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5.1.2 Consanguinity 
 
Consanguinity is defined as marriage between blood relatives and is 
commonly used to describe relationships that include up to second cousin 
marriages 446. At a biological level, consanguineous unions may increase the 
risk of the homozygous state in their offspring 446. This might be reflected in 
relatively higher probability of an autosomal recessive inherited disease and 
certain types of congenital malformations. The most common types of 
consanguineous unions include first cousin unions with uncle-niece unions or 
marriage to second cousins or distant relatives forming only a small 
proportion. 
 
In certain parts of the world, the rate of consanguineous marriages (those 
between second cousins or closer) may exceed 50% 446. Accepted in certain 
cultures, consanguinity may also help proliferate the expression of disease-
causing recessive alleles in the population. Evidence has also shown that 
level of consanguinity positively correlates to incidence of adult-onset complex 
diseases. In one example, Rudan and colleagues 447, showed that the genetic 
isolation of coastal island populations living in middle Dalmatia, Croatia is 
likely to be a factor in the high incidence of diseases such as cancer, heart 
disease, and stroke. Other investigators have linked the elevated levels of 
certain cancers among the Hutterites 448, Syrian Jewish community in 
Brooklyn, New York 449, Pakistanis 450, and Louisiana Acadians 451 to high 
incidence of consanguinity within these groups.  
Recent case studies have shown that two copies of highly penetrant 
colorectal cancer–causing alleles [PMS2 deletion 452 and the MYH frameshift 
mutation 453 may be passed down by consanguineous parents to their 
offspring. Autozygous segments may harbour alleles (Ac and Bc), which when 
present in homozygous form can increase cancer risk for the individual. The 
simplest explanation is that these genes in the autozygous regions can either 
be (a) a pair of recessive mutant cancer genes (such as MYH and ATM; 454, 
(b) highly penetrant dominant cancer genes (such as BRCA2, MSH2, and 
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MSH6) whose biallelic mutations may lead to distinct cancer phenotypes 455, 
or (c) low-penetrance, dose-dependent cancer predisposition SNPs such as 
the 8q24 SNPs recently linked to colorectal cancer 456 457. In addition, a large 
autozygous segment may contain multiple genes satisfying any of the above 
characteristics, with all of them effectively contributing to increased cancer 
predisposition. 
 
 
5.2 AIMS 
 
The aim of this study was to investigate the association of the VEGF 
polymorphism 1154 G/A and the risk for incident Epithelial Ovarian Cancer in 
a population based case control study from Pakistan. Included in this analysis 
were 606 subjects, including 303 controls and 303 cases who were matched 
with respect to age and ethnicity.  
 
 
5.3 MATERIALS, METHODS AND SUBJECTS 
 
5.3.1 Study Population 
 
A total of 606 subjects were enrolled into the study between September 2005 
to June 2007, consisting of 303 controls and 303 cases with a histologically 
confirmed diagnosis of epithelial ovarian cancer. These subjects were 
recruited from three centres in Pakistan (Shaukat Khanum Memorial Cancer 
Hospital in Lahore, Ziauddin University hospital and the Aga Khan University 
hospital , in Karachi), and were part of the ongoing Pakistan Ovarian Cancer 
Study. All subjects were of Pakistani origin belonging to the five main ethnic 
group (see table 1). All the EOC cases were histologically confirmed, and 
staging was performed according to the current International Federation of 
Gynaecology and Obstetrics (FIGO) classification. 
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Inclusion criteria for cases were a primary diagnosis of EOC for women under 
the age of 75years of age with histopathologically confirmed EOC. 
Pathological diagnosis was based on the International Histological 
Classification of Ovarian Tumour recommended by FIGO . Controls were 
recruited from patient attending hospital based outpatient clinics and were 
matched to cases by age and geographical area and ethnicity. The inclusion 
criteria for controls were women known not to have a personal or family 
history of breast or ovarian cancer, or bilateral oophorectomy.  
 
The study was approved by the ethical review committees of all the 
participating centres. 
 
 
5.3.2 Questionnaire and Interview 
 
A structured questionnaire was used to collect the requested information on 
reproductive, hormonal, and environmental risk factors as well as a detailed 
family history and the presence of consanguinity within the parents of the 
case subjects and controls. The questionnaire and consent was translated 
into Urdu and written consent was obtained from each study participant.  
 
The questionnaire was completed in a face to face interview with the 
assistance of research officer. An information leaflet outlining the study was 
given to each participant prior to completing the questionnaire.  
 
After appropriate and detailed counselling by a dedicated research officer a 
10mls blood sample was taken from each each study participant, in an EDTA 
sample tube for later DNA extraction. The sample was coded and 
anonymised. 
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5.3.3 Genomic DNA Extraction 
 
A total of 10 ml of venous blood was collected in an EDTA tube for DNA 
extraction from white blood cells. DNA was extracted using phenol-chloroform 
reference protocol. 
 
40ml of RBC lysis buffer at pH 8 (1mM Tris, 32mM sucrose, 0.5mM 
magnesium chloride(hexahydrate) and 10 ml of 100% triton) was added to 
approximately 10 ml of blood sample and centrifuged at 2500rpm for 20min. 
The blood was discarded, leaving behind a cell pellet. 2 ml of extraction buffer 
(40mM Tris, 7.63mM EDTA, 15mM sodium chloride and 3.5 mM SDS ) was 
then added and vortexed briefly to resuspend the cell pellet. 0.5ml of sodium 
per chlorate (5M) was added to cell suspension followed by manual mixing 
and incubation at 65°C for 25 min. 2ml of chloroform was added and the 
solution was vortexed and centrifuged at 2500 rpm for 15 min. The upper 
layer was transferred to another tube, 2 volumes of isopropanol was added to 
precipitate DNA by gently mixing the tube. DNA was rinsed by centrifugation 
in 1 ml of 70% ethanol at 10,000 rpm for 15 mins. Ethanol was decanted and 
DNA was air dried, re-suspended in DI water and incubated at 37°C for 12 
hours then placed at -20°C for storage. 
 
 
5.3.4 Selection of Polymorphism in VEGF Gene, 
Primer Design and SNP Genotyping 
 
Single nucleotide polymorphism (SNP) was selected in the VEGF gene (Table 
5.1). This polymorphism is non coding and in the promoter region of the 
VEGF gene. Flanking sequence was retrieved from ENSEMBL. The tetra 
primers ARMS-PCR procedure 365 was used to genotype the SNP. The 
method employs four primers to amplify a larger fragment from DNA 
containing the SNP and amplicons representing each of the two allelic forms 
(Table 1). Primers were designed using web based software made accessible 
by Ye et al. (2001)(http:// cedar.genetics.soton.ac.uk/public_html/-primer1. 
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html). PCR was performed in a total volume of 10 µl containing 200-300 ng of 
template DNA, 1 pmol of each inner primer, 0.1 pmol of each outer primers, 
200 µM dNTP, 2 mM MgCl2, 1xbuffer and 0.5 U of Taq DNA Polymerase 
(Promega). 
 
PCR conditions were: initial denaturation at 94°C for 7 minutes followed by 34 
amplification cycles each consisting of denaturation at 94°C for 45 seconds 
annealing at 66.2°C for 45 seconds and extention at 72°C for 45 seconds and 
final extention at 72°C for 7 min. The amplified products were electrophoresed 
in a 2.5 % agarose gels stained with ethidium bromide. Positive and negative 
controls were included on each run. Agarose gel was evaluated under 
ultraviolet light and polymorphisms were classified as AA, AG and GG.  
 
The genotyping results were after the TETRA ARMS PCR were read by two 
independent individuals. About 10% of the PCR assays were randomly 
repeated and the results checked for concordance. 
 
 
 
Table 5.1: SNP ID and Primer Sequences. 
 
refSNP  ID      Polymorphism          Primer Sequence(5'-3') Amplicon size  
        (bp)      
rs      1154  G/A 
 
Forward inner primer(A allele): 
GATTTTGGAAGGACTTGCCTGATGCA 
Reverse inner primer(G allele): 
CTGTAATGCCACTCTTTGGAGCTGCC 
Forward outer primer: 
GTGTGATCTCTGGAATGAAAACAGGCCT 
Reverse outer primer: 
ATCAGGGTACTCCTGGAAGATGTCCACC 
208(A allele) 
 
 
144(G allele) 
 
300(from two 
outer primers) 
 
 
5.3.5 Statistical/Data analysis 
  
The association between VEGF rs 1570360 and EOC was modelled through 
multivariate logistic regression analysis. Odd ratios and confidence intervals 
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were used to assess the occurrence of VEGF -1154G>A genotypes in 
patients with EOC cases compared with the control group. Significance 
testing was carried out by combining chi-square tests and then comparing the 
two independent proportions. Adjusted OR’s for the epidemiological covariant 
such as history of gynaecological cancer and/or other cancer types in the 
family, tumour stage and grade, age and ethnicity, were determined by using 
a multivariate logistic regression method. Survival associated with each of the 
three genotypes was estimated by Kaplan-Meier survival analysis. We 
considered results with P<0.05 as statistically significant. The statistical 
software package STATA 11.0 was used to carry out the statistical analyses. 
 
The measure of Hardy-Weinberg disequilibrium was calculated as the function 
of the difference between the observed and expected genotype frequencies. 
Estimation of departure from Hardy-Weinberg proportions was evaluated with 
the help of DA statistic and tests of statistical significance were applied as 
reported by 367. 
 
 
5.4 RESULTS 
  
The selected characteristics of the 303 cases and 303 controls are 
summarised in Table 5.2. The cases and controls appeared to be adequately 
matched on age and ethnicity as suggested by chi squared tests. 
 
The results of the genotype frequencies obtained are shown in Table 5.3. The 
genotype distributions and allele frequencies of the VEGF 1154 G/A 
polymorphism in patients were significantly different from those of the 
controls. The frequency of the G allele in patients (89.4%) was significantly 
higher than that in the controls (84.7%) (p=0.013). Genotype frequency 
distribution in the two groups (controls and cases) occurred in Hardy-
Weinberg proportions (P>0.1 in cases and controls).  
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Variable   
number or mean 
(SD) 
   
Total number of patients enolled  296 
   
Age at first diagnosis  43.98 
   
FIGO Stage I 2 
 II 19 
 III 155 
 IV 120 
   
Tumour grade I 17 
 II 38 
 III 241 
   
Histological subtype serous 222 
 mucinous 44 
 endometrioid 21 
  clear cell 9 
   
Table 5.2 Patient characteristics 
 
The frequencies of the G/G, G/A and A/A genotypes were significantly 
different from those in the controls (p=0.037) (Table 5.3). Compared with the 
A/A +G/A genotype the G/G genotype could significantly increase the risk of 
EOC development (OR 1.64; 95% CI; 1.12-2.39) (Table 5.3). Carriage of the 
A/A versus the G/G genotype may increase the susceptibility to EOC. 
 
No significant associations between the carriage of SNP VEGF 1154G/G and 
the clinicopathologic variables FIGO stage, tumour grade, and age of patients 
at diagnosis were ascertained. 
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Table 5.3. Genotype and Allele distribution of VEGF 1154 G/A Polymorphism in 
cases and controls and association with the risk of developing EOC.  
 
VEGF 1154A>G 
dimorphism (rs 1570360) 
Controls 
n (%) 
Cases 
n (%) 
OR 
P 
Genotypes 
G/A + G/G  
 
86 (28.4) 
 
59(19/5) 
 
 
1.00 
GG  217 (71.6) 244(80.5 1.64 (1.12-2.39) 
AG                 79 (26.1) 54(17.8) 0.037* 
AA                 7 (2.3) 5(1.7)  
    
Allele frequencies    
 G  513 (84.7) 542 (89.4) 0.013 
 A  93 (15.3) 64 (10.6)  
* P value was estimated     
using chi squared test for the G/G, G/A and A/A genotype of VEGF 1154G/A SNP. 
 
 
 
In a univariate analysis, FIGO stage, tumour grade, age of patients at 
diagnosis, and the carriage of all three genotypes VEGF 1154 AA, AG and 
GG, were associated with overall survival (Figure 5.1). Analysis indicated that 
the GG genotypes are associated with median survival of 15 weeks, 
compared to 60 weeks for the AA and AG genotypes (log rank test p < 
0.0001). In a multivariate Cox regression model, these results remain 
unchanged. No interactions were found between the carriage of the VEGF 
1154 G/G genotype and FIGO stage, tumour grade, or age of the patient at 
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diagnosis could be statistically verified  (p=0.9, p=0.9 and p=0.7 respectively). 
Therefore the effect of carriage of the VEGF 1154 G/G genotype found in 
multiple Cox regression analysis is independent of the level of a patient’s 
FIGO stage, tumour grade, or age at diagnosis. No significant violations of the 
proportional hazards assumption could be detected for any of the variables 
entering multivariate Cox model. 
 
 
5.5 Discussion  
 
In this population-based case-control study from Pakistan, we investigated the 
association of a polymorphism in the VEGF gene; VEGF 1154 A/G, to assess 
whether carriage of the polymorphism increases susceptibility to EOC in a 
population based case control study from Pakistan. We also investigated the 
association of VEGF 1154A/G polymorphism with the risk of development of 
EOC and its effects on overall survival. We decided to study this particular 
polymorphism, as it has been shown in other studies, to be associated with 
higher VEGF production, whereas VEGF 1154 A/A is associated with low 
VEGF production352 353 458. 
 
Our results illustrated a significant difference between the cases and controls 
in allele frequencies p<0.013 and carriage of the 1154 G allele was 
associated with an increased risk of ovarian cancer. This result may be 
explained, and is biologically plausible, as the VEGF 1154 G/G polymorphism 
is known to be associated with increased VEGF production.  
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Figure 5.1 Kaplan Meier curves  including the 95% confidence bands on overall 
survival of patients with ovarian cancer. Carriage of three genotypes AA= nucleotide 
1; AG = nucleotide 2 and GG = nucleotide 3 was correlated with overall survival. 
 
 
 
Angiogenesis the formation of new blood vessels from endothelial precursors 
is a prerequisite for the growth and progression of solid malignancies 104. 
VEGF is believed to be important for angiogenesis initiation 25 286. Functional 
polymorphisms of VEGF that regulate gene expression may contribute to the 
susceptibility to cancers. In ovarian cancer, in vitro studies showed that VEGF 
is critically important in the various steps of ovarian carcinogenesis 286 298. 
VEGF was shown to be associated with the promotion of angiogenesis in 
early stage ovarian cancer, suggesting that VEGF- driven angiogenesis might 
be an early event in ovarian carcinogenesis 293. Over-expression of VEGF 
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detected immunohistochemically and elevated serum levels of VEGF have 
been shown to confer a worse prognosis in ovarian cancer 459 460. 
   
Functional polymorphisms of VEGF that regulate gene expression may 
contribute to the susceptibility. The impact of these functional SNPS of the 
VEGF gene on tumour development has been studied using molecular 
epidemiological studies of several cancer types, including Prostate 351; Lung, 
breast 461 and gastric cancers. 
  
Konac et al did not show any association between VEGF 460 C/T and 936 
C/T polymorphisms and the development of gynaecological cancers including 
ovarian cancer. Poltaurer et al, investigated three VEGF polymorphisms, 
VEGF 405 G/C VEGF 460 C/T and VEGF 936 C/T and prognostic parameters 
in ovarian cancer. None of these VEGF genotypes and haplotypes showed 
any significant association with patient’s prognosis462 463. In contrast to this 
study and in agreement with our results Hefner et al, in a study investigating 
VEGF polymorphisms and prognosis in EOC, showed that the simultaneous 
carriage of the three homozygous genotypes VEGF 634 C/C; VEGF 1154 
G/G and VEGF 2578 C/C was associated with a shortened overall survival 280, 
but none of these genotypes alone showed any statistical significance.  
 
As the studied SNP VEGF 1154 G/G is associated with increased VEGF 
production therefore it can be reasonably speculated that the carriage of this 
genotype would lead to higher circulating VEGF levels. Furthermore our data 
illustrated that the carriage of the 1154 G/G SNP not only confers increased 
susceptibility to the development of EOC, but also the GG genotype is 
associated with survival estimates of 15 weeks compared to 60 weeks for AA 
or AG genotypes (p<0.0001), this is independent of the stage of tumour, 
histological grade of tumour. Furthermore we have shown that in the case 
control study, the carriage of VEGF 1154 G/G, which is a functional 
polymorphism and is known to be associated with increased VEGF 
production, leads to increased susceptibility to EOC, in addition, carriage of 
the 1154 G/G polymorphism, was found to be significantly associated with 
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poor prognosis in patients with EOC, independent of known established 
prognostic factors for EOC.  
 
Interestingly in this study we found that both cases and controls had 
increased proportion of homozygosity than would be expected from outbred 
populations. This may reflect and support the high rates of consanguinity 
known to exist within the Pakistani population, with rates reported of 60-70% 
464. 
 
The presence of these germ line homozygous segments may be explained by 
consanguinity somewhere in the individual’s ancestary. After all 1/16 and 1/64 
of a child’s genome is expected to be identical by descent if his/her parents 
are first and second cousins respectively 465. Individuals are frequently 
observed to have long segments of uninterrupted sequences of homozygous 
markers. These long homozygous segments arise through numerous 
mechanisms including consanguineous marriages, in which parent pass 
shared chromosomal segments also known as autozygous segments;ie the 
two alleles in a homozygous genotype are identical by descent (IBD). 
Evidence has shown that level of consanguinity positively correlates to the 
incidence of adult –onset complex disorders including cancer.  
 
Humans are believed to carry over a million distinct SNPs 466. Determination 
of SNPs is a means to study the aetiology of polygenetic disorders with 
complex inheritance patterns 465, 467 For instance they affect the process of 
cancer development and tumourigenesis via actions on the pathways of 
tumour angiogenesis. This may be achieved by enhanced or reduced 
transcription, altered posttranscriptional or posttranslational activity, or 
changes in the tertiary structure of the gene product 468. 
 
 Several limitations in our study need to be addressed. First the sample size 
of the current study may not be large enough to detect small effects from low 
penetrance genes, and a much larger sample size is needed to validate our 
finding, and to investigate the functional relevance of this polymorphism in 
ovarian cancer development and progression.  Secondly the 1154 
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polymorphism investigated in our study, based on its functional consideration, 
may not give a comprehensive view about genetic variability in VEGF. 
 
Due to the high level of consanguinity we observed large numbers of 
homozygous genotypes are present within our study, this may not 
represented in other populations and may explain the high rates of ovarian 
cancer seen in the Pakistani population.  
 
In the future our results should be further validated in gene expression studies 
and the linkage of these results to prognosis and response to platinum based 
chemotherapy would give us further insight into the functionality and role of 
the VEGF in ovarian cancer, and also identify individuals that are at increased 
risk of increased VEGF production. The clinical and prognostic value of this 
information in light of the new developments in the field of VEGF inhibitors 
such as Bevacizumab may prove a clinically useful tool. 
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Chapter 6. General Discussion 
 
 
 
“For every increment of tumour growth there is an increment 
of vascular growth” Judah Folkman 1971. 
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In this thesis I have presented data resulting from a series of experiments and 
observations that illustrate the importance of angiogenesis for tumour growth 
and prognosis in epithelial ovarian cancer.  
 
It is widely recognised that tumour angiogenesis is critical for tumour growth 
beyond 2mm 1 469 470 and is associated with prognostic significance in a 
variety of solid malignancies such as breast, prostate, gastric and non small 
cell lung cancer; 1. However results from studies  in EOC are conflicting and 
the clinicopathological significance has been debated 129 316 373. Vascular 
endothelial growth factor (VEGF) is a homodimeric glycoprotein expressed in 
a wide variety of normal and transformed cell types 55. It is a key angiogenic 
factor and acts as a highly specific mitogen promoting endothelial cell 
migration and inhibiting apoptosis12. Studies have suggested a specific role 
for VEGF in various phases of ovarian carcinogenesis with effects on tumour 
and neovascularisation illustrated in animal models and in humans. It has 
been shown to have prognostic value in predicting for metastases and overall 
survival in various solid tumours298 343. 
 
 
 
6.1 VEGF as an Independent Prognostic Factor in 
Epithelial Ovarian Cancer 
 
My results indicate that in patients with epithelial ovarian cancer, tumours that 
express high levels of VEGF have a worse overall survival rate compared to 
those with low intratumoural VEGF expression. A median survival advantage 
of approximately 25 months is seen with patients who have low VEGF 
expression (p<0.0001). This result is further substantiated when a multivariate 
Cox regression model was constructed in which established prognostic 
factors such as stage of tumour, grade of tumour and residual volume of 
disease after primary surgery, were accounted for. The expression of 
intratumoural VEGF maintained statistical significance with regards to patient 
survival (p<0.0001). My results conclude that the immunohistochemical 
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assessment of VEGF expression within a tumour can display further 
information about tumour behaviour and subsequent prognosis for the patient.  
 
The literature to date has been unclear as to the role of VEGF expression 
within ovarian tumours. Some studies have shown it is a significant 
independent prognostic factor and have supported the results that I have 
presented in this thesis.  Paley et al found that patients with early stage 
disease FIGO stages I and II, showed poorer prognosis with increased VEGF 
expression within the tumour301. Shen at al showed that survival of patients 
with high VEGF expression was significantly worse than those with low VEGF 
expression and in multivariate analysis VEGF expression together with stage 
was an independent prognostic indicator for overall survival380. This was in 
agreement with our data. I have demonstrated that there was no association 
between VEGF expression and any of the clinicopathological variables 
including stage, and grade of the tumour, other studies have also illustrated 
this 55 289 293 382. Some studies have suggested that stage and grade are 
associated with VEGF expression, although these studies have a larger 
proportion of early stage disease 380. High VEGF levels in the serum  have 
also been independently associated with shorter progression free survival, 
and have been shown to be in a prognostic factor in EOC. Prechemotherapy 
serum levels of CD105, transforming growth factor beta2, and vascular 
endothelial growth factor are associated with prognosis in patients with 
advanced epithelial ovarian cancer treated with cytoreductive surgery and 
platinum-based chemotherapy471. 
 
 Similarly VEGF levels in ascitic fluid have been shown to be a prognostic 
factor in EOC. Mesiano et al have shown higher levels of VEGF in the ascitic 
fluid of patients with high stage disease.ref 289 In addition Barton et al 
reported an increased concentration in the serum and ascitic fluid in patients 
with high stage disease.295 A possible limitation in our study is that we did 
not correlate the levels of VEGF in the serum or ascitic fluid of patients to 
examine its role as a prognostic factor in EOC. 
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There were are a number of technical limitations of our study, and the results 
may have been subject to bias due to these technical limitations. As it is 
difficult to standardise IHC techniques, the expression quantification of the 
VEGF protein  is subject to observer error, and the heterogeneous expression 
of VEGF, causes difficulties in maintaining a standardised scoring system for 
the quantification and assessment of VEGF. The scoring system formulated 
and used in this study was devised by JC and GS, the accuracy and 
reprodicibiliy of this system would need to be tested in larger prospective 
studies. I hope that further work is carried out in the future to develop a more 
reproducible and quantitative method for detection /estimation of levels of 
VEGF in the tumour, such as used in the Hercep Test tm. Currently breast 
cancer patients are selected for treatment with Herceptin by IHC with a semi 
quantitative estimation of the levels of erb B2 in their tumour. The most 
commonly adopted method has become the Hercep Test (Genentech, Inc) 
Formalin fixed paraffin sections are reacted with antibody to erb-B2 and 
analysed according to the quickscore method472. The staining intensity is 
scored as well as proportion of positive stained cells. A similar model could be 
developed to focus on VEGF to allow automated quantification of VEGF in 
order to create a clinical diagnostic tool.  
 
Another limitation of my work was that the study was retrospective which 
brings clinical bias into the result, and the number of patients was small. In 
further work, it would be useful to ascertain if these results could be 
reproduced in a larger prospective study to address these issues. 
 
I examined the role of VEGF as a marker of the angiogenic response in EOC; 
however it could be argued that VEGF is only one of the factors associated in 
the angiogenic pathway and further work should be carried out to ascertain 
the role of the other factors involved in the angiogenic response to further our 
understanding of this process. Furthermore I did not use microvessel counts 
(MVD) as a measure of angiogenesis, as the results of other studies, using 
this method as a means of assessing the degree of angiogenesis have been 
contradictory, in EOC. Hollingsworth et al reported that microvessel counts 
correlated with progression free and overall survival in advanced ovarian 
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cancer289. Univariate analysis showed that high MVD counts confer a worse 
prognosis for overall/progression free survival whereas a low MVD count was 
correlated with better survival. This however failed to show significance in 
multivariate analysis291 379. 
 
In summary my study illustrates that the use of VEGF IHC can be used to 
predict for disease progression and poor prognosis in EOC. This may allow 
the selection of a sub group of patients, who may have more aggressive 
disease, for adjuvant chemotherapy and, or upfront therapy with anti 
angiogenic or biological therapies. 
 
 
 
6.2 Platinum sensitivity and VEGF 
 
For patients with epithelial ovarian cancer (EOC) cytoreduction together with a 
combination of taxane and platinum is the standard of care. Despite this 
approximately 50% of advanced disease will relapse and moreover about 15-
20% of cases with EOC will fail  to respond to platinum based chemotherapy. 
The data presented in this thesis further go onto illustrate that in EOC, VEGF 
expression in the tumour as assessed by IHC, is significantly associated with 
platinum sensitivity, with high VEGF expression in the tumour predicting 
resistance to platinum based chemotherapy. Demonstration of over 
expression of VEGF in patients by IHC, not only provides the basis for a 
biomarker assay for assessing disease progression, but also identifies those 
patients that are likely to be platinum resistant and who may benefit from the 
addition of anti angiogenic therapy to their therapeutic regimen.  
Other investigators, have reported that the elevated expression of VEGF in 
tumours of patients with EOC is associated with poor prognosis39 275 301 304 39 
304, the data presented in this thesis and the results of our study are one of the 
first to show that the pre-treatment intratumoural expression of VEGF is a 
predictor of response to platinum based chemotherapy.  
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Data from other groups support these findings; Bamias et al showed that high 
VEGF levels in the ascites of patients with advanced epithelial ovarian cancer 
were of poor prognostic significance. This group also reported an association 
of VEGF expression, within the ascites of patients with platinum resistance 
433. 
 
One possible biologically plausible mechanism for the prognostic capacity of 
high tumour VEGF expression may be related to its function as a regulator of 
angiogenesis. However the exact pathway that is involved in causing platinum 
resistance, in association with high VEGF levels remains unclear and it is 
hypothsised that other factors in the angiogenic pathway would be involved. 
Future work in this area could explore these factors and ascertain their role in 
platinum resistance. 
 
Recent interest has focussed on the use of anti angiogenic drugs in an 
attempt to inhibit the pro tumour effects of VEGF. Evidence that these 
targeted therapies were biologically active came from the studies in 
2004,using Bevacizumab (Avastin) Genentech Inc San Francisco US). 
Avastin, a monoclonal antibody to VEGF A, was the first agent to target 
angiogenesis. It has been shown to improve survival in patients with 
advanced disease alone, and in combination with existing chemotherapy 
regimens. More recently smaller molecular weight Tyrosine Kinase Inhibitors 
(TKIs) have also shown the ability to interfere with the VEGF signalling 
network.  
 
Further work should be carried out in the future to validate the results from our 
study in a larger prospective study. In the future it may be possible to detect 
recurrence of cancer by these and other Biomarkers, within the genetic profile 
of patients, to predict groups of patients more at risk of having more 
aggressive disease, and likely to be resistant to platinum based 
chemotherapy. This will enable us to stratify patients, and individualise patient 
treatment. It may allow us to guide anti angiogenic therapy as upfront therapy, 
in patients who are likely to be resistant to platinum based chemotherapy 
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6.3 VEGF Polymorphism 1154 A/G and the risk of EOC 
 
To further explore the role of VEGF in EOC. I studied the association of a 
polymorphism in the VEGF gene; VEGF 1154 A/G, to assess whether 
carriage of the polymorphism increases susceptibility to EOC in a population 
based case control study from Pakistan. I also investigated the association of 
VEGF 1154A/G polymorphism with the risk of development of EOC and its 
effects on overall survival. We decided to study this particular polymorphism, 
as it has been shown in other studies, to be associated with higher VEGF 
production, whereas VEGF 1154 A/A is associated with low VEGF production. 
352-354 458.  
 
My results illustrated a significant difference between the cases and controls 
in allele frequencies p<0.013 and carriage of the 1154 G allele was 
associated with an increased risk of ovarian cancer. This result may be 
explained and is biologically plausible, as the VEGF 1154 G/G polymorphism 
is known to be associated with increased VEGF production.  
 
Functional polymorphisms of VEGF that regulate gene expression may 
contribute to the susceptibility. The impact of these functional SNPS of the 
VEGF gene on tumour development has been studied using molecular 
epidemiological studies of several cancer types, including prostate351 lung , 
breast461 and gastric cancers473 474. The results however remain inconsistent.  
 
Kataoka et al conducted a population based case control study of 1093 breast 
cancer cases and 1093 controls in Chinese women and found that VEGF 936 
C/T was associated with a reduced risk of breast cancer in  premenopausal 
women (Kataoka, Cai et al. 2006). In contrast another large case control study 
of 1489 women with breast cancer (565 women familial breast cancer from 
Poland and Germany and 924 unselected breast cancer cases from Sweden) 
showed no difference in the allele or genotype frequencies of VEGF 935 C/T 
between the cases and controls 475.  
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Konac et al  did not show any association between VEGF 460 C/T and 936 
C/T polymorphisms and the development of gynaecological cancers including 
ovarian cancer. Poltaurer et al, investigated three VEGF polymorphisms, 
VEGF 405 G/C VEGF 460 C/T and VEGF 936 C/T and prognostic parameters 
in ovarian cancer. None of these VEGF genotypes and haplotypes showed 
any significant association with patient’s prognosis; 462,463. In contrast to this 
study and in agreement with our results Hefner et al, in a study investigating 
VEGF polymorphisms and prognosis in EOC, showed that the simultaneous 
carriage of the three homozygous genotypes VEGF 634 C/C; VEGF 1154 
G/G and VEGF 2578 C/C was associated with a shortened overall survival280, 
but none of these genotypes alone showed any statistical significance. 
Furthermore in agreement with our findings, Steffenson et al Gynae Oncol 
117(1); 109-16, illustrated in his work that VEGF serum levels were 
significantly higher in carriers of the 2578C, 460T and 405C polymorphisms of 
the VEGF gene, these polymorphisms are known to have functional activity 
and thus affect the production of VEGF protein. However, unlike our studu no 
clear association was observed between individual VEGF genotypes and 
overall survival but in haplotype analysis, it was found that patients with the 
AGCGC haplotype,(associated with reduced VEGF production), in 
multivariate analysis had longer progression free survival, compared to other 
haplotypes.  
 
As the studied SNP VEGF 1154 G/G is associated with increased VEGF 
production therefore it can be reasonably speculated that the carriage of this 
genotype would lead to higher circulating VEGF levels. Furthermore our data 
illustrated that the carriage of the 1154 G/G SNP not only confers increased 
susceptibility to the development of EOC, but also the GG genotype is 
associated with median survival estimates of 15 weeks compared to 60 weeks 
for AA or AG genotypes (p<0.0001), this is independent of the stage of 
tumour, grade of tumour and residual disease status. In conclusion these data 
further substantiate our findings that estimation of VEGF is a prognostic factor 
in EOC. We have illustrated this through a series of experiments looking both 
at protein expression and also at a genetic level. Both sets of results are in 
concordance with each other. Furthermore we have shown that in the case 
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control study, the carriage of VEGF 1154 G/G, which is a functional 
polymorphism and is known to be associated with increased VEGF 
production, leads to increased susceptibility to EOC, in this population. In 
addition, carriage of the 1154 G/G  polymorphism, was found to be 
significantly associated with poor prognosis in patients with EOC, independent 
of known established prognostic factors for EOC.  
 
 
6.4 Study Design and Sample size 
 
There were limitations to this study. We used a hospital based case control 
study, which is an appropriate strategy to easily get participants’ agreement to 
provide tissue samples. All the study samples were obtained from hospital 
sources including healthy controls, the controls represented all the 
geographical areas of Pakistan and all ethnic groups were included. As the 
controls were selected from a population sample this could potentially present 
higher rates of participation refusal, thus inducing selection bias. In order to 
have an adequately powered study to test the effect of gene polymorphisms, 
calculations of sample sizes depend upon population prevalence, as well as 
the size of the effect to be estimated. Case-control studies are known for large 
variations, inconclusive results and lack of biological plausibility. These are 
usually due to small sample sizes, lack of power to show statistical 
significance, and control selection 352 476. 
 
Additional problems are faced in gene polymorphisms studies in cancer. 
Some risk factors are unknown or resources are not available to measure the 
known risk factors that could influence the development of cancer and access 
to entire statistical population of cases in not possible. In this study we did not 
have access to the complete demographic data of the control population. In 
calculating sample size if it is known that a given allele increases susceptibility 
for a specific cancer and its prevalence in the population is known e.g. 15%, a 
case-control study will need around 200 cases and similar number of controls 
to estimate the effect of that allele. However, if it is unknown whether the gene 
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causes susceptibility, as it was in our study, additional information is required 
for sample size calculation. This includes a biologically relevant effect size, 
Type 1 error (usually 0.05) and the required power of the study (usually 80% 
or more). Moreover, testing interactions between genes and environmental 
factors requires studies with additional participants 331. 
 
The study of SNP markers is an indirect association study because the 
susceptibility gene is not known. The power of indirect association studies is 
not well understood 477. The power of indirect association studies in case-
control design is reduced compared with direct susceptibility gene studies. 
Moreover, the greater the number of independent SNP markers, the more 
difficult it is to achieve a significance level because of Bonferroni correction. In 
this study the VEGF 1154 A/G SNP was found to be in complete linkage. 
Moreover, we had hypothesized that the VEGF gene considered in this study 
is a candidate susceptibility gene because of the functional role of their 
polymorphisms in angiogenesis and carcinogenesis as suggested by other 
studies 352. Hence the power of the study was not reduced significantly. 
 
This study had only one genetic polymorphism and this has different 
prevalence’s in different ethnic groups. We had chosen that particular SNP 
based on the known important role of VEGF driven angiogenesis in ovarian 
carcinogenesis and based on previously published data on the role of VEGF 
polymorphisms in other malignancies 478-480. 
 
It was difficult to predict a biological effect on size because it was not known 
to what extent does a given SNP increases the susceptibility to ovarian 
cancer. To achieve an acceptable sample size, an effect size of 20% was 
assumed to be biologically relevant and other values mentioned previously 
were included in calculating sample size, as described in the Methods and 
Materials section. Since a number of variables, described previously, were to 
be used in the analysis, all efforts were made to recruit as many study 
subjects as possible to maintain an acceptable power for subgroup analysis 
irrespective of the initial sample size calculation. 
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The study was carried out exclusively on a population of Pakistani ancestery. 
In this study we found that both cases and controls had an increased 
proportion of homozygosity, than would be expected from outbred 
populations. This may reflect and support the high rates of consanguinity 
known to exist within the Pakistani population, with rates reported of 60-
70%442.We decided to study the Pakistani population due to the presence of 
high rates of consanguinity in its population, as several studies link 
consanguinity to cancer. They suggest that autozygosity (a genomic 
consequence of consanguinity) may be factor in cancer predisposition, there 
are clear correlations between the incidence of cancer and degrees of 
inbreeding on a number of population based studies 450 481.  
 
Individuals from consanguineous unions frequently have been observed to 
have long segments of interrupted sequences of homozygous markers, after 
all 1/16 and 1/64 of a child’s genome is expected to be identical by descent if 
his or her parents are first cousins and second cousins respectively; 465. 
These long segments arise by various mechanism including consanguineous 
marriages, in which parents pass shared chromosomal segments also known 
as autozygous segments, the two alleles in a homozygous genotype are 
identical by descent (IBD)482. Evidence has shown that the level of 
consanguinity positively correlates to the incidence of adult onset complex 
disorders. The fact that I studied the Pakistani population may also be viewed 
as a limitation of our study as the homozygous gene pool may be postulated 
to be greater than would be expected in other populations. To show an 
association you would need a smaller number of cases and controls, as 
expected genotype frequencies in individuals from different genetic 
background vary raising the problem of genetic background. It is difficult to 
compare genotype frequencies derived from our study in patients with ovarian 
cancer to other populations, and a multiethnic trial would be needed to further 
validate the effect we have observed.   
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Age, stage and grade of disease and residual disease status, did not affect 
the distribution of genotypes in the control and the case populations. 
Association of a SNP with the dependent variable does not imply a causal 
relationship, so the confounding effect of the known and unknown variables 
had minimal impact on the interpretation of the findings. An important purpose 
of this study was to evaluate the role of VEGF 1154 G/A as a potential 
biomarker of ovarian cancer. The sensitivity and specificity of the biomarker 
would be validated by future studies on a much larger sample sizes and over 
a longer period of time. 
 
 
6.5 Future Work and Clinical Relevance 
 
 
Over the last several decades, oncology research and cancer treatment have 
concentrated primarily on the cancer cells. Unfortunately, despite the 
intensive quest to find new and more effective compounds for chemotherapy, 
the survival rate of patients has not significantly changed. In 1971 Judah 
Folkman proposed that a solid tumor cannot grow without inducing 
angiogenesis. Target based therapies, are emerging as the new frontier in 
solid tumour oncology. Extensive research has been invested in identifying 
novel therapeutic targets and biological targets that might enhance the 
therapeutic index in treating ovarian cancer. Recent interest has focussed on 
the use of antiangiogenic drugs in an attempt to inhibit the pro-tumour effects 
of VEGF. Evidence that these targeted therapeutics were biologically active 
came from studies in 2004, using bevacizumab (Avastin®) - Genentech Inc. 
San Francisco, US) and was the first agent to target angiogenesis. It was 
licensed as a recombinant humanised monoclonal antibody (administered 
three-weekly) for the treatment of advanced solid cancers, and its mode of 
action is by targeting the isoforms of VEGF, which circulate in the 
bloodstream, preventing the ligand binding to its cognate receptor. Avastin® 
has been shown to improve survival in patients with advanced disease alone, 
and in combination with existing chemotherapy. More recently, smaller 
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molecular weight tyrosine kinase inhibitors (TKIs) have also shown the ability 
to interfere within the VEGF signaling network. This class of agents 
(aminophthalazines) includes Vatalinib (PTK787/ZK222584, Novartis, Basel, 
Switzerland) which acts by targeting VEGFR-1, -2 and -3, PDGFR-β and c-
Kit, and has shown to improve progression-free survival of colorectal cancer 
patients when administered in combination with FOLFOX in Phase III trials; 
(429. Anti-VEGF therapy causes a slowing of tumour progression, resolution of 
malignant effusions and synergy with cytotoxic agents. It is also being studied 
as a first line treatment in a US trial (GOG 218) and a European Trial (ICON 
7) in EOC.  
 
Currently, there are many ongoing efforts to develop biological markers that 
predict sensitivity/resistance to particular strategies in EOC. The clinical 
relevance and pertinence of this study shows that measurement of the level of 
VEGF, determined by IHC in archival material, might be used for selection of 
patients likely to benefit from the addition of anti-VEGF therapies to front line 
platinum/ paclitaxel chemotherapy, and involve the development of a 
diagnostic clinical test. In the future it may be possible to detect recurrence of 
cancer by these and other Biomarkers, within the genetic profile of patients, to 
predict groups of patients likely to have more aggressive disease, and likely to 
be resistant to platinum based chemotherapy. This will enable us to stratify 
patients, and individualise patient care. It will allow us to guide anti angiogenic 
therapy as upfront therapy, in patients who are likely to be resistant to 
platinum based chemotherapy. 
 
The present study shows that the SNP in the VEGF gene 1154 G/A is 
associated with increased susceptibility and poor prognosis in patients with 
ovarian cancer. These results would need to be validated in larger,prospective 
gene expression studies. Future work could examine other functional 
polymorphisms in the VEGF gene as well as other polymorphisms in 
candidate genes in the angiogenic pathway to establish a combination of 
genotypes that may serve as markers for susceptibility to EOC, prognosis, 
and drug response in EOC, This will, we hope improve the prognosis of 
patients with this disease. 
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